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Abstract 
Leukemia is a hematopoietic cancer that is characterized by the abnormal differentiation 
and proliferation of hematopoietic cells. It is ranked 7th by death rate among cancer types 
in USA, even though it is not one of the top 10 cancers by incidence (USCS, 2010). This 
indicates an urgent need for more effective treatment strategies. In order to design the 
new ways of prevention and treatment of leukemia, it is important to understand the 
molecular mechanisms involved in development of the disease. 
In this study, we investigated mechanisms involved in the development of acute 
myeloid leukemia (AML) that is associated with CBF fusion genes. The RUNX1 and 
CBFB genes that encode subunits of a transcriptional regulator complex CBF, are 
mutated in a subset (20 – 25%) of AML cases. As a result of these mutations, fusion 
genes called CBFB-MYH11 and RUNX1-ETO arise. The chimeric proteins encoded by 
the fusion genes provide block in proliferation for myeloid progenitors, but are not 
sufficient for AML development. Genetic studies have indicated that activation of 
cytokine receptor signaling is a major oncogenic pathway that cooperates in leukemia 
development. The main goal of my work was to determine a role of two factors that 
regulate cytokine signaling activity, the microRNA cluster miR-17-92 and the 
thrombopoietin receptor MPL, in their potential cooperation with the CBF fusions in 
AML development. 
We determined that the miR-17-92 miRNA cluster cooperates with Cbfb-MYH11 
in AML development in a mouse model of human CBFB-MYH11 AML. We found that 
vi 
the miR-17-92 cluster downregulates Pten and activates the PI3K/Akt pathway in the 
leukemic blasts. We also demonstrated that miR-17-92 provides an anti-apoptotic effect 
in the leukemic cells, but does not seem to affect proliferation. The anti-apoptotic effect 
was mainly due to activity of miR-17 and miR-20a, but not miR-19a and miR-19b. 
Our second study demonstrated that wild type Mpl cooperated with RUNX1-ETO 
fusion in development of AML in mice. Mpl induced PI3K/Akt, Ras/Raf/Erk and 
Jak2/Stat5 signaling pathways in the AML cells. We showed that PIK3/Akt pathway 
plays a role in AML development both in vitro and in vivo by increasing survival of 
leukemic cells. The levels of MPL transcript in the AML samples correlated with their 
response to thrombopoietin (THPO). Moreover, we demonstrated that MPL provides pro-
proliferative effect for the leukemic cells, and that the effect can be abrogated with 
inhibitors of PI3K/AKT and MEK/ERK pathways. 
Taken together, these data confirm important roles for the PI3K/AKT and 
RAS/RAF/MEK pathways in the pathogenesis of AML, identifies two novel genes that 
can serve as secondary mutations in CBF fusions-associated AML, and in general 
expands our knowledge of mechanisms of leukemogenesis. 
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Preface 
This work included input from several people from Dr. Castilla‟s laboratory and from our 
collaborators in other laboratories. Below I will specify my role in each project. 
Chapter I “Introduction” was written by me and edited by Lucio Castilla. 
All experiments described in Chapter II “Cooperation between Cbfb-MYH11 and miRNA 
cluster miR-17-92 in development of AML” were performed by me. I also analyzed data 
and wrote the manuscript. Lucio Castilla provided intellectual input and edited the 
manuscript. 
In Chapter III “THPO/MPL signaling participates in the initiation and maintenance of 
RUNX1-ETO acute myeloid leukemia via PI3K signaling” the experiments that were 
performed by me are shown in figures 3.2 (with participation by Sean Landrette), 3.3, 
3.5C, 3.7, 3.8D. I also participated in generation and analysis of RUNX1-ETO/PlagL2 
AML samples depicted in figure 3.6, although it was mainly done by Sean Landrette. I 
was also involved in data analysis and writing and editing of the manuscript. Lucio 
Castilla provided intellectual guidance and wrote the manuscript. 
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CHAPTER I 
Introduction 
Leukemia is a diverse family of blood diseases characterized by expansion of abnormal 
hematopoietic progenitors. It represents 4% of cancers and ranks as 7th most deadly 
cancer in the United States (American Cancer Society, www.cancer.org). These statistics 
underscore the importance of understanding the molecular mechanisms driving leukemia 
development and drug resistance in order to develop more specific and effective methods 
of treatment. 
Regulation of hematopoietic differentiation 
Hematopoiesis is the process of generation of blood cells by an organism. The mature 
hematopoietic cells, including macrophages, granulocytes, megakaryocytes and 
thrombocytes, erythrocytes, T- and B-cells, dendritic cells and natural killers, are 
generated from a rare cell population called hematopoietic stem cells (HSCs). In addition 
to providing multilineage differentiation, the HSCs have the capacity to generate more 
HSCs in a process called self-renewal. 
Hematopoiesis is a tightly regulated process that balances self-renewal and 
differentiation, dormancy and proliferation of its progenitor cells. This regulation 
involves cellular and environmental cues, including the activity of transcription factors 
2 
(TFs), signaling cascades, and non-coding RNAs. Deregulation of hematopoiesis due to 
mutations in the regulating genes can result in blood disorders characterized by impaired 
differentiation and/or increased proliferation. 
The characterization of hematopoietic differentiation has benefited from the 
development of antibodies, flow cytometry technology, and in vitro colony forming 
assays, which allowed researchers to specifically identify particular hematopoietic 
subpopulations of cells with defined differentiation capacity. The studies at Weissmann‟s 
laboratory led to the definition of a classic model of hematopoietic differentiation in mice 
(Figure 1.1A). They identified a population in the mouse bone marrow based on cell 
surface markers expression Thy1lowSca1+Lin- (where Lin- is defined as cells that are 
negative for lineage specific markers: CD4, CD8, B220, Mac1, Gr1) that was enriched 
for cells exhibiting properties of HSCs. The HSC population is mostly dormant (van der 
Wath et al., 2009; Wilson et al., 2008), and can reconstitute all hematopoietic lineages in 
vitro and in vivo (Spangrude et al., 1988). The same group later identified a multipotent 
progenitor (MPP) that derived from HSC and possessed limited self-renewal capacity but 
was able to provide multilineage differentiation (Morrison et al., 1997). The MPPs were 
suggested to differentiate into progenitors that were restricted to either myeloid or 
lymphoid lineages based on the identification of corresponding populations: a myeloid 
restricted IL-7Rα-Lin-c-Kit+Sca1-FcgRloCD34+ progenitor called common myeloid 
progenitor (CMP (Akashi et al., 2000)), and a lymphoid restricted Lin-IL-7R+Thy1-
Sca1lowc-Kitlow progenitor called common lymphoid progenitor (CLP (Kondo et al., 
1997)). The CMPs were shown to differentiate into more restricted granulocytic-   
3 
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monocytic progenitors (GMPs) and megakaryocytic-erythroid progenitors (MEPs) 
(Akashi et al., 2000). In the thymus, an MPP-derived population, called early T-lineage 
progenitors (ETP) with Sca2+ Rh123+ B220- immunophenotype, is capable of T-cell 
differentiation (Wu et al., 1991b), but these cells do not seem to be restricted to T-cell 
differentiation in environments outside of the thymus (Wu et al., 1991a). Later, Kondo‟s 
group defined a lymphoid-primed MPP population, the CCR9+ MPP, as the intermediate 
between MPP and ETP, with lymphoid (T, B and dendritic cell) and limited myeloid 
potential (Lai and Kondo, 2007). 
This scheme of differentiation has recently been challenged by several studies that 
identified downstream of MPP two progenitor populations: Lin-c-kit+Sca1+Flt3+ 
lymphoid primed multipotent progenitor (LMPP) and megakaryocytic-erythroid 
progenitor (MEP). The LMPP then gives rise to both myeloid and lymphoid cells, but no 
megakaryocytic and erythroid cells (Adolfsson et al., 2005). This scheme suggests that 
differentiation of immune system cells is separated from megakaryocytic and erythroid 
differentiation (Figure 1.1B). 
Many cell fate decisions are controlled by specific TFs that either cooperate or 
antagonize, thus resulting in a binary switch. An elegant example of a binary switch is the 
control of GMP (or LMPP) vs. MEP specification. The TFs Purine-rich binding protein 
(PU.1) and GATA-binding factor 1 (GATA-1) at the MPP stage exhibit antagonistic 
regulation, i.e. PU.1 inhibits GATA-1 targets, and GATA-1 inhibits PU.1 targets 
(Rekhtman et al., 1999; Zhang et al., 1999). This mutual regulation is based on physical 
binding of the proteins to each other at gene promoters and changing components of 
5 
protein complexes that regulate transcription (Rekhtman et al., 1999; Zhang et al., 2000). 
Additionally, both GATA-1 and PU.1 provide a positive feedback regulation of 
themselves (Okuno et al., 2005; Tsai et al., 1991). Therefore, when PU.1 and GATA-1 
are co-expressed in a progenitor cell, minor changes in balance between PU.1 and 
GATA-1 will lead to switching to either activated PU.1 and repressed GATA-1 state 
leading to myeloid and/or lymphoid differentiation, or to activated GATA-1 and 
repressed PU.1 state leading to megakaryocytic and erythroid differentiation (Arinobu et 
al., 2007). 
PU.1 is also involved in regulation of myeloid differentiation together with a 
regulator of myeloid differentiation CCAAT-enhancer binding protein (C/EBPα). PU.1 
and C/EBPα cooperatively regulate the differentiation decision of GMPs to neutrophils 
and macrophages. The PU.1-null mice exhibit a mixed neutrophil/macrophage 
differentiation pattern, whereas addition of PU.1 results in upregulation of a macrophage-
specific gene expression profile and a block in the expression of neutrophil-specific genes 
(Dahl et al., 2003). At the core of this regulation another binary switch was found that 
involved antagonizing TFs Early growth response 1 and 2 (Egr-1,2), and Growth factor 
independent 1 (Gfi-1). Expression of PU.1 activates Egr-1,2 leading to macrophage 
differentiation and inhibition of Gfi-1 targets, while low level of PU.1 activity allows 
Gfi-1 together with C/EBPα to activate neutrophil differentiation and inhibit targets of 
Egr-1,2 (Laslo et al., 2006). 
The regulation of GMP differentiation to basophils and eosinophils depends on 
C/EBPα and GATA-binding factor 2 (GATA-2), and in this case, the order of activation 
6 
of the TFs determines an outcome (Iwasaki et al., 2006). When C/EBPα is exogenously 
expressed in CLPs (that do not express either of the TFs) followed by expression of 
GATA-2, the cells are reprogrammed to become eosinophils. When the order of 
expression is reversed (i.e. GATA-2 is expressed first, followed by expression of 
C/EBPα), the cells differentiate into basophils. This example illustrates that function of 
an individual TF depends on the expression of other factors in a particular cell context 
(Iwasaki et al., 2006). 
The switch between myeloid and lymphoid lineages is complex and seems to 
require orchestrated functions of multiple TFs. Ectopic expression of C/EBPα in 
committed B cell progenitors induces cell type trans-differentiation, reprogramming them 
to macrophages (Xie et al., 2004). Additionally, PU.1 dosage seems to be a critical 
determinant of B-cell vs. macrophage development, as ectopic expression of low level of 
PU.1 in PU.1-/- mouse hematopoietic progenitors stimulates B-cell commitment, whereas 
5-fold higher PU.1 expression level induces macrophage differentiation and blocks B-cell 
differentiation (DeKoter and Singh, 2000). Recent data suggest that the PU.1 block of 
lymphoid differentiation may be due to activity of a transcription factor upregulated by 
PU.1 called Myocyte enhancer factor 2C (Mef2c), but PU.1 role in regulation of 
lymphoid vs. myeloid fate is still under investigation (Stehling-Sun et al., 2009). 
Several TFs are necessary for differentiation of B-cells, including Early B-cell 
factor 1 (EBF1), Ikaros, E2A (encoded by Transcription factor 3 (Tcf3) gene) and later B-
cell determinants like Pax5. EBF1 is an essential early determinant of B-cell 
commitment, inhibiting expression of C/EBPα and PU.1, although it is not sufficient for 
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the commitment (Pongubala et al., 2008). Ectopic expression of Ebf1 can rescue B-cell 
differentiation in Tcf3-/- and Ikaros-/- background (Kikuchi et al., 2005; Seet et al., 2004), 
but in a context of wild type cells expression of EBF must be sustained by E2A 
(O'Riordan and Grosschedl, 1999), Ikaros (Reynaud et al., 2008) and in part by Pax5 
(Nutt et al., 1999) proteins in order for normal B-cell commitment to occur. Recent work 
combining the expression profile of gain and loss of Ebf1 function, and genome wide 
chromatin immunoprecipitation determined that Ebf1 not only regulates Pax5 expression 
but it is also found in a third of promoter regions of Pax5 target genes, highlighting its 
participation in Pax5 regulatory role during B cell commitment (Treiber et al., 2010). 
This study also suggests that Ebf1 may act as a "pioneer in a hematopoietic chromatin 
context”, remodeling chromatin before a cell undergoes further differentiation, therefore 
predisposing a particular gene expression profile that will play a role as the cell continues 
to differentiate into later stages. 
Cell fate decision between B- and T-cell differentiation is mainly driven by the 
Notch-1 receptor in the thymus (Maillard et al., 2005). Regulation of Notch signaling in 
bone marrow (BM) depends on a TF called Leukemia/lymphoma related factor (LRF). 
Absence of LRF expression in BM results in increased Notch signaling and precocious 
appearance of T-cell progenitors (Maeda et al., 2007). GATA-binding factor 3 (GATA-3) 
that drives T-cell differentiation at multiple steps, also plays a role in emergence of early 
T-lineage progenitors (ETP) that upon Notch-1 signaling in the thymus can differentiate 
into mature T-cells (Hosoya et al., 2010). Activity of Notch-1 in early thymocyte 
development is tightly regulated by several transcription factors. Upon cleavage with 
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ADAM and γ-secretase, Intracellular Notch-1 (ICN) domain of Notch-1 is transported to 
the nucleus where it binds to Recombination signal binding protein for immunoglobulin 
κJ region (RBPJ, also known as CSL) and activates expression of multiple target genes 
by recruiting activators of transcription (CBP/p300, PCAF) (Yashiro-Ohtani et al., 2010). 
This regulation is counteracted by transcriptional repressor Ikaros that has the same DNA 
binding specificity as CSL (Kleinmann et al., 2008). Loss of Ikaros function results in 
increased Notch-1 signaling and development of T-cell leukemias (Beverly and 
Capobianco, 2003). Another example of Notch-1 regulation is E2A that activates Notch-1 
expression and functions as a co-activator in a subset of Notch-1 target genes (Ikawa et 
al., 2006; Yashiro-Ohtani et al., 2009). 
Interestingly, some proteins can be involved in regulation of several independent 
cell fate decisions. For example, in addition to the role of Gfi-1 in late myeloid 
development, it is involved in regulation of self-renewal vs. differentiation balance in 
HSCs, together with B lymphoma Mo-MLV insertion region 1 (Bmi-1) promoting self-
renewal of HSCs, whereas C/EBPα and myelocytomatosis oncogene (c-Myc) promote 
HSC differentiation (Hock et al., 2004; Park et al., 2003; Wilson et al., 2004; Zhang et 
al., 2004). 
The regulation of hematopoiesis by TFs is modulated by environmental cues, 
including cytokines, oxygen and calcium levels (Kaushansky, 2006). For example, the 
differentiation decision of MEPs into megakaryocytic vs. erythroid lineages is mediated 
by the antagonistic roles of Erythroid Krüppel-like factor (Eklf) and Friend leukemia 
integration 1 (Fli-1) TFs, both cooperating with GATA-1(Bouilloux et al., 2008; Frontelo 
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et al., 2007; Starck et al., 2003). Eklf promotes expression of erythroid-specific genes and 
inhibits activity of Fli-1, whereas Fli-1 promotes expression of megakaryocytic-specific 
genes and inhibits activity of Eklf. In megakaryocytic progenitors, GATA-1 and Fli-1 
upregulate Myeloproliferative leukemia virus oncogene homolog (c-Mpl), a receptor for 
thrombopoietin that is a major cytokine promoting megakaryocytic maturation and 
platelet production (Deveaux et al., 1996; Jackers et al., 2004). Mature megakaryocytes 
and platelets can absorb thrombopoietin providing a feedback loop that supports steady 
state level of platelets in blood among other mechanisms (Yang et al., 1999). In erythroid 
cells GATA-1 induces expression of the erythropoietin receptor (EpoR), which in turn 
further activates GATA-1 (Zhao et al., 2006a; Zon et al., 1991). Erythropoietin (Epo) is a 
major regulator of erythrocyte production and stimulates proliferation and differentiation 
of erythroid progenitors. Synthesis of Epo is controlled in renal cells in an oxygen-
dependent manner by regulation of stability of Hypoxia induced factor 1α (HIF1α) that 
upregulates Epo gene transcription (Ratcliffe et al., 1998). Therefore, EpoR and Epo 
provide sensitivity of erythropoiesis to oxygen levels in blood, allowing it to be 
responsive to environmental conditions. It is noteworthy that stem cell factor (SCF) and 
its receptor c-Kit play a synergistic role with Epo/EpoR in inducing differentiation and 
proliferation of erythroid progenitors (Munugalavadla and Kapur, 2005). 
Other cytokines are involved in regulation of hematopoiesis, promoting 
differentiation of specific lineages. Granulocytic-monocytic colony stimulating factor 
(GM-CSF), monocytic-colony stimulating factor (M-CSF) and granulocyte-colony 
stimulating factor (G-CSF) are involved in myeloid differentiation and stimulate 
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proliferation and differentiation towards GMP, monocytes and granulocytes, 
correspondingly (Lieschke et al., 1994). Upon inflammation, release of inflammatory 
cytokines stimulates production of G-CSF by epithelial cells and monocytes, therefore 
increasing production and function of innate immunity cells when they are needed 
(Hareng and Hartung, 2002). 
Two essential (but not exclusive) cytokines that regulate HSC are SCF and 
thrombopoietin. Null mutations in genes that encode SCF or its receptor c-KIT result in 
severe reduction of HSC numbers and their self-renewal ability (Bernstein, 1962; 
McCulloch et al., 1965). C-KIT receptor tyrosine kinase (RTK) type III is expressed in 
all hematopoietic progenitor cells at similar levels (Ashman et al., 1991; Cambareri et al., 
1988; Papayannopoulou et al., 1991; Simmons et al., 1994) and, upon ligation with SCF 
activates signaling cascades that involve PI3K/AKT, RAS/RAF/MEK/ERK and 
JAK2/STAT3,5 pathways. Through these pathways (see below) c-KIT signaling 
regulates hematopoietic progenitor cell cycle (Leary et al., 1992), survival (Borge et al., 
1997; Li and Johnson, 1994; Wineman et al., 1993), maintenance (Thorén et al., 2008) 
and adhesion to stromal cells in their niche (Kodama et al., 1994; Levesque et al., 1996; 
Levesque et al., 1995). Other hematopoietic functions of c-KIT involve myeloid (Sharma 
et al., 2007), erythroid (Munugalavadla and Kapur, 2005) and megakaryocytic 
differentiation (Avraham et al., 1992; Imai and Nakahata, 1994). To a lesser extent, 
lymphoid differentiation also depends on c-KIT function (Colucci and Di Santo, 2000; 
Sharma et al., 2007). C-KIT mutations leading to its constitutive receptor activation are 
common in leukemias (Zaker et al., 2010), and most AML cells express c-KIT on the cell 
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surface (Muroi et al., 1998; Wang et al., 1989). 
Thromobpoietin (THPO) and its receptor Myeloproliferative leukemia virus 
oncogene (MPL) are also essential regulators of hematopoiesis and HSC function in 
particular, as absence of either of the genes results in diminished production of HSCs and 
their inability to compete with WT cells in lineage repopulation (Kimura et al., 1998a). 
Similar to c-KIT, MPL is also a cytokine receptor. MPL is a surface marker of a 
subpopulation within an HSC-enriched compartment, and the MPL+ subpopulation 
exhibits higher multilineage repopulation potential than MPL- population, indicating that 
MPL is a surface marker of functional HSCs (Ninos et al., 2006; Solar et al., 1998). 
Detailed studies of MPL functions in HSCs suggest that it promotes self-renewal and 
maintenance, controls cell cycle entry, regulates HSC expansion after transplantation and 
interaction of HSC with their niche (Fox et al., 2002a; Qian et al., 2007; Yoshihara et al., 
2007). MPL is also essential for megakaryocytic maturation (Alexander et al., 1996), 
erythroid and myeloid differentiation (Carver-Moore et al., 1996). An activating mutation 
W515L that disrupts an auto-inhibitory juxtamembrane domain of MPL (Staerk et al., 
2006), is found in a fraction of primary myelofibrosis/idiopathic myelofibrosis and acute 
megakaryoblastic leukemias (AMKL) (Hussein et al., 2009a). Loss-of-function mutations 
in THPO and/or MPL genes result in development of a rare bone marrow failure 
syndrome called congenital amegakaryocytic thrombocytopenia (CAMT) (Ballmaier and 
Germeshausen, 2009). 
Another receptor involved in regulation of hematopoiesis is FMS-like tyrosine 
kinase 3 (FLT3). It is expressed on early hematopoietic progenitor and stem cells and to a 
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lesser extent on B-cell committed progenitors (Brasel et al., 1995; Rosnet et al., 1996; 
Turner et al., 1996). Targeted disruption of the gene encoding this receptor, results in 
multiple hematopoietic abnormalities indicating a role for Flt3 in lymphoid 
differentiation, as well as in myeloid development. Specifically, Flt3-null mice have 
reduced number of B-cell progenitors and exhibit deficiency in reconstitution of T-cell 
and myeloid lineages by HSCs after transplantation (Mackarehtschian et al., 1995). FLT3 
promotes survival of early hematopoietic progenitors and, in cooperation with other 
factors, regulates proliferation (Rasko et al., 1995). FLT3 activating mutations are 
commonly found in AMLs and myelodysplastic syndromes (Yokota et al., 1997), while 
high expression levels of FLT3 are found in a variety of hematopoietic cancers, including 
AML, B- and T-ALL and chronic myeloid leukemia (CML) (Drexler, 1996; Rosnet et al., 
1996). 
As we have discussed above, hematopoiesis is regulated by cytokines, their 
corresponding receptors and TFs. Another layer of hematopoietic regulation was recently 
discovered due to identification of miRNAs (see below) and their function in gene 
expression regulation. Hundreds of miRNAs have been described that are involved in 
regulation of hematopoiesis-related genes. While a role of miRNAs in HSCs is not yet 
determined, a crucial role of miRNAs in lymphoid differentiation was shown by lineage-
specific ablation of Dicer that is a necessary effector of miRNA maturation (Koralov, 
2008; Muljo et al., 2005). Several miRNAs are involved in differentiation of both B- and 
T-cell lineages, including miR-150, miR-181, miR-17-92 and miR-146 (Havelange and 
Garzon, 2010). Regulation of differentiation in other lineages is also affected by 
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miRNAs. For example, miR-221 and miR-222 downregulate c-kit expression, thereby 
inhibiting erythroid differentiation in an in vitro assay and hematopoietic stem cell 
activity in a NOD-SCID mouse transplantation assay (Felli et al., 2005). The miR-17 
miRNA family targets expression of Runx1 TF (see below) and inhibits myeloid 
differentiation by failing to induce M-CSF receptor expression (Fontana et al., 2007). 
Recently an interesting feedback loop regulating both granulocytic and macrophage 
development was found involving downregulation of TF Nuclear factor I type A (NFI-A) 
by miR-223 (in granulocyte progenitors) or miR-424 (in macrophage progenitors). The 
miRNAs are in turn downregulated by NFI-A, but the downregulation is alleviated upon 
overexpression of C/EBPα or PU.1, correspondingly (Fazi et al., 2005; Rosa et al., 2007). 
This brief introduction into regulation of normal hematopoiesis introduced major 
players involved in the regulation (except for CBF transcription complex, see below). As 
we will show later, many of these players are deregulated in leukemia development. 
Core binding factor 
The Core Binding Factor (CBF) is a master regulator of hematopoietic development, 
maintenance and differentiation, in embryonic and adult hematopoiesis. CBF is a 
heterodimeric TF that consists of subunits called α and β (Kamachi et al., 1990). In 
mammals, the α-subunit is encoded by three alternative genes with high level of 
homology (over 90% identity at the amino acid level) called Runt-related transcription 
factors 1-3 (RUNX1, RUNX2 and RUNX3). The nomenclature of the CBF factors has 
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been confusing due to its history until the year 2004 when researchers from these fields 
working with the CBF proteins proposed a unified nomenclature in which the mammalian 
homologs of the Drosophila gene runt would be officially called RUNX1, RUNX2, and 
RUNX3, while the cofactor would remain with the name given in the developmental field 
as CBFB (van Wijnen et al., 2004). Henceforth, we will use the RUNX and CBFB 
nomenclature. 
Interaction between RUNX1 and CBFβ subunits is critical for CBF function 
(Wang et al., 1996b). The RUNX protein binds to the DNA consensus sequence 
YGYGGTY in promoters, enhancers and silencer regions (Wang and Speck, 1992). This 
binding is dependent on heterodimerization with CBFβ, as CBFβ increases RUNX 
affinity to DNA over five-fold (Golling et al., 1996; Wang et al., 1993), and protects it 
from proteasomal degradation (Huang et al., 2001).  
All three RUNX proteins share similar conserved domains with defined functions 
(Figure 1.2). The highly conserved Runt-homology domain (RHD) between amino acids 
50 and 177 is responsible for binding to DNA and CBFβ (Golling et al., 1996). The RHD 
also participates in RUNX binding a variety of cofactors. For example, the v-Ets avian 
erythroblastosis virus E26 oncogene homolog 1 (ETS1) TF binds to the RHD as RUNX1 
recruits it to the T-cell receptor α (TCRα) enhancer in T cells (Giese et al., 1995). The 
RHD also binds to and is methylated by a methyltransferase Suppressor of variegation 3-
9 homolog 1 (SUV39H1), which decreases RUNX1 affinity for DNA and, as a result, 
reduces its transactivation activity (Chakraborty et al., 2003). A similar competition is 
found in T-regulatory cells, as TF Forkhead Box P3 (FOXP3) binds to the RHD and  
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inhibits RUNX1 activation of IL-2 expression (Ono et al., 2007). 
Another regulatory domain of RUNX proteins is the Negative Regulatory 
regionfor DNA Binding (NRDB) between amino acids 177 and 291, which affects the 
DNA binding affinity of RUNX proteins and is positively regulated upon acetylation by 
the acetyltransferase p300 (Yamaguchi et al., 2004). The Transactivation Domain (TAD) 
between amino acids 291 and 371 is critical for RUNX binding to a variety of co-factors 
that modulate its transactivation capacity (Kanno et al., 1998). For example, the TAD 
interacts with the aforementioned the p300 (Kitabayashi et al., 1998), C/EBPα (Petrovick 
et al., 1998), Yes-associated protein (YAP) (Yagi et al., 1999), and MAD homologs 
(SMADs) (Pimanda et al., 2007). Studies using RUNX1 deletion constructs have 
identified an Inhibition Domain (ID) between amino acids 371 and 411, which inhibits 
both CBFβ binding and affinity of RUNX1 to DNA, although the specific amino acids 
involved and the mechanism of action is poorly understood (Gu et al., 2000; Kanno et al., 
1998). 
RUNX proteins can both activate and silence target gene expression, depending 
on the cell context. The interactions listed above highlight some mechanisms of RUNX 
mediated transactivation. RUNX proteins can also repress the expression of target genes 
by interacting with mSin3A co-repressor via the RHD and NRDB (Imai et al., 2004; 
Satoh et al., 2008a) or with the Transducing-like Enhancer of Split 1-4 (TLE1-4) co-
repressors on the RUNX C-terminal end amino acid VWRPY motif (Imai et al., 1998; 
Javed et al., 2000; Levanon et al., 1998). 
The transport of CBF from the cytoplasm to the regulatory DNA regions is 
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regulated by two main RUNX domains: the Nuclear Localization Signal (NLS; amino 
acids 178-187) is essential for the translocation of CBF complex into the nucleus, and the 
Nuclear matrix targeting signal (NMTS; amino acids 346-387) acts on the transport of 
CBF into the RUNX1 nuclear foci (Harrington et al., 2002; Tang et al., 1999; Zeng et al., 
1998; Zeng et al., 1997). This localization is functionally critical for activity of RUNX 
proteins in myeloid and lymphoid tissues (Telfer et al., 2004; Vradii et al., 2005). The 
nuclear localization of RUNX1 is also affected by a number of mechanisms, resulting in 
inhibition of RUNX function. For example, the three RUNX factors bind to Signal 
transducer and activator of transcription 5 (STAT5) with their RHD, which inhibits their 
nuclear transport (Ogawa et al., 2008). Interestingly, this interaction seems to have a 
mutual negative effect because it also inhibits STAT5 transactivation function on 
expression of its target, the Cytokine-inducible SH2 protein-1 (CIS3). 
Finally, RUNX activity is positively regulated by phosphorylation at multiple 
sites by several kinases. For example, the Extracellular signal-regulated kinase (ERK) 
potentiates RUNX-mediated transactivation by phosphorylating serines 249 and 266 
(Tanaka et al., 1996), and Proviral integration site 1 (PIM-1) kinase provides a similar 
effect by phosphorylating serine 307 (Aho et al., 2006). 
Contrary to the complexity in RUNX structure and protein organization, the 
organization and interactions of the 21 kD CBFB protein seems to be relatively simple. 
The CBFβ is encoded in three isoforms by alternative splicing, resulting in 187, 182, and 
155 amino acid proteins, respectively (Ogawa et al., 1993). The CBFβ187 and CBFβ182 
are thought to be functional, as these maintain an intact RUNX binding domain, its only 
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known domain. Deletion of this domain abrogates CBF function due to absence of CBFβ 
binding to RUNX1 (Golling et al., 1996). In addition to RUNX binding, CBFβ was 
shown to associate with Filamin A, which inhibits CBFβ association with RUNX1 and 
prevents its nuclear transport due to retention in lipid rafts of the cell membrane (Yoshida 
et al., 2005). Recently, the U-three protein 3 (UTP3), a member of the rRNA-processing 
small subunit processome, was reported to bind to CBFβ and direct its localization to the 
nucleus via an unknown mechanism (Park et al., 2009). 
The CBF complex is essential for embryonic definitive hematopoiesis. Studies 
using Cbfb and Runx1 knock-out (KO) mice showed an absence of definitive 
hematopoiesis and embryonic death at 12.5 days post conception (d.p.c.) due to severe 
hemorrhages, (Okuda et al., 1996; Sasaki et al., 1996; Wang et al., 1996a). This critical 
role of Runx1 in establishment of definitive hematopoiesis was shown in vitro at the 
hemangioblast stage (Lacaud et al., 2002). The fetal liver HSCs originate from the VE-
cadherin+ endothelium at day 10.5 d.p.c. (Zovein et al., 2008), and studies by Speck‟s 
group demonstrated that Runx1 is required in endothelial cells on the ventral side of the 
dorsal aorta for the formation of the hematopoietic clusters and emergence of the HSCs 
(Chen et al., 2009). This critical role of Runx1 seems to be defined within two days (9.5 
to 11.5 d.p.c.) of embryo development, and Runx1 may be dispensable thereafter. 
Differentiation studies of 9.5 d.p.c. Runx1-null progenitors from the para-aortic 
splanchnopleural region showed a rescue in differentiation in cells transduced with 
Runx1 (Goyama et al., 2004) while this rescue failed in 11.5 d.p.c. Runx1-null progenitor 
cells from the aorta-gonads-mesonephros (AGM) region (Mukouyama et al., 2000). 
19 
Similarly, definitive hematopoiesis is blocked when Runx1 is deleted using the vascular 
endothelial cadherin Cdh5 promoter driven-Cre transgene but not when using the Vav1-
Cre transgene, expressed later in the fetal liver hematopoietic progenitors around day 
11.5 d.p.c. (Chen et al., 2009). To date it is unclear whether Runx1 function ceases after 
fetal HSCs develop, or expression of other Runx proteins (Runx2 or Runx3) may 
compensate for Runx1 deficiency in regulation of its target genes. 
In adult hematopoiesis, Cbfb or Runx1 expression is not essential for maintenance 
of hematopoietic differentiation (Growney et al., 2005; Ichikawa et al., 2004). Instead, 
conditional deletion of Runx1 and graded reduction of Cbfb have identified subtle defects 
in specific hematopoietic compartments, highlighting a lineage specific differential 
sensitivity for CBF function (Talebian et al., 2007). 
In the HSC compartment, loss of the Runx1 gene results in a moderate expansion 
of the HSC pool and a mild reduction of long-term HSC reconstitution (Ichikawa et al., 
2004; Jacob et al., 2010; Sun and Downing, 2004). This expansion could be attributed to 
direct regulation of proliferation by Runx1, as Runx1-null HSCs exhibited higher levels 
of expression of Bmi-1 and B cell lymphoma 2 (Bcl2, a negative regulator of apoptosis) 
genes (Motoda et al., 2007). RUNX1 could also affect cell cycle progression of HSCs 
due to direct regulation of cell cycle regulators p21 (Lutterbach et al., 2000) and cyclins 
D (CCND) (Bernardin-Fried et al., 2004), although in this case loss of Runx1 would be 
expected to lead to decreased cycling of HSCs, as recently suggested (Ichikawa et al., 
2008). Importantly, Runx1 also affects HSCs in their ability to interact with their niche 
by downregulating expression of a C-X-C chemokine receptor type 4 (CXCR4) (Jacob et 
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al., 2010), therefore providing another potential mechanism of regulation of HSC 
quiescence, cell cycle and differentiation. 
Several abnormalities were also found in lymphoid differentiation in the absence 
of normal CBF function. Reduced or absent function of either CBFB or RUNX1 genes 
resulted in impaired differentiation of T-cells with partial block at early double negative 
(DN) stages and decreased percentage of common lymphoid progenitors (CLP). Further 
studies identified CD4 (Nishimura et al., 2004) and GATA-3 (Komine et al., 2003) as 
some of the main targets of RUNX1 and RUNX3 in T-cell differentiation, implicating 
both RUNX proteins in regulation of T-cell development at two distinct stages (DN and 
CD8 single positive (Taniuchi et al., 2002)). B-cell development was also affected in 
conditional Runx1 KO or Cbfb hypomorphic mice, but to a lesser extent, resulting in 
decreased percentage of B-cell progenitors, and inability to repopulate B220+ cell 
compartment in competitive repopulation assays (Growney et al., 2005; Ichikawa et al., 
2004; Talebian et al., 2007). 
A significant difference between the Cbfb and Runx1 genes was observed in 
monocyte/granulocyte differentiation, as it was almost undisturbed in Runx1 conditional 
KO model, but reduction of Cbfb dosage resulted in 10-20-fold decrease in myeloid cells 
in fetal liver. The residual cells were enriched in immature monocytic progenitors, while 
mature bands and segmented neutrophils were not observed. This difference suggests that 
loss of Runx1 activity may be compensated by other Runx family members in the myeloid 
development (Ichikawa et al., 2004; Talebian et al., 2007). It is also noteworthy that 
Runx1 conditional KO mice exhibited a mild, but significant myeloproliferative 
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phenotype and myeloid extramedullary hematopoiesis (Growney et al., 2005). 
Studies have also revealed critical roles for CBF in megakaryocytic maturation. 
Loss of Runx1 or Cbfb genes resulted in lower number of platelets and, in case of Cbfb, 
appearance of abnormal small megakaryocytes (Ichikawa et al., 2004; Talebian et al., 
2007). Data suggest that the effect of Runx1 on megakaryocytic maturation may be due 
to physical interaction and functional cooperation between Runx1 and GATA-1 (Elagib 
et al., 2003). 
Taken together, CBF is an essential regulator of definitive hematopoiesis and is 
required for HSC emergence in the fetus and establishment of definitive hematopoiesis. It 
also plays multiple roles in differentiation of all hematopoietic lineages at different 
stages, with probably the exception of the erythroid lineage. 
Acute myeloid leukemia 
Acute myeloid leukemia is a diverse disease characterized by abnormal expansion and/or 
differentiation of hematopoietic progenitors. It arises as a result of genetic mutations that 
alter proliferation, survival and differentiation programs in the hematopoietic progenitor 
cells.  
The classification of AML is complex due to the diversity of cytology, clinical 
prognosis, and genetic diversity. Two main classifications for AML have been defined 
over the years. The earliest was designed by a French-American-British cooperative 
group (FAB) in 1976, and was based on cytological and cytochemical criteria assessing   
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lineage of origin of leukemic cells and stage of differentiation block. The AMLs were 
divided into 8 groups from M0 to M7 with later groups presenting more differentiated 
cells than the earlier ones (Table 1.1). 
Later findings confirmed the relevance of the FAB classification for disease 
prognosis. For example, the AML-M0 subtype had a significantly lower rate of complete 
remission (CR) and overall survival (OS) than other types (Stasi et al., 1994), while AML 
subtype M3 cases presented a significantly higher CR and OS rates (Bennett et al., 1991). 
Moreover, cytogenetic studies of genetic aberrations involved in AML (including 
karyotype changes or mutations in individual genes) showed some correlation between 
identified common mutations and FAB subtypes. For instance, an inversion of 
chromosome 16 [inv(16)] was found in all cases included in M4Eo subtype (acute 
myelomonocytic leukemia with abnormal eosinophils) (Larson et al., 1986; Solé et al., 
1992), and genomic rearrangements involving a gene encoding retinoic acid receptor α 
(RARα) completely defined M3 subtype (acute promyelocytic leukemia) (Borrow et al., 
1994; Tong et al., 1992), whereas the majority of cases within the M2 subtype carry the 
t(8;21)(q22;q22) chromosome translocation (Oshimura et al., 1982; Takeuchi et al., 
1981). However, it was clear that in many cases FAB classification failed to distinguish 
between borderline cases, and prognostic values of AMLs classified according to other 
criteria (genomic rearrangements, secondary AMLs) were higher than those of the 
original M0 – M7 subtypes. 
Later, identification of recurrent genetic abnormalities (chromosomal 
rearrangements and genetic mutations) resulted in definition of new, clinically relevant 
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AML subtypes that only partially correlated with the FAB subtypes. Additionally, 
clinical and biological differences between myelodysplastic syndromes (MDS)-related 
and MDS-unrelated AMLs was recognized, as well as between primary and therapy-
related AMLs (Vardiman et al., 2002). These differences could not be adequately 
reflected in the FAB classification. In order to accommodate the body of new research, 
the World Health Organization (WHO) introduced a new leukemia classification that was 
revised several times, last time in 2008 (Jaffe, 2009; Vardiman, 2010; Vardiman et al., 
2002; Vardiman et al., 2009). This classification is not limited to cytological or 
cytochemical characteristics of the cells, but was designed to include all currently 
available information, including morphology, cytochemistry, immunophenotype, 
genetics, and clinical features (Vardiman et al., 2009) in order to define clinically 
relevant diseases. 
The latest WHO classification includes a number of entities that are defined by 
the common genomic rearrangements rather than other cellular characteristics. Two 
provisional entities were included that are defined based on mutations in 
CCAAT/enhancer binding protein α (CEBPA) and nucleophosmin (NPM1) genes. 
Although FLT3 mutations did not define a separate category, screening was 
recommended due to their profound effect on prognosis. Separate entities include 
myeloid neoplasms with therapy-related changes, as they have significantly different CR, 
OS and response to treatment. Another interesting change was the introduction of a 
separate group for myeloid proliferations related to Down syndrome that are often 
associated with mutated GATA-1. As for not otherwise specified AMLs (AML, NOS),  
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they generally incorporate FAB classification based on stage of maturation of myeloid 
leukemia cells (Table 1.2). 
It has been acknowledged that these classifications are useful for research and 
clinical purposes, but they are far from ideal because they may not in all cases include 
diseases that are clinically significant, mutually exclusive and diagnosable with currently 
available technologies (Vardiman, 2010). Clinical significance means that when a 
diagnosis is identified, it should dictate an optimal treatment that leads to the best 
prognosis possible for the disease. Therefore, response to treatment and accuracy of 
prognosis are very important in the significance of a classification. 
Recently advances on the molecular characterization of AML provide valuable 
information on the expression signature of leukemias, which may further refine the 
current AML classifications. Examples are the expression profiling studies identifying 
either microRNA expression (Jongen-Lavrencic et al., 2008; Li et al., 2008), gene 
methylation (Bullinger et al., 2010; Figueroa et al., 2010) or gene expression profiling 
(GEP (Haferlach et al., 2005; Neben et al., 2004; Song et al., 2006; Valk et al., 2004c; 
Wilson et al., 2006)) in panels of AML. Some microarray studies focused on particular 
AML subtypes and refined them into additional categories (Bullinger et al., 2007; Silva et 
al., 2009). The classifications based on the microarray data correlate with WHO entities 
and identify new clusters that are novel. Importantly, in many cases the identified clusters 
of AML samples were shown to be clinically relevant due to specific prognostic 
characteristics (Radmacher et al., 2006; Wilson et al., 2006). The advantages of GEP 
classifications are that (1) they are quantitative and unbiased, and (2) they identify the 
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molecular characteristics of a disease, allowing putatively tailored approaches to 
treatment. The limitations of expression profiling classification include the high cost and 
requirement of special technology, precluding its routine use in hospital settings. 
Treatment of AML 
The treatment for AML is in most cases independent of the subtype, and has followed a 
similar treatment regime for several decades. The first standard treatment step in AML is 
called induction therapy with the goal of reducing the number of leukemic cells, and 
usually includes chemotherapy with cytosine arabinoside (also called Cytarabine or Ara-
C) and anthracyclines. Cytarabine is a pyrimidine nucleoside analogue with an arabinose 
sugar moiety instead of a ribose. It was first shown to inhibit tumor cell growth in 1961 
(Evans et al., 1961) and approved by the Food and Drug Administration in 1969 as a drug 
for treatment of AML (www.fda.gov). The main role of Cytarabine is to compete with 
the cytidine nucleotide to be incorporated into the new DNA strand during S-phase of cell 
cycle, stalling DNA replication and blocking its transition into mitosis.  
The anthracyclines doxorubicin and daunorubicin were first isolated from the 
bacteria Streptomyces sp. and shown to act as antineoplastic drugs in the 1960‟s and 
placed into clinical protocols with very effective outcome (Arcamone et al., 2000; 
Cassinelli and Orezzi, 1963; Dubost et al., 1963; Grein et al., 1963). It is thought that 
anthracyclins act as DNA intercalators, causing single stranded DNA breaks and 
apoptosis (Laurent and Jaffrézou, 2001). The use of these antibiotics has the limitations 
of (1) showing significant side effects when used in patients when administered 
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chronically or at high doses (chronic cardiomyopathy and congestive heart failure), and 
(2) spontaneous and acquired resistance. However, they are still used today in the 
treatment of a variety of cancers, including AML. 
After the induction therapy, AML patients usually undergo a consolidation phase 
to further reduce the number of leukemic cells, and achieve a complete remission. The 
drug of choice is usually Cytarabine, and depending on the AML subtype complete 
remission can be achieved in approximately 64% of cases (Hamadani and Awan, 2010). 
The next step in standard AML treatment is called post-remission therapy and is aimed at 
complete eradication of the disease. Post-remission therapy has more options and is 
assessed based on a prognosis for a particular disease. The options include a low-dose 
maintenance therapy, intensive chemotherapy and hematopoietic stem cell transplantation 
(Rowe, 2009). 
The most promising treatment approaches are molecularly targeted therapies, but 
their feasibility and efficiency vary between AML subtypes and for specific mutations 
found in samples (Hamadani and Awan, 2010). One prominent example is treatment of 
acute promyelocytic leukemia (APL) that in majority of cases carries PML-RARA fusion 
gene. As RARA encodes a receptor for retinoic acid, treatment of APL with all-trans 
retinoic acid or similar chemicals proved to be a very efficient treatment regimen, and it 
is now a standard treatment for APL (Hu et al., 2000; Jeddi et al., 2010; Liu et al., 
2010b). 
Other examples of targeted molecular treatment include treatment of chronic 
myeloid leukemia carrying BCR-ABL fusion gene with RTK inhibitor imatinib 
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(Buchdunger et al., 1996; Druker et al., 2001; le Coutre et al., 1999), AML treatment with 
c-KIT inhibitors (Faderl et al., 2009) and specific FLT3 inhibitors (Pratz and Levis, 
2010). Activating mutations in FLT3 RTK (internal tandem duplications (ITD) or 
tyrosine kinase domain (TKD) mutations) are found in 30% of AMLs and commonly are 
associated with poor prognosis. They are not associated with any particular subtype of 
AML (Nakao et al., 1996; Schnittger et al., 2002). Inhibition of aberrant activation of 
FLT3 seems to be a good strategy, but currently the results are not clearly positive due to 
mechanisms of resistance that include effects of other mutations in the same AML, 
resistance mutations in FLT3 kinase domain and activation of compensatory signaling 
pathways (PI3K/AKT and MAPK) (Pratz and Levis, 2010). 
A promising strategy for cancer treatment (including leukemia and specifically 
AML) is the use of rapamycin and rapamycin analogs (rapalogs) for inhibition of 
Mammalian target of rapamycin (mTOR), one of the main effectors of PI3K/AKT 
pathway (see below), alone or in combination with other inhibitors (Chapuis et al., 
2010b; Martelli et al., 2007). Potential molecular feedback loops make this treatment less 
efficient than could be presumed. For example, mTORC1 complex that is a target of 
rapamycin inhibition, exists in a dynamic equilibrium with mTORC2 complex that is 
largely resistant to rapamycin (see below). mTORC2 activates PI3K/AKT pathway by 
phosphorylation of AKT, therefore treatment with rapamycin or rapalogs can result in a 
PI3K/AKT-activating feedback loop by shifting the equilibrium towards mTORC2. 
Another possible mechanism of rapamycin resistance is based on mTORC1-depedent 
indirect inhibition of PI3K subunit p110 (see below). Inhibition of mTORC1 activity with 
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rapamycin can, therefore, lead to activation of PI3K and its downstream pathway 
(Tamburini et al., 2008). Additional inhibitors targeting Tuberous sclerosis protein 1 and 
2 (TSC1 and TSC2), mTOR itself (rather than as part of mTORC1 complex), and 
combinations of rapalogs with other PI3K/AKT pathway inhibitors should help in 
increasing efficiency of mTOR targeting (Chapuis et al., 2010a; Park et al., 2008). 
CBF-related hematopoietic neoplasias 
Approximately 20-25% of AML cases are associated with genomic alterations involving 
CBFB or RUNX1 genes (Look, 1997). Specifically, 12% of cases of AML have 
chromosomal inversion inv(16)(p13q22), disrupting the CBFB gene and fusing it in-
frame with the second half of the Myosin heavy chain 11 (MYH11) gene that encodes the 
Smooth muscle myosin heavy chain (SMMHC) protein. The resulting gene is called 
CBFB-MYH11, and its encoded fusion protein is called CBFβ-SMMHC (Liu et al., 
1993). In 12% of AML cases the translocation t(8;21)(q22;q22) results in the creation of 
the RUNX1-ETO fusion gene that fuses RUNX1 in exon 5 with Eight twenty one (ETO, 
also known as RUNX1T1) gene starting from exon 2 (Rowley, 1973). In addition to these 
rearrangements, AML samples can also harbor point mutations in RUNX1 that create a 
protein with dominant negative or hypomorphic function (Schnittger et al., 2011; Silva et 
al., 2009). 
By FAB classification, 68% of cases associated with the CBFB-MYH11 fusion 
gene fall into M4Eo group, while 20% are M4 and 12% are M2 (Marcucci et al., 2005; 
Schnittger et al., 2007a). There are rare cases of myelodysplastic syndrome and chronic 
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myeloid leukemia crisis also associated with CBFB-MYH11 expression (Tirado et al., 
2010), but these are temporary conditions that lead to development of AML. More than 
90% of the M4Eo cases carry an abnormality that leads to CBFB-MYH11 expression, 
whether it is inv(16), t(16;16) or del(16)(q22) (Hernandez et al., 2000; Pirc-Danoewinata 
et al., 2000). However, the fusion transcript CBFB-MYH11 has been detected in all M4Eo 
cases tested, suggesting the presence of micro-rearrangements in some cases. Since the 
the presence of the CBFB-MYH11 fusion in AML samples is unique at the molecular and 
clinical levels, the WHO classification defined it as a separate AML subtype (Vardiman, 
2010). The CBFB-MYH11-expressing AML subtype is considered to have a favorable 
prognosis, with CR rate around 90% and OS rate around 50% (Appelbaum et al., 2006; 
Delaunay et al., 2003; Marcucci et al., 2005). The CR and OS rates were lower in older 
patients, patients with complex genotype and high white blood cell (WBC) counts 
(Appelbaum et al., 2006). 
AML cases in M4Eo group are characterized by myeloblastic and/or monoblastic 
infiltration into BM, elevated monocytic counts in peripheral blood (PB), and the 
presence of atypical eosinophils in both BM and PB. The eosinophil population usually 
accounts for 5% or more of white blood cells and carries the inv(16), being therefore part 
of the leukemic population and not a secondary change in AML (Haferlach et al., 1996). 
Immunophenotype of the leukemic cells is somewhat heterogeneous, and while all AML 
cells express pan-myeloid CD13 marker, they are also partially positive for 
monocytic/myeloid markers CD11b, CD11c, CD14, CD33, marker of immature cells 
CD34 and a multilineage hematopoietic marker CD36. Surprisingly, some cells co-
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expressed lymphoid CD2 marker together with the mentioned above myeloid markers, 
indicating either abnormal differentiation or a modified gene expression pattern. In vitro 
experiments indicated that the AML cells exhibit high spontaneous proliferation 
(Adriaansen et al., 1993). Taken together, the data from human patients suggest that 
CBFB-MYH11 causes development of AML with partial abnormal differentiation into 
monocytic/myeloid lineage with small populations keeping expression of early 
hematopoietic stem/progenitor markers. 
A majority (91%) of AML cases associated with the fusion gene RUNX1-ETO are 
in the FAB subtype M2, while only 6% are in the less differentiated subtype M1 and 3% 
in the more differentiated subtype M4 (Marcucci et al., 2005). The WHO classification 
defines a separate subtype based on the presence of t(8;21) translocation expressing 
RUNX1-ETO. The AML subtype is considered to have a favorable prognosis, but the OS 
rate is lower in the RUNX1-ETO-related AMLs than in CBFB-MYH11-related AMLs 
(Appelbaum et al., 2006; Marcucci et al., 2005), being around 45%. The risk factors were 
similar to those for CBFB-MYH11 subtype: age, WBC count, complex genotype with 
additional genomic alterations. Race was an additional factor that was not found 
significant in CBFB-MYH11 AML subtype, but was significant for OS of patients with 
RUNX1-ETO AMLs (Marcucci et al., 2005). 
Morphologically, the RUNX1-ETO-carrying leukemic cells are immature 
basophilic myeloid cells that expressed myeloperoxidase and represented abnormal 
granulocytic development (Andrieu et al., 1996; Kita et al., 1994). The variable pattern of 
immunophenotypical markers shows that it is unreliable to determine a specific 
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immunophenotype of the AML cells, but CD19 and CD34 overexpression was shown to 
be a common feature of the AML populations with RUNX1-ETO expression (99% of the 
samples overexpressed the markers with specified thresholds). Conversely, CD7 and CD2 
are rarely expressed. Although their expression varies, CD56 and CD54 were 
overrepresented, whereas CD45R0, CD33, CD36, CD11b and CD14 were expressed less 
than in control (Andrieu et al., 1996; Gustafson et al., 2009; Kita et al., 1994). Taken 
together, these data show the AML cells as a mixture of myeloid blasts and maturing 
myeloid cells. 
Other hematopoietic disorders involving CBF genes include a subtype of AML 
with minimal differentiation that carries RUNX1 mutations (Schnittger et al., 2011; Silva 
et al., 2009) and familial platelet disorder (FPD) – a hereditary disease that is associated 
with haploinsufficiency of RUNX1 (Buijs et al., 2001; Kirito et al., 2008; Song et al., 
1999). FPD patients frequently develop AMLs that often harbor additional RUNX1 
mutations including loss of heterozygocity (LOH) for RUNX1 (Preudhomme et al., 2009). 
Molecular functions of CBFB-MYH11 
Due to a prominent role that the CBFB-MYH11 fusion gene plays in human AML, it was 
thoroughly studied in cell lines and animal models. The main questions asked about this 
fusion were: what is its role in regulation of proliferation, apoptosis and differentiation in 
hematopoietic lineages; what are the specific molecular activities and pathways involved 
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in CBFB-MYH11-associated leukemogenesis; are there functional differences and 
interactions between CBFβ-SMMHC and wild type CBF complex components? 
Studies performed in Cbfb+/MYH11 knock-in mice suggested that the fusion protein 
acted as a dominant negative factor over wild type CBF function. Indeed, heterozygous 
expression of the fusion gene under transcriptional control of the Cbfb promoter resulted 
in the absence of definitive hematopoiesis after embryonic day 10.5 post conceptus 
(d.p.c.), severe hemorrhages in the dorsal root ganglia, and death around d.p.c.12.5, 
recapitulating the phenotype of the homozygous Cbfb-/- and Runx1-/- KO mice (Castilla et 
al., 1996; Kundu et al., 2002; Okuda et al., 1998; Yergeau et al., 1997). Importantly, 
embryonic stem (ES) cells expressing the fusion protein failed to contribute to 
hematopoiesis in chimeric embryos despite high level of chimerism (over 70%), and they 
did not produce hematopoietic colonies in vitro, further confirming a block in definitive 
hematopoiesis caused by dominant negative function of Cbfβ-SMMHC. The dominant 
inhibition of myeloid differentiation by the fusion protein was confirmed in vitro in ES 
cells that failed to produce mature myeloid cells, instead producing immature myeloid 
blasts in the presence of Cbfbβ-SMMHC (Miller et al., 2001). 
Besides recapitulation of Cbfb KO phenotype, Cbfb+/MYH11 knock-in embryos also 
presented a distinct phenotypic trait, as majority of primitive erythroid cells in the knock-
in embyos also presented a delay in primitive (erythroid) hematopoiesis at 11.5 d.p.c. 
This delay was not observed in Cbfb-/- embryos, suggesting that the fusion gene may have 
other activities besides dominant inhibition of CBF (Castilla et al., 1996). 
The mechanism by which Cbfβ-SMMHC represses CBF function and induces 
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leukemogenesis is unclear. Two main models have been proposed: The sequestration 
model proposes that the fusion protein forms dimers and oligomers, and is localized in 
the cytoplasm, associated with the actin filaments. RUNX1 binds to the fusion protein at 
higher affinity than to CBFβ, thereby sequestering RUNX1 from the nucleus and the 
regulatory regions if the target genes (Adya et al., 1998; Kanno et al., 1998). This model 
is based on in vitro studies showing that CBFβ-SMMHC binds RUNX1 with higher 
affinity than wild type CBFβ due to the presence of a high affinity binding domain 
(HABD) found in CBFβ-SMMHC (Lukasik et al., 2002). This affinity imbalance is 
abrogated in the presence of DNA, probably because RUNX1 binding site responsible for 
the high-affinity interaction specifically with CBFβ-SMMHC is also involved in DNA 
binding (Lukasik et al., 2002). It was also shown that the fusion protein oligomerizes into 
large structures that supposedly sequester RUNX1 from its target promoters (Adya et al., 
1998; Huang et al., 2004; Wijmenga et al., 1996). The ability of CBFβ-SMMHC to form 
oligomeric structures depends on an Assembly competence domain (ACD) (Zhang et al., 
2006b) located in SMMHC (Figure 1.4A). Recently, the sequestration model has been 
challenged by the observation that a knock in mouse carrying a sequence of the fusion 
gene lacking the HABD region does not abrogate leukemia development but rather 
accelerates the disease (Kamikubo et al., 2010). 
The competing repression model proposes that the CBFβ-SMMHC:RUNX1 
heterodimer directly represses expression of target genes (Lutterbach et al., 1999). This 
model is based on the observation that the fusion protein can be found in the nucleus and 
associates with RUNX1 and a co-repressor mSin3A in transfection assays. A defined 
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Repression domain (RD) is required for the repression of gene expression (Lutterbach et 
al., 1999). Considering that RUNX1 is expressed at low levels, and that overexpression 
of CBFβ-SMMHC is toxic and may result in cellular mislocalization, the appropriate 
studies that can unequivocally establish the mechanism of action has proven challenging. 
Of note, the observation that the HABD loss accelerates AML development, raises a 
possibility that the leukemogenic role of CBFβ-SMMHC is not limited to a dominant 
negative inhibition of CBF function (via either sequestration or repression mechanisms). 
The fusion protein could be involved in gene regulation via RUNX-independent 
mechanisms. Chromatin immunoprecipitation microarrays for mouse or human promoter 
regions could determine whether CBFβ-SMMHC is associated with promoters that are 
not targets of RUNX1. 
Expression of the fusion protein in Cbfb-MYH11 chimeric mice showed to be 
present in HSCs but not in peripheral white blood cells, suggesting that the fusion protein 
induces a differentiation block in the bone marrow (Castilla et al., 1999). Lymphoid 
differentiation defects were detected in the CLP to pre-pro B cells transition (Kuo et al., 
2008) and in the double negative T cell progenitors (Zhao et al., 2007). Expression of 
CBFB-MYH11 from human myeloid-restricted Myeloid-related protein 8 (hMRP8) 
promoter showed only mild impairment of myeloid differentiation suggesting that the 
block in myeloid differentiation occurs in earlier hematopoietic progenitors (Kogan et al., 
1998). 
Expression of CBFB-MYH11 in chimeric mice did not result in leukemia 
development within the first year of life. When the mice were treated with N-ethyl-N-
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nitrosourea (ENU), a potent mutagen, they developed a disease that recapitulated AML 
with inv(16)(p13.1q22) (M4Eo by FAB classification). High WBC counts, infiltration of 
the leukemic cells into spleen and other peripheral organs and well as presence of 
abnormal granulocytes were evident in the mice (Castilla et al., 1999). Therefore, CBFB-
MYH11 is not sufficient for AML development that requires additional genetic mutations 
to occur in the mouse model. 
The understanding of CBFB-MYH11 AML function benefited from the generation 
of a conditional inducible knock-in mouse, which bypassed the embryonic lethality 
associated with the fusion gene expression and allowed the expression of CBFB-MYH11 
in the adult HSCs (Figure 1.3 (Kuo et al., 2006)). Examination of the hematopoietic 
progenitor compartment in these mice revealed an impaired ability of HSCs for 
multilineage repopulation, but did not affect HSC maintenance. Importantly, an abnormal 
myeloid progenitor (AMP) population accumulates in the myeloid compartment of BM, 
with MEP-like immunophenotype (lin-c-kit+Sca1-CD34-FcgRII/III-) and CMP-like in 
vitro differentiation potential. Limiting dilution transplantations showed that both HSCs 
and AMPs could give rise to leukemia with similar efficiency and latency, indicating that 
the AMPs as well as HSCs contain leukemia-initiating cells. Together, these studies 
suggest that HSCs expressing CBFβ-SMMHC undergo partial differentiation to create a 
myeloid leukemia precursor that induces leukemia in cooperation with additional 
mutations. These findings are in concordance with the “two-hit hypothesis” posed by 
Gary Gilliland (Deguchi and Gilliland, 2002; Kelly and Gilliland, 2002a). This 
hypothesis postulates that at least two mutations are necessary for AML to develop: a  
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mutation that confers pro-survival and/or pro-proliferative advantage to the abnormal 
progenitor cell (class I mutation) and a mutation that blocks normal differentiation of a 
hematopoietic lineage (class II mutation), allowing proliferation and accumulation of 
leukemic cells. This hypothesis is useful for explaining various aspects of AML 
progression, although simplistic because some mutations can have functions from 
bothclasses and still required additional mutations for transformation, like the RUNX1-
ETO fusion protein (see below). According to this hypothesis, CBFB-MYH11 can be 
classified as a classic class II mutation because it does not provide self-renewal or 
proliferative advantage but induces a differentiation block. The search for the cooperating 
mutations both in human and mouse AMLs resulted in identification of a number of 
cooperating class I mutations, among which in human AMLs were c-KIT, FLT3, and N- 
and K-RAS mutations (see below). Using the conditional Cbfb+/MYH11 knock-in mice our 
laboratory has identified the cooperating genes Pleomorphic adenoma gene-like 2 
(PlagL2) (Landrette et al., 2005), Runx2 (Kuo et al., 2009) and Myeloproliferative 
leukemia virus oncogene (Mpl) (Landrette et al., 2011), as well as other potential 
oncogenes (Castilla et al., 2004). 
Despite the intensive research, the mechanism(s) of CBFB-MYH11-mediated 
transformation remains unclear. In addition to blocking CBF function, it is possible that 
inv(16) AML samples may have other genetic alterations that contribute to leukemic 
transformation. For example, the inv(16) rearrangement invariably breaks in half the gene 
Nude nuclear distribution gene E homolog 1 (NDE1) transcribed from the inverse strand 
of the MYH11 gene, resulting in decreased expression of NDE1 transcript (Van der 
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Reijden et al., 2010). NDE1 is a scaffold protein known to control self-renewal and 
differentiation of cortical neuron progenitors (Pawlisz et al., 2008), suggesting that 
reduction in NDE1 expression may contribute to inv(16) leukemogenesis. Of note, Nde1 
expression is not altered in the Cbfb+/MYH11 knock in mice, and its participation in 
transformation has not yet been directly tested. 
CBFβ-SMMHC may also have CBF-independent roles in leukemia development. 
Based on the observation that primitive hematopoiesis is delayed in Cbfb+/MYH11, but not 
in Cbfb-/- embryos (Castilla et al., 1996), recent studies identify that Cbfβ-SMMHC, but 
not Cbfβ, upregulates expression of Csf2b2 and Gata2 during primitive hematopoiesis. 
These genes are also expressed in the inv(16) human AML-derived ME-1 cell line (Hyde 
et al., 2010). However, whether these genes play a role in leukemia development is 
unclear. 
Molecular functions of RUNX1-ETO 
The the t(8;21) fusion protein RUNX1-ETO also affects CBF function and causes AML 
in humans and in mouse models. It has been extensively studied in cell and mouse 
models in order to determine its effect on normal hematopoiesis and mechanisms of 
leukemic transformation. In some aspects this fusion proved to be similar to CBFβ-
SMMHC, but there are important biological differences as well. 
Similarly to CBFB-MYH11, a knock-in mouse model for RUNX1-ETO 
recapitulated the embryonic lethal phenotypes of Cbfb-/- and Runx1-/- mice, prompting a 
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conclusion that RUNX1-ETO functions as a dominant negative inhibitor of the CBF 
complex (Okuda et al., 1998; Yergeau et al., 1997). Unlike a complete failure to produce 
hematopoietic progenitors in CBFB-MYH11 knock-in embryos, it was possible to obtain 
a few progenitor cells from fetal livers of embryos expressing RUNX1-ETO at 11.5 d.p.c. 
These progenitors did not undergo normal hematopoietic differentiation, but rather 
proliferated in vitro in a cytokine-dependent manner, giving rise to abnormal erythroid, 
megakaryocytic and myeloid cells. Serial replating assays revealed that while erythroid 
and megakaryocytic progenitors exhausted their self-renewal capacity, the myelo-
monocytic progenitors displayed enhanced replating ability and readily immortalized into 
cytokine-dependent cell lines (Okuda et al., 1998). This increased in vitro self-renewal 
capacity of RUNX1-ETO-expressing myeloid progenitors was later confirmed in BM 
transplantations of progenitors transduced with a RUNX1-ETO retrovirus (de Guzman et 
al., 2002a). 
Using conditional Runx1-ETO knock-in mouse model it became possible to 
bypass the embryonic lethality phenotype and determine the role of Runx1-ETO in adult 
hematopoiesis. Studies in these mice further confirmed that the fusion protein confers 
increased proliferation and self-renewal capabilities to myeloid progenitors in vitro 
without complete abrogation of myeloid differentiation (Higuchi et al., 2002; Rhoades et 
al., 2000). 
The conditional RUNX1-ETO knock-in mice did not develop any hematopoietic 
abnormalities within the first 11 months of life despite high representation of RUNX1-
ETO-expressing cells in BM and PB, although by the end of their first year 10% of mice 
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developed lymphoma (Higuchi et al., 2002). However, 47% of these mice developed 
hematopoietic neoplasms 2-10 months after treatment with a chemical mutagen ethyl-
nitrosourea. Thirty three percent of affected mice developed T cell lymphomas, probably 
unrelated to the fusion protein (Higuchi et al., 2002). The remaining mice developed 
granulocytic sarcomas/AMLs similar to what is observed in patients that express 
RUNX1-ETO fusion protein (Byrd et al., 1997; Tallman et al., 1993). Similar results 
were obtained with a transgenic RUNX1-ETO mouse model where expression of the 
fusion gene was driven by hMRP8 promoter, restricting RUNX1-ETO expression to the 
myeloid compartment (Yuan et al., 2001a). Taken together, these studies provide 
evidence that RUNX1-ETO is an oncogene that predisposes mice to development of AML 
in cooperation with other mutations. While in some studies RUNX1-ETO provides a 
maturation deficiency in myeloid lineage (Higuchi et al., 2002; Rhoades et al., 2000) and 
can therefore be considered a class II mutation according to the two-hit hypothesis, the 
ability of RUNX1-ETO to simultaneously increase proliferation of immature myeloid 
progenitors illustrates limitations of the two-hit hypothesis. Moreover, in a mouse model 
expressing RUNX1-ETO from HSC-specific Ly6A promoter, the mice do not exhibit 
differentiation block in myeloid lineage, but develop MPD characterized by abnormal 
proliferation of mature myeloid cells (Fenske et al., 2004). While these data may suggest 
that RUNX1-ETO is a class I mutation, human data in commonly found cooperating 
mutations in t(8;21) AMLs (Boissel et al., 2006a; Care et al., 2003; Schessl et al., 2005b; 
Speck et al., 1999; Valk et al., 2004a) indicate that RUNX1-ETO requires additional pro-
proliferative and pro-survival signaling for AML development. While RUNX1-ETO can 
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provide both class I and class II mutation functions, these functions are not sufficient for 
AML, and addition of a class I mutation results in AML development. Therefore, it can 
be functionally considered a class II mutation, but clearly illustrates limitations of the 
two-hit hypothesis. 
The fusion protein contains N-terminal region of RUNX1 that includes the RHD 
and NLS, but does not include TA, ID, and repression domains (see Figures 1.2 and 
1.4B) (Lenny et al., 1995). Therefore, while the fusion protein relies on CBFβ binding 
and using the CBF DNA-binding activity, its transregulation activity and association to 
cofactors is mediated by the ETO sequences (Lenny et al., 1995). ETO is a member of an 
E-box family of TFs, and it contains four domains called Nervy homology regions 
(NHR). The NHRs recruit several repressors of transcription, including mSin3A, Histone 
deacetylases 1-3 (HDAC1-3), Nuclear receptor corepressor (N-CoR), Silencing mediator 
for retinoid and thyroid receptors (SMRT) mainly through cooperative function of NHR2 
and NHR4 (Amann et al., 2001; Gelmetti et al., 1998; Hildebrand et al., 2001; Wang et 
al., 1998), as well as GFI-1, which can also exhibit transcriptional repression activity 
(McGhee et al., 2003). Importantly, the NHR2 domain is required for ETO 
homooligomerization and for interaction with other ETO family proteins. Mutations of 
NHR2 that abrogate oligomerization dramatically reduce effects of RUNX1-ETO on 
proliferation and differentiation of murine BM cells, indicating that oligomerization plays 
an important role in RUNX1-ETO function, probably by providing a interacting surface 
for several RUNX1-ETO-binding corepressors (Liu et al., 2006; Zhang et al., 2001). 
The RUNX1-ETO protein acts, at least in part, as a repressor of CBF targets.   
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Examples of CBF targets repressed by the fusion protein include the Alternative reading 
frame p14 (p14ARF) (Linggi et al., 2002), T-cell receptor β (TCRβ) (Meyers et al., 1995), 
and GM-CSF (Frank et al., 1995). The activity of RUNX1-ETO also seems to regulate 
gene expression by a CBF-independent mechanism. Studies have shown that RUNX1-
ETO upregulates expression of BCL2 (Klampfer et al., 1996), and c-Jun (Elsasser et al., 
2003; Frank et al., 1999). The CBF-independent gene regulation hypothesis is further 
supported by the observation that RUNX1 and RUNX1-ETO localize to different regions 
of the nucleus (Bakshi et al., 2008). Considering that ETO is part of the fusion protein, it 
is possible that this cofactor may guide it to other transcriptionally active loci. 
Acute myeloid leukemia samples carrying the t(8;21) express two RUNX1-ETO 
isoforms by alternative splicing (Yan et al., 2006b). In addition to the full length isoform 
into exon 11, some transcripts show splicing into an alternative exon 9a, terminating the 
transcript prematurely. The RUNX1-ETO9a protein lacks the C-terminal NHR3 and 
NHR4 domains, associated with binding to HDAC1/2/3 corepressors and the 
NCor/SMRT complex (Figure 1.4B). The loss of these domains creates a protein with 
strong leukemogenic function, since RUNX1-ETO9a induces leukemia in BM-
transplantation assays, and does not inhibit proliferation in vitro (Yan et al., 2004). 
Indeed, significant differences were found between the isoforms on the regulation of 
Cyclin-dependent kinase 4 (CDK4), cyclin D3 (CCND3) and p27kip1 (CDKN1B). The 
leukemogenic ability of RUNX1-ETO9a is dependent on the DNA binding capacity from 
the RHD and the oligomerization function of the NHR2 domain (Yan et al., 2009). In 
addition, a single point mutation that disrupts the zinc finger structure of the NHR4 
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domain is sufficient to strongly enhance leukemogenic activity of RUNX1-ETO protein, 
making it similar to that of RUNX1-ETO9a (Ahn et al., 2008). Therefore, considering the 
relevance of the RUNX1-ETO9a function to AML development, and that patient AML 
blasts carrying t(8;21) express both isoforms at different proportions, it is possible that 
RUNX1-ETO9a may be the main isoform contributing to AML development in vivo at 
least in a fraction of t(8;21) AMLs. Of note, RUNX1-ETO9a provides a more potent 
myeloid differentiation block in a mouse model (Yan et al., 2006b). This suggests that 
ambiguous data obtained for RUNX1-ETO in its effect on differentiation and 
proliferation (see above) may not accurately represent the RUNX1-ETO(9a) function in 
actual human AMLs. Stronger effect of RUNX1-ETO9a on myeloid differentiation may 
also explain why class I and not class II mutations most commonly are found in t(8;21) 
AML. 
Tyrosine Kinase Receptor Signaling 
The C-KIT and FLT3 are receptor tyrosine kinase receptors, which together with Platelet-
derived growth factor (PDGF) and Colony stimulating factor-1 (CSF-1) receptors are 
members of the structurally related type III RTKs. These RTKs contain five extracellular 
immunoglobulin-like domains, the transmembrane and juxtamembrane domains (JM), 
and a cytoplasmic tyrosine kinase domain (TKD). Upon binding to their ligands, c-KIT 
and FLT3 homodimerize (Blume-Jensen et al., 1991; Verstraete et al., 2011) and undergo 
autophosphorylation at several tyrosine residues in JM and TKD (Heiss et al., 2006; 
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Razumovskaya et al., 2009; Reith et al., 1991; Rottapel et al., 1991; Serve et al., 1994). 
The autophosphorylation step is critical for determination of the specific downstream 
signaling for each RTK because the phosphorylated tyrosines provide a substrate for 
phospho-tyrosine specific Src homology 2 (SH2) domains found in proteins that bind to 
the RTKs and recruit additional components of signaling pathways (Figure 1.5) 
(Anderson et al., 1990; Kanner et al., 1991). One of the SH2-containing proteins that bind 
to both c-KIT and murine Flt3 is p85 regulatory subunit of Phosphatidylinositol 3-kinase 
(PI3K) (Lev et al., 1992; Rottapel et al., 1994). Importantly, human FLT3 does not 
directly bind p85, but instead recruits it via the SH2 adaptor proteins GTP-exchange 
complex growth factor receptor bound-2 (GRB-2), GRB2-associated binding proteins 1 
and 2 (GAB-1/2) and Protein tyrosine phosphatase, non-receptor type 6 (PTPN6, also 
known as SHP1) (Zhang and Broxmeyer, 1999; Zhang and Broxmeyer, 2000). The 
recruitment of p85 to the RTK results in its phosphorylation and release of its inhibitory 
function over PI3K catalytic subunit p110 (Cuevas et al., 2001). Activation of PI3K 
results in accumulation of phosphatidylinositol-3,4,5-triphosphate (PIP3) in cell 
membrane and subsequent recruitment and activation of Pleckstrin homology (PH) 
domain-containing proteins, including 3-phosphoinositide-dependent protein kinase 1 
(PDK1). Accumulation of PIP3 is negatively regulated by a tumor suppressor 
Phosphatase and tensin homolog (PTEN) (Li et al., 1997) that is a phosphatase that 
dephosphorylates PIP3 (Maehama and Dixon, 1998) and is a major negative regulator of 
PI3K pathway (Stambolic et al., 1998). The best known PI3K downstream target is v-Akt 
murine thymoma viral oncogene homolog (AKT) that is phosphorylated by PDK1 at   
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Thr308 (Carnero, 2010). AKT kinase phosphorylates a variety of substrates involved in 
control of cell proliferation and apoptosis. One of the AKT substrates is Tuberous 
sclerosis complex 2 (TSC2) that together with TSC1 negatively regulates a small GTPase 
Ras homolog enriched in brain (Rheb). Phosphorylation of TSC2 by AKT inhibits its 
activity and allows Rheb to accumulate in an active GTP-bound state, which in turn 
activates mammalian Target of Rapamycin (mTOR) and stimulates its assembly into a 
protein complex called mTORC1. mTORC1 exists in dynamic equilibrium with another 
mTOR complex mTORC2 (whose assembly is stimulated by TSC1/2) that provides an 
important feedback loop by stimulating AKT activity by phosphorylating AKT at Ser473. 
mTORC1 indirectly negatively regulates AKT by influencing PI3K activity (Huang and 
Manning, 2009). Importantly, mTORC1, one of the main effectors of AKT, 
phosphorylates two substrates: p70 S6 kinase 1 (S6K1) and 4E-binding protein 1 (4E-
BP1), stimulating protein synthesis and proliferation (Shah et al., 2000). In addition, 
PI3K/AKT signaling prevents apoptosis due to direct phosphorylation and inhibition of 
pro-apoptotic TFs of the Forkhead box (FOXO) family (Rena et al., 1999), BCL2-
associated agonist of cell death (BAD) (Peso et al., 1997), caspase-9 (Cardone et al., 
1998). Nuclear factor κB (NFκB) signaling pathway is also activated by phosphorylation 
of IκB kinase (IKK) with AKT (Nidai Ozes et al., 1999; Romashkova and Makarov, 
1999). While NFκB pathway can provide both pro- and anti-apoptotic signaling, there is 
evidence for an anti-apoptotic effect of the pathway in several types of hematopoietic 
cancers, including a fraction of CBF-associated AML (Lück et al., 2010). 
The PI3K/AKT signaling also increases cell proliferation as a result of inhibitory 
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phosphorylation of cyclin-dependent kinase inhibitors p27 and p21, and indirect 
activation of Cyclin-dependent kinase 1 (CDK1) via inhibition of the protein kinases 
WEE1 and Myelin transcription factor 1 (MYT1) (Martelli et al., 2006). In general, 
PI3K/AKT signaling pathway provides major functions necessary for uncontrolled 
proliferation and survival of a transformed cell. Not surprisingly, activating mutations in 
its components (and loss-of-function mutations of PTEN) are commonly found as 
oncogenic mutations in solid tumors (Samuels and Ericson, 2006). The reason for low 
incidence of such mutations in AML is unknown, although a large fraction of AMLs 
exhibit constitutive activation of PI3K/AKT pathway (Tamburini et al., 2007). It was also 
shown that knocking-out PTEN (Yilmaz et al., 2006; Yu et al., 2010a; Zhang et al., 
2006a) or constitutive activation of AKT (Kharas et al., 2010) leads to leukemogenesis in 
mice. 
Upon RTK activation, Shc protein is recruited to the TKD domains of c-KIT and 
FLT3 via its SH2 domain. This in turn results in recruitment of adaptor protein GRB-2, 
guanine exchange factor (GEF) Son of sevenless (SOS), and Rat sarcoma (RAS), 
resulting in RAS activation by its binding to guanosine triphosphate (GTP) (Dosil et al., 
1993; Duronio et al., 1992; Thommes et al., 1999; Zhang and Broxmeyer, 2000). The 
activation of RAS is negatively regulated by GTPase activating protein Neurofibromin 1 
(NF1) that stimulates RAS GTPase activity (Xu et al., 1990). Active GTP-bound RAS 
recruits Rapidly Accelerated Fibrosarcoma (RAF) proteins to the cell membrane where 
they become activated and besides other activities phosphorylate Mitogen-
associated/extracellular regulated kinase 1 (MEK1), which in turn activates by 
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phosphorylation Extracellular regulated kinases 1 and 2 (ERK1/2). ERK1/2 serine 
kinases phosphorylate variety of substrates resulting in anti-apoptotic signaling by 
directly inhibiting activity of BIM, BAD and MCL-1. One of the main functions of ERK 
is phosphorylation and activation of several transcriptional regulators in the nucleus, 
including cAMP response element-binding (CREB) TF, ELK and STAT. These 
regulators alter the expression of multiple target genes promoting cell proliferation and 
anti-apoptotic signaling (Steelman et al., 2008). Importantly, ERK also phosphorylates 
TSC2 at a site distinct from the AKT phosphorylation site, providing a synergistic effect 
between PI3K/AKT and RAS signaling pathways on TSC2 and mTOR regulation 
(Winter et al., 2011). Other mechanisms of cross-talk between the pathways include 
interaction between RAS and p110 resulting in induction of PI3K activity (Kodaki et al., 
1994; Rodriguez-Viciana et al., 1994), inhibition of RAF by AKT via direct 
phosphorylation (Rommel et al., 1999; Zimmermann and Moelling, 1999), indirect 
activation of RAF-1 by AKT (Majewski et al., 1999), and a number of common 
phosphorylation targets, including CREB and BCL2-like 11 (BCL2L11, also known as 
BIM) (Steelman et al., 2008). The activation of PI3K by RAS proteins is of particular 
importance, as it is critical for oncogenic activity of RAS (Gupta et al., 2007), indicating 
PI3K/AKT as an important RAS downstream effector pathway. 
Wild type C-KIT RTK also activates Janus kinase 2 (JAK2) that is constantly 
associated with the receptor and is phosphorylated upon SCF binding (Linnekin et al., 
1996; Weiler et al., 1996). Unlike c-KIT, wild type FLT3 can activate JAK/STAT 
pathway only upon overexpression of FLT3 or if it is constitutively activated by 
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mutations (Spiekermann et al., 2003). In this case, though, the mechanism of JAK/STAT 
pathway activation occurs through direct, JAK-independent (Choudhary et al., 2007), but 
GRB2-dependent (Masson et al., 2009) activation of STAT5. JAK/STAT pathway is also 
involved in oncogenesis, as JAK2 mutations are commonly found in CML and MDS 
(Reuther, 2008). JAK is an intracellular kinase that is activated by different receptors and 
in turn phosphorylates STAT proteins. The phosphorylated STAT TFs dimerize, are 
transported into nucleus and become active as regulators of transcription. Among 
different genes regulated by STAT is anti-apoptotic BCL family member BCL-xL. 
STAT5 also promotes cell survival by inducing PIM1 expression (Steelman et al., 2008). 
Additionally, it is shown that activation of STAT5 by mutant FLT3 increases 
proliferation and alters differentiation of hematopoietic stem cells (Moore et al., 2007). 
Activation of STAT5 may be enhanced by ERK phosphorylation, indicating a possible 
cross-talk between JAK/STAT and MAPK pathways (David et al., 1995; Winston and 
Hunter, 1995). 
The most commonly mutated genes found in human AMLs, as well as many of 
the genes constantly upregulated in AMLs, are involved in the described pathways. C-
KIT RTK, which is almost ubiquitously expressed on AML cells, results in direct 
activation of PI3K/AKT pathway and activates STAT3 (Ning et al., 2001a; Ning et al., 
2001b). RAS GTPases are also directly activated by c-KIT receptor, leading to 
upregulated RAF/MEK/ERK cascade (Scholl et al., 2008a). FLT3-ITD and other 
activating mutations of FLT3 activate AKT phosphorylation, RAS/RAF/MEK/ERK and 
STAT5 in AML cells (Brandts et al., 2005; Hayakawa et al., 2000; Kim et al., 2005; 
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Mizuki et al., 2000; Spiekermann et al., 2003). JAK2, as described above, is a member of 
JAK/STAT oncogenic pathway. Commonly mutated in AML RAS proteins are 
downstream targets of type III RTKs (including c-KIT and FLT3) and activators of 
RAF/MEK/ERF pathway. Finally, a major player in PI3K/AKT pathway AKT is 
overexpressed in a large human AML (Tamburini et al., 2007). Many of these players of 
leukemic transformation are targets for specific inhibitors therapy (see above), although 
cross-talks between the pathways and autoregulatory feedback loops make a task of 
cancer prevention by signaling inhibition challenging (Breitenbuecher et al., 2009; Chu 
and Small, 2009; Huang et al., 2003; Huang and Houghton, 2001). 
Receptor tyrosine kinase pathways are frequently deregulated 
in CBF fusions-associated leukemias 
Mutations in components of the RTK signaling pathway are the most common mutations 
found in CBF leukemias (Haferlach et al., 2010). Approximately 90% of CBF AML 
samples present cooperating mutations in NRAS, KRAS, KIT, and FLT3. The KIT and 
FLT3 genes play crucial roles in proliferation and survival of hematopoietic progenitors 
(Ikeda et al., 1991; Pollard et al., 2010; Wang et al., 1989; Yokota et al., 1997). The 
oncogenic mutations that activate the FLT3 receptor are found in 5% to 7% of CBF AML 
cases, including the ITD and TKD mutations (Boissel et al., 2006b; Care et al., 2003; 
Schnittger et al., 2002; Shih et al., 2008), and have an unfavorable prognosis (Döhner et 
al., 2010; Mrózek et al., 2007). The activating mutations in KIT (the most common are 
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D816V and N822K) are found in approximately 25% of CBF AML and are rare in other 
AMLs (Boissel et al., 2006b; Care et al., 2003; Goemans et al., 2005; Paschka, 2008; 
Shih et al., 2008). It was also proven by using mouse models that both FLT3-ITD (Kim et 
al., 2008; Schessl et al., 2005a) and mutant KIT (Wang et al., 2011b) cooperate with CBF 
fusions in leukemia development in mice. 
The CBF AMLs can also present oncogenic mutations in NRAS and KRAS, but 
rarely in HRAS (Neubauer et al., 2008). Rat sarcoma (RAS) genes encode membrane-
anchored GTPases that are involved in multiple signaling pathways and were shown to 
have oncogenic activity (McCubrey et al., 2007). In inv(16) AML cases around 30% 
harbored constitutively active mutated RAS genes with the most commonly mutated 
NRAS. The incidence of RAS mutations in t(8;21) AML cases is around 10% (Boissel et 
al., 2006b; Care et al., 2003; Goemans et al., 2005; Shih et al., 2008). It is noteworthy 
that KIT, FLT3 and RAS mutations in inv(16) and t(8;21) human AML cases were 
mutually exclusive, thus supporting the idea that they act as class I mutations in the “two-
hit” model for leukemia development (Care et al., 2003; Shih et al., 2008). 
Approximately 8 to 10% of t(8;21) AML cases show oncogenic mutations in the 
tyrosine kinase Janus kinase 2 (JAK2) gene, frequently at residue V617F (Dohner et al., 
2006; Schnittger et al., 2007b), but this occurs less frequently in inv(16) AML. 
Interestingly, these mutations in JAK2 are often found in CML and MDS, but are rare in 
non-CBF AMLs (Illmer et al., 2007). Although JAK2 is a non-receptor tyrosine kinase, 
the signaling pathways activated by the constitutively active JAK2V617F are similar to 
those activated by RTKs (Reuther, 2008). Finally, heterozygous and homozygous loss of 
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tumor suppressor Neurofibromin 1 (NF1) expression have been identified in 10% of CBF 
AMLs. NF1 catalyzes GTPase activity of RAS proteins, thereby reducing RAS signaling, 
so identification of the NF1 loss-of-function mutations in CBF AMLs further strengthens 
the relevance of RTK signaling in leukemia development (Haferlach et al., 2010). 
Taken together, these studies highlight the critical involvement of constant RTK 
activation in AML development. They also underscore functional connection between 
commonly found class I mutations in AML and provide mechanisms by which the 
mutations confer leukemic cells proliferative and survival advantages. 
Prognostic significance of RTK pathways mutations in CBF AML 
Frequent deregulation of RTK signaling in CBF AML may present an opportunity for 
efficient treatment strategies of AML cases by targeting the RTK pathways. The decision 
for use of particular inhibitors, however, should take into account both potential benefits 
for a patient and risks due to toxicity. Below I will briefly review the prognostic values of 
RTK pathways mutations in CBF AMLs and current or potential treatments based on 
RTK targeting. 
While KIT activating mutations are frequently found in CBF AML (see above), 
the effect of the mutations on the disease prognosis is not clear. Some studies of adult 
AML determined there is reduced survival in t(8;21)-associated AML cases carrying KIT 
mutations, but not in inv(16)-associated AML (Boissel et al., 2006b; Cairoli et al., 2006). 
Other studies showed increased rate of relapse, but no changes in survival of CBF AML 
positive for KIT mutations (Care et al., 2003). Finally, a study by Pashka e al. showed 
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effects of KIT mutations on survival and relapse of both inv(16)- and t(8;21)-associated 
AMLs (Paschka et al., 2006). Disease prognosis for childhood CBF AMLs was not 
shown to be affected by KIT mutations (Goemans et al., 2005; Pollard et al., 2010; Shih 
et al., 2008). Due to a relatively good prognosis and an unclear effect of KIT mutations 
on CBF AML, the treatment of the CBF AML cases is generally not changed when 
presence of the mutations in KIT is detected. Occasional trials that used RTK inhibitor 
imatinib on the CBF AMLs carrying mutations in KIT indicate mixed results and suggest 
that efficiency of imatinib may depend on the particular mutation of KIT (Cairoli et al., 
2005; Nanri et al., 2005). Further studies are necessary to determine whether inhibition of 
KIT activity is beneficial for the treatment of CBF AML. More potent inhibitors that 
affect a wider range of KIT mutations than imatinib may prove to be effective in the 
future (Schittenhelm et al., 2006). 
Activating FLT3 mutations are less commonly found in CBF AML than in other 
subtypes of AML (see above). However, presence of the mutations in AML in general 
significantly worsens the prognosis (Schnittger et al., 2002), and screening for FLT3 
mutations was recommended for all AML subtypes in the latest WHO classification of 
hematopoietic diseases (Vardiman et al., 2009). The adverse effect of FLT3 mutations on 
survival and relapse rate was also detected in CBF AML (Boissel et al., 2006b; Goemans 
et al., 2005). Therefore, efficient inhibition of mutated FLT3 signaling should 
theoretically benefit the patients that carry mutation in this RTK. To our knowledge, no 
clinical trials using FLT3 inhibitors focusing on CBF AML were conducted probably due 
to relatively low incidence of FLT3 mutations in CBF AML. Trials conducted in AML in 
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general determined that use of FLT3 inhibitor sorafenib can be beneficial in some cases, 
but many AML cases were resistant to it indicating presence of widespread resistance 
mechanisms (Parmar et al., 2011; Pratz and Levis, 2010). More efficient FLT3 inhibitors 
are required to make the treatment more beneficial to the patients. In the meantime, due 
to adverse effect of FLT3 mutations on survival of CBF AML patients, it may be 
necessary to evaluate effectiveness of bone marrow transplantation in these patients. The 
bone marrow transplantation is usually not used for CBF AML patients, but it is used for 
other subtypes of AMLs with more poor prognosis (Rowe, 2009). 
Presence of the activating mutations of RAS genes in CBF AML is not considered 
a reason for altering standard therapy. Although these mutations are frequently found in 
CBF AML, they do not have prognostic significance (Boissel et al., 2006b; Goemans et 
al., 2005). Moreover, AMLs carrying RAS mutations have more favorable prognosis 
when treated with high-dose cytarabine during post-remission phase (Neubauer et al., 
2008), therefore it is unlikely that introduction of RAS inhibitors in AML treatment will 
lead to a better prognosis. Rather, CBF AMLs carrying RAS mutations are some of the 
least aggressive secondary mutations in AML and may benefit from novel treatment 
strategies targeting the CBFβ-SMMHC or RUNX1-ETO fusion proteins functions. These 
strategies have not been developed yet, but potentially can be very effective in treatment 
of CBF AML. 
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Novel and potentially cooperating genes in CBF-related AML 
The identification and characterization of factors that cooperate with CBF fusion proteins 
in AML is an important task that can be beneficial in several aspects: (1) they can 
identify genes mutated or deregulated in human leukemia cells, and (2) they can represent 
valid targets of therapeutic inhibitors for the reversal of the pathways activated by 
mutations. A previous study in the Castilla laboratory used a retorviral insertional 
mutagenesis approach in Cbfb-MYH11 knock-in mice to identify candidate cooperating 
genes in leukemia (Castilla et al., 2004). Some of the common retroviral insertion sites 
(CIS) identified were located in the promoter regions of the related transcription factors 
PLAG1 and PLAGL2 and the micro-RNA cluster miR-17-92. The PLAG genes were later 
shown to synergize with Cbfb-MYH11 in leukemia development in mice (Landrette et al., 
2005). Since these genes are the focus of this thesis, I will summarize their function in the 
following sections. 
PLAG Transcription Factors are oncogenes that cooperate with CBFB-
MYH11 in AML development 
The Pleomorphic adenoma of salivary gland (PLAG) is a small family of transcription 
factors, including the PLAG1, PLAGL1 and PLAGL2. The PLAG1 protein has an NLS 
signal at the N-terminus and 7 C2H2 type zinc finger domains, three of which bind to the 
DNA consensus sequence GRGGC(N)6-8RGGK (Hensen et al., 2002; Kas et al., 1998), 
and the only known PLAG1 target is Insulin-like growth factor 2 (IGF2) at its promoter 3 
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(Voz et al., 2000). The upregulation of PLAG1 expression is the most frequent mutation 
in pleomorphic adenomas of the salivary gland, and results from a translocation-mediated 
promoter swapping involving the 8q12 locus (Kas et al., 1998). Its oncogenic function 
was later extended to other tumor types, including chronic lymphocytic leukemia (CLL) 
(Pallasch et al., 2009; Patz et al., 2010), salivary gland tumors (Matsuyama et al., 2011), 
lipoblastomas (Astrom et al., 2000), hepatoblastomas (Zatkova et al., 2004), and breast 
cancer (Declercq et al., 2008). In NIH3T3 cells the PLAG genes were shown to provide 
pro-proliferative and oncogenic activity upon overexpression (Hensen et al., 2002). 
Further, a 250 kb region on chromosome 20q11 was found amplified in MDS/AML 
cases. This region includes PLAGL2, and the amplifications resulted in upregulation of its 
transcript levels (MacKinnon et al., 2010). In addition, PLAG1 and PLAGL2 have been 
involved in the regulation of Wingless-type MMTV integration site family (WNT) 
signaling pathway in neuronal stem cells, gliomas, and salivary gland tumors (Zhao et al., 
2006b; Zheng et al., 2010). 
After the identification of retroviral insertions upstream of Plag1 and Plagl2 
genes in Cbfb-MYH11-associated leukemias in mice (Castilla et al., 2004), our laboratory 
demonstrated that upregulation of both genes act as efficient cooperating oncogenes in 
leukemia development (Landrette et al., 2005). Furthermore, we have recently shown that 
PlagL2 induces expression of Mpl and activates the Mpl signaling pathway and thereby 
cooperates with Cbfb-MYH11 in AML development (Landrette et al., 2011). 
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Mutations in the Thrombopoietin/MPL signaling pathway are associated 
with hematopoietic malignancies 
The Myeloproliferative leukemia virus oncogene MPL (also known as CD110) is the 
cognate receptor for the cytokine thrombopoietin (THPO), and both are essential for 
megakaryocyte function and HSC maintenance (Kaushansky and Ranney, 2009a). The 
MPL receptor belongs to the type I tyrosine kinase receptor family, characterized by the 
conserved WSWXWS motif in the extracellular region, and the lack of intrinsic kinase 
activity in the intracellular region (Kaushansky, 2009a). Upon interaction with Thpo 
ligand, homodimers of MPL receptor are formed to activate a signaling cascade. 
Cytoplasmic domains of the MPL units change conformation and become closer to each 
other, allowing cross-phosphorylation of specific tyrosines of MPL cytoplasmic domains 
by JAK2 kinase (Drachman et al., 1995; Drachman et al., 1999). Upon activation, 
phosphorylated tyrosine residues of MPL serve as docking sites for SHP2 and GAB2 
SH2 motif-containing proteins that in turn bind p85 subunit of PI3K, leading to 
PI3K/AKT pathway induction (Miyakawa et al., 2001). Similarly, MPL binds GRB2 and 
SOS1 that serve to activate MAP kinase (MAPK) signaling (RAS/RAF/MEK/ERK) 
(Sasaki et al., 1995). As mentioned above, MPL and THPO are involved in regulation of 
HSCs and megakaryocytes (Kaushansky and Ranney, 2009b), supporting HSC 
maintenance (Kaushansky, 2009b) and self-renewal capacity (Fox et al., 2002b; Qian et 
al., 2007) and megakaryocytic maturation (Broudy et al., 1995; de Sauvage et al., 1994; 
Kaushansky et al., 1994). THPO also induces proliferation in several hematopoietic cell 
types (Ku et al., 1996; Pang et al., 2009; Rasko et al., 1997; Tang et al., 2008). 
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Although THPO is the best studied and accepted MPL ligand, studies in human and 
mouse cells have reported the activation of MPL signaling via the mammalian homolog 
of the nuclear distribution gene (nud) from Aspergilus nidulans (Nuclear distribution 
gene C, NUDC). The NUDC is expressed in early myeloid and erythroid progenitors, and 
in acute leukemia samples (Miller et al., 1999). As a cytokine, NudC promotes 
megakaryocyte maturation and platelet formation (Wei et al., 2006) by activation of MPL 
signaling (Pang et al., 2009; Tang et al., 2008; Zhang et al., 2007), providing an 
explanation for the residual platelet levels in Tpo-null mice (Pan et al., 2005). Although 
the role of hNUDC in normal and neoplastic hematopoiesis remains unclear, involvement 
of hNUDC in AML is an interesting possibility that may complement the results obtained 
in this study showing cooperation of wild type Mpl with RUNX1-ETO in AML 
development. If the observed hNUDC upregulation in human leukemia (Miller et al., 
1999) is functional in upregulating MPL signaling (Tang et al., 2008), this could be one 
of the ways for increasing MPL signaling and, therefore, cooperation of wild type MPL 
with other oncogenes in leukemia. 
Loss of function mutations in MPL or THPO genes are associated with congenital 
amegakaryocytic thrombocytopenia, severe thrombocytopenia and aplastic anemia 
(Ballmaier and Germeshausen, 2009). Somatic activating mutations in MPL (most 
commonly W515L/K) cause constitutive JAK2 activation and are associated with 
myeloproliferative neoplasms, including myelofibrosis with myeloid metaplasia and 
essential thrombocythemia (Pardanani et al., 2006; Pikman et al., 2006). Mutations in 
MPL have only been detected in a quarter of acute megakaryoblastic leukemia cases 
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(Hussein et al., 2009b). 
MicroRNA cluster miR-17-92 is an oncogene that affects cell proliferation 
and survival 
The microRNAs (miRNAs, miRs) are small non-coding RNA molecules (21-25 
nucleotides) that regulate a variety of cellular processes, including apoptosis, metabolism, 
cell cycle and differentiation (Ambros, 2004; Bartel, 2004; Bushati and Cohen, 2007). 
The miRNAs can be located in intergenic regions of the genome or within gene 
structures. Intergenic miRNAs are thought to be regulated by specific promoters and 
transcribed using RNA polymerases II or III (Borchert et al., 2006; Ozsolak et al., 2008). 
The miRNAs located in the gene introns are preferentially co-transcribed with the host 
gene (Rodriguez et al., 2004). 
Most miRNAs are present as individual miRNAs, but in some cases they are 
grouped in clusters and transcribed from a single primary miRNA molecule (pri-
miRNA). In either case, the pri-miRNAs are then processed by the ribonuclease Drosha 
into a precursor miRNA (pre-miRNA) of about 70 nt and a stem-loop structure (Figure 
1.6) (Lee, 2003). Processing of different pre-miRNAs from one cluster can be 
independently regulated, involving specific factors and leading to different expression 
patterns of mature miRNAs from the same cluster (Guil and Caceres, 2007; Wang et al., 
2011a). The precursors are then transported into cytoplasm where they are further 
processed into mature miRNAs by the Ribonuclease (RNase) III enzyme Dicer. The 
mature miRNAs are incorporated into the RNA-induced silencing complex (RISC) to  
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destabilize mRNA targets of the miRNAs (Olena and Patton, 2010). The targeting is 
based in part on homology to a seed sequence within the miRNA (6-8 nt) that imperfectly 
base-pairs to a miRNA binding site(s) usually located at the 3‟-UTR (untranslated region) 
of an mRNA target. To date, more than 500 miRNAs were described in human genome, 
36% of them localized in clusters. They are estimated to regulate up to a third of all 
protein coding genes (Griffiths-Jones et al., 2008). 
The miRNAs have been shown to play a role in tumorigenesis, acting as tumor 
suppressors or “oncomiRs” (i.e., promoting cancer development). The earliest example of 
tumor suppressor miRNAs are the closely located miR-15 and miR-16 in chromosome 
13q14, commonly deleted in CLL (Calin et al., 2002; Calin et al., 2005), and also found 
to be also deleted in other cancers, such as high-stage prostate cancer (Bonci et al., 2008; 
Dong et al., 2001). They have been shown to induce apoptosis via negative regulation of 
an anti-apoptotic protein Bcl2 (Cimmino et al., 2005). Other examples of miRNA tumor 
suppressors are miR-451 in gliomas (Nan et al., 2010), and miR-96 in pancreatic cancers 
(Yu et al., 2010c). The oncomiR role, mainly when upregulated by transcription factors 
or chromosome amplifications, include miR-21 in breast cancer (Si et al., 2007), miR-155 
in B-cell lymphoma (Eis et al., 2005), and miR-17-92 cluster in leukemias (He et al., 
2005; Xiao et al., 2008). 
The miRNA cluster miR-17-92 is transcribed from the intronic sequence of the 
non-coding MIR17 host gene (MIR17HG), and encodes 6 miRNAs (miR-17-5p, miR-18a, 
miR-19a, miR-20a, miR-19b-1 and miR-92a). Two paralogous clusters present in the 
mammalian genome, are the miR-106a-363 cluster in chromosome Xq26.2 and miR-  
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106b-25 in chromosome 7q22.1, with specific tissue expression patterns (Figure 1.7 
(Mendell, 2008)). They are thought to have emerged through a complex series of 
duplications and losses of individual members (Tanzer and Stadler, 2004). 
The miRNAs from this cluster can be divided into four functional families 
according to their target seed sequences: miR-17 family (miR-17-5p, miR-20a), miR-19 
(miR-19a, miR-19b-1), miR-18a and miR-92. Since these families also include the miRs 
of the paralog clusters, the expression of either miR of a family is expected to regulate 
the same group of targets (Mendell, 2008). The miR-17-92 cluster plays important roles 
in development of various tissues by regulating differentiation, proliferation and/or 
apoptosis. For example, it inhibits differentiation and promotes proliferation of lung 
epithelial cells (Lu et al., 2007), promotes cell cycle during neuronal differentiation in 
vitro (Trompeter et al., 2011), and enhances differentiation in an in vitro model of 
adipocyte differentiation (Wang, 2008). 
In hematopoietic tissues, miR-17 family of miRNAs was found to be 
downregulated during monocytic differentiation. Forced overexpression of miR-17 
miRNAs inhibited monocytic differentiation due to downregulation of RUNX1 and 
consequently M-CSFR expression (Fontana et al., 2007). Clues to the role of the miR-17-
92 cluster role in B-cell development were found in a study of Dicer ablation in B cell 
lineage (Koralov, 2008). The study showed upregulation of miR-17-92 targets in B-cells 
and a subsequent block of B-cell differentiation at the pro-B to pre-B cell transition. The 
block could be rescued by ablation of Bim or upregulation of Bcl2, suggesting an anti-
apoptotic role of miR-17-92 in B-cell development. Both lung and B-cell defects were 
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evident in a miR-17-92-null study. These KO mice exhibited lung hypoplasia and B-cell 
defects similar to the ones observed in B-cell specific Dicer KO mice. Other tissues 
appeared normal, suggesting possible compensation of miR-17-92 function by miR-17-92 
paralogs, as double KO of miR-17-92 and its paralog miR-106b-25 had a much more 
severe phenotype resulting in midgestation lethality (Ventura et al., 2008). 
The miR-17-92 cluster is located on chromosome 13q31 that is often amplified in 
several types of human cancers, including diffuse large B-cell lymphoma (Lenz et al., 
2008), primary cutaneous B-cell lymphoma (Inomata et al., 2009), follicular lymphoma, 
mantle cell lymphoma (Ota et al., 2004). While invariably correlating with amplification 
of the 13q31, miR-17-92 cluster is also upregulated in small cell lung cancer (Hayashita 
et al., 2005), pancreatic cancer and some other cancers (Chow et al., 2010; Guo et al., 
2009; Novotny et al., 2007; Takakura et al., 2008). The presumption that miR-17-92 may 
be an oncogene was further supported by the fact that miR-17-92 was a frequent target of 
RIS in RIM screenings for erythroleukemia and T cell leukemia (Cui et al., 2007; Wang 
et al., 2006). In addition, it was shown that miR-17-92 overexpression increases 
penetrance and shortens latency in an Eµ-Myc mouse model of B-cell lymphoma (He et 
al., 2005). Enhanced leukemia development upon increased miR-17-92 expression was 
also shown in a mouse model of Mixed-lineage leukemia (MLL) fusions-associated 
leukemia (Mi et al., 2010; Wong et al., 2010). Finally, lymphocyte-specific conditional 
overexpression of the miR-17-92 cluster in mice induced a lympoproliferative disease by 
providing lymphocytes with pro-proliferative and anti-apoptotic signaling. The 
mechanism of this signaling was shown to involve downregulation of Pten and Bim by 
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the miR-17-92 cluster, although other unidentified effectors were likely involved (Xiao et 
al., 2008). 
MiR-17-92 is predicted to regulate hundreds of genes based on seed sequence 
homology, although it is now accepted that this regulation is highly cell type specific. 
Known targets that were shown to be downregulated by the cluster include PTEN, a 
negative regulator of PI3K/AKT pathway, the cell cycle regulators E2f1, Rb2, and p21, 
the pro-apoptotic protein Bim, the transcription factor Runx1, and members of TGFβ 
signaling pathway Tgfβ type II receptor, Smad2 and Smad4 (Table 1.3) (Cloonan et al., 
2008; Ernst et al., 2010; Hong et al., 2010; Mestdagh et al., 2010; Sun et al., 2010; 
Trompeter et al., 2011). All aforementioned genes have been implicated in cancer 
regulation by providing anti-proliferative and/or pro-apoptotic signaling. Besides direct 
regulation of target genes, miR-17-92 is also involved in regulatory feedback loops. For 
example, c-Myc and E2f proteins upregulate miR-17-92 expression by binding to the 
miR-17-92 cluster promoter and activating its transcription. In turn, miR-17-92 
downregulates E2F1 protein expression. (Novotny et al., 2007; O'Donnell et al., 2005; 
Sylvestre et al., 2007). Another example is a feedback loop between miR-17/20a and 
STAT3: miR-17/20a downregulate STAT3 expression, whereas STAT3 activates 
transcription of miR-17-92 (Dai et al., 2011; Zhang et al., 2011). 
As mentioned above, the miR-17-92 cluster can affect both cell cycle and 
apoptosis in cell type specific manner. In HEK293 (human embryo kidney) cells 
overexpression of miR-17-5p alone accelerates transition from G1 to S phases of cell 
cycle resulting in increased proliferation (Cloonan et al., 2008). Acceleration of cell cycle  
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Table 1.3. Confirmed target genes of miRNAs 
expressed from miR-17-92 cluster 
Gene miRNA family Reference 
AIB1 miR-17 (Hossain et al., 2006) 
BCL2L11 miR-17 (Cloonan et al., 2008) 
CDKN1A miR-17 (Hong et al., 2010) 
E2F1 miR-17 (O'Donnell et al., 2005) 
E2F2 miR-17 (Sylvestre et al., 2007) 
E2F3 miR-17 (Sylvestre et al., 2007) 
FN1 miR-17 (Shan et al., 2009) 
FNDC3A miR-17 (Shan et al., 2009) 
GAB1 miR-17 (Cloonan et al., 2008) 
IRF miR-17 (Cloonan et al., 2008) 
JNK2 miR-17 (Cloonan et al., 2008) 
NR4A3 miR-17 (Cloonan et al., 2008) 
PCAF miR-17 (Cloonan et al., 2008) 
PKD1 miR-17 (Cloonan et al., 2008) 
PKD2 miR-17 (Sun et al., 2010) 
PPARA miR-17 (Cloonan et al., 2008) 
PTEN miR-17 (Xiao et al., 2008) 
RB miR-17 (Volinia et al., 2006) 
RBL1 miR-17 (Cloonan et al., 2008) 
RBL2 miR-17 (Lu et al., 2007) 
RUNX1 miR-17 (Fontana et al., 2007) 
STAT3 miR-17 (Zhang et al., 2011) 
TGFBR2 miR-17 (Volinia et al., 2006) 
TSG101 miR-17 (Cloonan et al., 2008) 
CTGF miR-18 (Dews et al., 2006) 
SMAD2 miR-18 (Mestdagh et al., 2010) 
SMAD4 miR-18 (Mestdagh et al., 2010) 
BIM miR-19 (Mavrakis et al., 2010) 
BNIP3 miR-19 (Mavrakis et al., 2010) 
PPP2R5E miR-19 (Mavrakis et al., 2010) 
PRKAA1 miR-19 (Mavrakis et al., 2010) 
PTEN miR-19 (Olive et al., 2009) 
TNF miR-19 (Liu et al., 2011) 
TSP1 miR-19 (Dews et al., 2006) 
BIM miR-92 (Xiao et al., 2008) 
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by miR-17-5p was also shown on human primary pancreatic cancer cells (Yu et al., 
2010b). Yet in lung cancer cells the miR-17 and miR-20a miRNAs provide anti-apoptotic 
effect (Matsubara et al., 2007). An interesting illustration of cell type specificity on an 
example of B-cell lymphoma cell lines was shown by Inomata et al. They showed that 
miR-17-92 downregulated BIM in Burkitt‟s lymphoma derived cell line Raji, but not in 
mantle cell lymphoma derived Jeko1 cells, where Bim is homozygously deleted. Instead, 
miR-17-92 downregulated p21 in Jeko1 cell, resulting in cell cycle progression (Inomata 
et al., 2009). Taken together, the data suggest that miR-17-92 cluster could potentially 
serve as class I mutation in cancer development by providing either or both pro-
proliferative and anti-apoptotic signals. 
General research objectives of this Thesis 
In this study I focused on the identification of novel cooperating mutations that cooperate 
with CBF-related fusion proteins in development of AML, and investigated their 
potential mechanisms of cooperation. First I hypothesize that upregulation of the miR-17-
92 cluster is a novel cooperating mutation in CBF-related AMLs. I provide functional 
evidence that the miR-17 family is responsible for the oncomiR activity within the 
cluster. Second, I hypothesize that the oncogenic role of PlagL2 is, at least in part, the 
upregulation of the Mpl receptor. Furthermore, based on similarity of signaling pathways 
involved in MPL signaling and signaling of known cooperating receptor kinases KIT and 
FLT3, I proposed that MPL overexpression can synergize with RUNX1-ETO to induce 
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AML. Therefore, this thesis research identifies miR-17-92 and Mpl genes as cooperating 
genetic factors in CBF leukemia. 
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CHAPTER II 
The miR-17 family miRNAs cooperate with CBFβ-
SMMHC in leukemia development by activating 
antiapoptotic responses 
Introduction 
The microRNAs (miRs) are small non-coding RNA molecules (21-23 nucleotides) that 
regulate protein levels by reducing translation and stability of target mRNAs (Djuranovic 
et al., 2011; Lee and Ambros, 2001). They have been shown to regulate cellular 
processes, such as apoptosis, metabolism, cell cycle and differentiation (Ambros, 2004; 
Bartel, 2004; Bushati and Cohen, 2007), and their deregulation can participate in 
tumorigenesis functioning as oncogenic miRNAs (oncomiRs) or tumor suppressors 
(Cimmino et al., 2005; Eis et al., 2005; Esquela-Kerscher and Slack, 2006; Kent and 
Mendell, 2006; Nan et al., 2010; Si et al., 2007). 
The miR cluster miR-17-92 is an intronic miR transcribed by the miR-17-92 
cluster host gene (MIR17HG) as a single primary transcript, and encodes 6 mature miRs: 
miR-17-5p, miR-18a, miR-19a, miR-20a, miR-19b-1 and miR-92a. This miR cluster (also 
called oncomiR-1) is implicated as an oncogene in different tumors, including B-cell 
lymphoma (Inomata et al., 2009; Lenz et al., 2008), small cell lung cancer (Hayashita et 
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al., 2005), pancreatic cancer and some other cancers (Chow et al., 2010; Guo et al., 2009; 
Novotny et al., 2007; Takakura et al., 2008). The presumption that miR-17-92 may be an 
oncomiR was further supported by studies of murine hematopoietic cancer models 
suggesting that miR-17-92 cooperate with variety of oncogenes in development of 
erythroid, lymphoid and myeloid malignancies (Cui et al., 2007; He et al., 2005; Mi et al., 
2010; Wang et al., 2006; Wong et al., 2010). This cluster has 4 functional families, based 
on their seed sequences that determine DNA target specificity: The miR-17 (miRs-17-5p 
and -20a), miR-18 (miR-18a), miR-19 (miR-19a and -19b-1), and miR-92 (Mendell, 
2008). 
Individual members of this cluster have been shown to regulate a variety of 
targets, including Pten, E2f1, Rb2, p21, Bim, Runx1 (Cloonan et al., 2008; Ernst et al., 
2010; Hong et al., 2010; Mestdagh et al., 2010; Sun et al., 2010; Trompeter et al., 2011).  
In normal hematopoiesis, miR-17 members regulated differentiation of monocytes and B 
cells (Fontana et al., 2007; Lu et al., 2007; Ventura et al., 2008). The miR-17 family 
promoted proliferation in human primary pancreatic cancer cells and inhibited apoptosis 
in lung cancer cells (Cloonan et al., 2008; Matsubara et al., 2007; Yu et al., 2010b). 
The activation of the cluster miR-17-92 has been shown to induce lymphoid 
neoplasia in cooperation with MYC, using mouse models and human samples (He et al., 
2005; Mu et al., 2009), and later reported that miR-19b, but not miR-17 family acted as an 
oncomiR by hindering Pten levels (Olive et al., 2009). 
Mutations in components of the heterodimeric transcription factor CBF RUNX1 
and CBFB are frequently present in acute myeloid leukemia (AML) samples (Paschka, 
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2008). One of these alterations is the inversion in chromosome 16 inv16(p13;q22), 
generating the fusion oncogene CBFB-MYH11 (Liu et al., 1993). The encoded chimeric 
protein CBFβ-SMMHC blocks myeloid differentiation and induces leukemia in 
cooperation with other mutations (Castilla et al., 1999; Castilla et al., 2004). Considering 
that the fusion protein does not provide self-renewal or proliferative advantage, these 
functions acquired in the leukemic cells may be provided by the cooperating mutations 
(Kuo et al., 2006). 
In order to identify candidate mutations that cooperate with CBFβ-SMMHC in 
leukemia development we screened for candidate oncogenes using a retroviral insertional 
mutagenesis (RIM) approach (Castilla et al., 2004). In the present study we identify and 
characterize two retroviral insertions upstream of the miR cluster miR-17-92 in mice and 
human AML samples. We validated the upregulation of 4 miRs in the cluster, including 
miRs-17-5p, -20a, 19a, and -92a. Expression analysis of a panel of inv(16) human AML 
samples shows expression of these miRs in a fraction of samples. We use a conditional 
CBFB-MYH11 knock in mouse to show that the miR cluster induces myeloid leukemia. 
Furthermore, we show that expression of miR-17-92 upregulates PI3K/Akt pathway, and 
that miRs-17-5p, -20a, and -19a can regulate Pten and increase Bad phosphorylation 
levels in the leukemic blasts. Finally, we show that miR-17 and miR-20a, but not miR-19a 
and -19b, provide anti-apoptotic capacity to the leukemic samples. These studies provide 
evidence that miRNAs of the miR-17 family are the oncomiRs in AML. 
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Materials and methods 
Linker-mediated PCR. A collection of previously obtained by RIM Cbfb-MYH11 AML 
samples (Castilla et al., 2004) was used for identification of retroviral insertion sites with 
linker-mediated genomic PCR as described elsewhere (Schmidt et al., 2001). Briefly, 1µg 
of tumor genomic DNA was digested with NlaIII (cat. #R0125, NEB, Ipsich, MA) or 
MseI (cat. #R0525, NEB, Ipswich, MA). After heat inactivation of the restriction 
enzymes, the DNA was ligated with T4 DNA ligase (cat. #M0202, New England Biolabs 
(NEB), Ipswich, MA), and ligated with double stranded NlaII or MseI linkers. The 
linkers were obtained by annealing the following sense and antisense DNA oligos: NlaIII 
linker+ 5′-GTA ATA CGA CTC ACT ATA GGG CTC CGC TTA AGG GAC CAT G-3′ 
and NlaIII linker- 5′-Phos-GTC CCT TAA GCG GAG-C3spacer-3′; MseI linker+ 5′-
GTA ATA CGA CTC ACT ATA GGG CTC CGC TTA AGG GAC-3′ and MseI linker- 
5′-Phos-TAG TCC CTT AAG CGG AG-C3spacer-3′. Ligation reaction was digested 
with EcoRV (cat. #R0195, NEB, Ipswich, MA) and used for PCR amplification with the 
following primers: MuLV LTR3 5′-GCT AGC TTG CCA AAC CTA CAG GTG G-3‟ 
and Linker long primer 5′-GTA ATA CGA CTC ACT ATA GGG CTC CG-3′. The PCR 
product was diluted and used for secondary PCR amplification with the following 
primers: MuLV LTR1 5′-CCA AAC CTA CAG GTG GGG TCT TTC-3′ and Linker 
nested primer 5′-AAG GCT CCG CTT AAG GGA C-3′. PCR conditions are 94°C for 2 
min, 94°C for 15 sec, 60°C for 30 sec, 72°C for 90 sec (25 cycles) 72°C for 5 min for 
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both primary and secondary PCR. The polymerase used was Platinum Taq polymerase 
(SKU #10966, Invitrogen, Carlsbad, CA). 
The secondary PCR product was separated on 3% agarose gel, individual bands were 
isolated with QIAquick gel extraction kit (cat. #28706, QIAgen, Valencia, CA) and used 
for cloning into pGEM-T vector system (cat. #A3600, Promega, Madison, WI). The E. 
coli clones that contained the plasmid were selected with blue/white screening, plasmid 
DNA was isolated with QIAprep Miniprep kit (cat. #27106, QIAgen, Valencia, CA) and 
sent for sequencing (Macrogen, Rochville, MD) with universal pUC/M13 primers. 
Genomic PCR. The following primers were used to identify presence and direction of 
retroviral insertions in the miR-17-92 genomic locus: genome-specific primers C (miR-
17flnk.Fwd) 5‟-CTT GTG GTC CTG GCT CTC TC-3‟, D (miR-17flnk.Rev) 5‟-GGT 
GGG GTG AAG ACA GAG AA-3‟, and retrovirus-specific primers A (LTR5) 5‟-TCG 
TGG TCT CGC TGT TCC TTG G-3‟, B (LTR4) 5‟-GCG TTA CTT AAG CTA GCT 
TGC-3‟ (Figure 2.1A). For identification of the presence of the retroviral insertion in the 
miR-106a-363 genomic locus the following primers were used: E 5‟- AGT GCT GGC 
ACT GCA GTA GA-3‟, F 5‟- TGG ACA GCC GTC TAT CAG TG-3‟, G 5‟-GTC TGA 
TGC CAC CTT CTG GT-3‟. PCR was performed using the following prigram: 94°C for 
5 min, 94°C for 30 sec, 60°C for 30 sec, 72°C for 60 sec (40 cycles) 72°C for 5 min. The 
polymerase used was Platinum Taq polymerase (SKU #10966, Invitrogen, Carlsbad, 
CA). 
MiRNA quantification. Total RNA was isolated with Trizol reagent (cat. #15596-018, 
Invitrogen, Carlsbad, CA) from cryopreserved AML cells isolated from BM or spleen. 
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MiRNAs miR-17-5p, miR-20a, miR-19a, miR-19b-1, miR-18a and miR-92a were 
quantified using TaqMan miRNA assays (part #4427975, Applied Biosystems, Carlsbad, 
CA) according to the manufacturer‟s protocol. MiRNA microarrays were performed and 
analyzed by LC Sciences (Houston, TX). 
Vectors and cloning. MiR-17-92 genomic sequence was amplified from murine genomic 
DNA using the following primers: 5‟-CTG GTC AAT GTG AGG CTT TC-3‟ and 5‟-
CCG TTT TAC ACA CCA ACG AA-3‟. Vent DNA polymerase (cat. #M0254, NEB, 
Ipswich, MA) was used with the following PCR program: 94°C for 5 min, 94°C for 30 
sec, 60°C for 30 sec, 72°C for 60 sec (30 cycles), 72°C for 5 min. The PCR fragment was 
purified using QIAquick PCR purification kit (cat. #28106, QIAgen, Valencia, CA) and 
cloned into pGEM-T vector (cat. #A3600, Promega, Madison, WI). After isolation of 
plasmid DNA from positive clones, the insert was cut out of the vector with EcoRI 
restriction enzyme (cat. #R0101, NEB, Ipswich, MA) and cloned into pMSCV-PIG 
vector (generously provided by Scot Lowe, Cold Spring Harbor Laboratory, Cold Spring 
Harbor, NY) by the same site. Obtained clones were screened for forward orientation and 
sequenced. 
Retroviral construct that expressed shRNA targeting human and mouse Pten was 
purchased from Open Biosystems (oligo ID #V2SHS_231477, Huntsville, AL). The 
vector backbone for the construct is pSMP. 
Retroviral production. Phoenix packaging cells (generously provided by Gary Nolan, 
Stanford University, CA) were co-transfected with 2 µg miR-17-92-pMSCV-PIG or 
shPten-pSMP constructs and 2 μg ψ-Eco packaging plasmid with Effectene reagent (cat. 
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#301425, QIAgen, Valencia, CA) according to manufacturer's protocol. Retrovirus 
supernatants were collected at 48, 56, and 72 hrs and titered in NIH3T3 cells by FACS 
analysis of GFP expression or by serial dilutions and selection with puromycin at 4 
mkg/ml. 
Bone marrow transduction and transplantation (tBMT). Cbfb+/56M/Cre or Cbfb+/56M 
conditional knock-in mice were treated with polyinosinic-polycytidylic acid (pIpC, cat. 
#tlrl-pic, Invivogen, San Diego, CA). BM progenitor cells from both groups of mice were 
spin-infected twice with retrovirus supernatants, and 5x105 to 1x106 BM cells 
transplanted by intravenous injection (i. v.) into 6- to 8-week of age sublethally (650 
rads) irradiated 129SvEv wild-type recipient mice. Mice were under daily observation for 
early signs of leukemia, and peripheral blood was taken periodically to monitor for the 
presence of immature cells. The early signs included limited motility, pale paws, and 
dehydration. FACS analysis of peripheral blood was performed by using antibodies to 
cell-surface markers Sca1, Gr1, CD11b, B220, CD3, Ter119, CD71, and c-kit (BD 
Biosciences, San Diego, CA). Staining of peripheral blood smears and spleen sections 
were ordered from Histoserv (Germantown, MD). 
For secondary transplantations of miR-17-92/Cbfb-MYH11 AML, leukemic cells 
were harvested from the BM or spleen of affected mice in PBS, and 200,000 to 500,000 
cells were transplanted iv. into sublethally irradiated 6- to 8-week-old 129SvEv 
recipients. 
Akt induction. For induction of Akt phosphorylation via IL-3 stimulation, cryopreserved 
miR-17-92/Cbfb-MYH11 or spontaneous Cbfb-MYH11 AML cells were thawed and 
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immediately serum starved in RPMI media with 1% BSA for 60 min at 37°C (Invitrogen, 
Carlsbad, CA). Cells were then incubated with RPMI media with 0.1% BSA and 0, 10, or 
20 ng/ml IL-3 (cat. #213-13, Peprotech, Rockyhill, NJ) for 10 min. Cells were washed 
with PBS and resuspended in RIPA buffer with protease-inhibitor-cocktail III 
(Calbiochem, Darmstadt, Germany) and phosphatase inhibitor cocktails 2 and 3 (cat. # 
P5726, P0044, Sigma, St. Louis, MO). Antibodies included anti-phospho-Akt S473 (cat. 
#4058 Cell Signaling Technology, Danvers, MA) and anti-Akt (cat. #9272). 
Inhibition of miRNA function with antagomirs. Cryopreserved miR-17-92/Cbfb-MYH11 
AML cells were thawed and plated into Accell medium (cat. #B-005000-500, Thermo 
Scientific, Lafayette, CO) supplemented with 1% FBS (cat. #SH30088.03, HyClone, 
Logan, UT) and 6 ng/ml IL-3 (cat. # 213-13, Peprotech, Rockyhill, NJ), at 1,000,000 
cells/ml in 12- or 24-well plates. 24 hrs later the cells were treated with antagomirs at 
final concentration of 1 µM. 72 hrs after soaking with antagomirs, the cells were 
analyzed for apoptosis, cell cycle distribution or protein expression. 
The antagomirs are 2‟-OMe modified RNA oligos covalently linked to cholesterol 
moiety at 3‟-end. They were ordered from Dharmacon (custom RNA systhesis, Thermo 
Scientific, Lafayette, CO) and have sequences complementary to mature miRNA 
sequence of targeted miRNA. 
For immunoblot analysis, cells were washed with PBS and resuspended in RIPA 
buffer with protease-inhibitor-cocktail III (Calbiochem, Darmstadt, Germany) and 
phosphatase inhibitor cocktails 2 and 3 (cat. # P5726, P0044, Sigma, St. Louis, MO). 
Antibodies included anti-Pten (cat#9559, Cell Signaling Technology, Danvers, MA), 
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anti-phospho-Bad S136 (cat. #9295), anti-Bad (cat. #9292), anti-β-actin (cat. #5125). 
Immunoblot analysis of miRNA targets. Primary Cbfb-MYH11 spontaneous or miR-17-
92/Cbfb-MYH11 cryopreserved AML cells were thawed, washed with PBS and enriched 
for c-kit+ cells with EasySep mouse CD117 positive selection cocktail kit (cat. #18757, 
StemCell Technologies, Vancouver, Canada). The enriched cells were resuspended in 
RIPA buffer with protease-inhibitor-cocktail III (Calbiochem, Darmstadt, Germany) and 
phosphatase inhibitor cocktails 2 and 3 (cat. # P5726, P0044, Sigma, St. Louis, MO). 
Antibodies included anti-Pten (cat#9559, Cell Signaling Technology, Danvers, MA), 
anti-Mcl-1 (cat. #sc-819, Santa Cruz Biotechnology, Santa Cruz, CA), anti-p21 (cat. 
#ab7960, Abcam, Cambridge, MA), anti-Rb2 (cat. #610261, BD Transduction 
laboratories, Franklin Lakes, NJ), anti-Runx1 (cat. #PC285, Calbiochem) and anti-β-actin 
(cat#5125, Cell Signaling Technology, Danvers, MA). 
Apoptosis and cell cycle analyses. Cbfb+/MYH11/MiR-17-92 AML cells treated with 
antagomirs for 72 hrs (see above) were analyzed for apoptosis by flow cytometry as 
Annexin V+/7AAD- (BD Pharmingen, San Jose, CA) according to manufacturer‟s 
instructions. Alternatively, apoptosis was analyzed at the same time point by flow 
cytometry with Caspase Detection Kit (cat. #QIA92-1KIT, Calbiochem, Merck 
Biosciences, Darmstadt, Germany). For cell cycle analysis, the cells were fixed in 70% 
etnanol, 24 hrs later stained with propidium iodide and analyzed by flow cytometry. 
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Results 
Retroviral insertions upstream of miR-17-92 cluster upregulate expression 
of miRNA-17-5, -20a, and -19a 
A retroviral insertional mutagenesis (RIM) screen in mice expressing Cbfb-MYH11 
identified candidate cooperating genes in leukemia development (Castilla et al., 2004). 
Two retroviral insertions (called R1 and R2) were located within 1.2 kb upstream of miR-
17-92 cluster. Another insertion was identified upstream of miR-17-92 paralog miR-106a-
363 (Figure 2.1A, Table 2.1). We pursued further analysis with tumor samples with the 
R1 and R2 insertions. The presence of the insertions at miR-17-92 locus was confirmed 
by genomic PCR using virus-specific and genome-specific primers, and their forward 
orientation was identified by using alternative viral primers A and B (Figure 2.1B). 
Furthermore, Southern blot analysis of genomic DNA from spleens of affected mice 
using a probe from the viral sequence identified an insertion in the R1 but not the R2 
samples (Figure 2.1C). These results show that both leukemia samples include retroviral 
insertions upstream of the miR-17-92 cluster, and that in one case the majority of the 
sample included a leukemia cell population with the R1 insertion, while the other 
included a minor cell population with the R2 insertion. 
The expression of mature miRNAs in samples R1 and R2 was determined using a 
murine miRNA microarray plate assay. The expression of miRs-17-5p, -17-3p, -20a, -19b 
and -92a were upregulated in R1 (p < 0.01) in comparison to a control AML sample  
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Table 2.1. Retroviral insertion sites identified upstream of miR-17-92 
and miR-106a-363 miRNA clusters 
Insertion Clone Location Sequence 
R1 pc26 846 bp 
upstream of 
miR-17-5p 
TTTCAAGTAATTTTGAGCAAATGTGCTTACC
CTTTCTCTGTCTTCACCCCACCCCCAACCCT
AGTCATACACGTGGACCTAGCAGCACCCGA
AGCATTGCCCAAG 
R2 A26 425 bp 
upstream of 
miR-17-5p 
TTTCAACAATAATCATTAATCTTGTCGAGTA
TCTGACAATGTGGAGGACAGAAGAAAGGG
ATTGCTGCCTGGTCAATGTGAGGCTTTCCTC
TAAAGGTAGTACCA 
R3 A21 1472 bp 
upstream of 
miR-106a 
TTTCACCACCAACCCGAGAATGGAGGGAGA
GGCTTAAGCTTGGCGCGTTTTGGGGGCTTT
GAATGGAGAACTCCGTTTCCCATAATGCTT
TGTTTCTTTCTGTTT 
Insertion sites correspond to a genomic position following the LTR sequence TTTCA. 
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with no retroviral insertion in the locus, and in R2 there were no significant changes 
detected (Figure 2.1D, E). The expression changes were confirmed using a miRNA qPCR 
for miR-20a and miR-92a (p < 0.0001). In addition, we also identified low, but significant 
upregulation of miR-20a (p < 0.0001) and miR-92a (p = 0.016) in AML sample R2 
(Figure 2.1F). Taken together, these data show the retroviral insertions R1 and R2 within 
1.2 kb upstream of the miR-17-92 cluster in a forward direction, inducing upregulation of 
its miRNAs. 
MiR-17-92 cooperates with Cbfb-MYH11 in development of AML in vivo 
Based on identification of retroviral insertions at the miR-17-92 locus, and corresponding 
upregulation of miR17-92 miRNAs, we hypothesized that expression of miR-17-92 
cluster could cooperate with Cbfb-MYH11 in development of AML. We utilized a 
conditional Cbfb+/MYH11 knock in mouse that activated Cbfb-MYH11 expression after Cre-
mediated recombination of the CbfbMYH11 allele in hematopoietic progenitors (Kuo et al., 
2006). The protein Cre was temporarily induced from the Mx1-Cre transgene (Kuhn, 
1995). The expression of Cre is regulated by Inf/, induced by treatment with the 
double stranded ribonucleic polyinosinic-polycytidylic acid (pIpC). We performed bone 
marrow transplantation assays using donor Cbfb+/MYH11; Mx1Cre BM cells transduced 
with pMSCV-PIG retrovirus expressing the miR-17-92 cluster under the LTR regulation 
and Puromycin resistance gene and GFP regulated by the PGK promoter (Figure 2.2A). 
Control groups included floxed Cbfb+/MYH11 BM transduced with pMSCV-PIG or  
88 
   
89 
  
90 
pMSCV-PIG-miR17-92 viruses. The three groups of cells were transplanted with i. v. 
injections into sublethally irradiated wild type recipient mice (Figure 2.2B). 
Ninety percent of mice (9/10) transplanted with Cbfb+/MYH11/miR-17-92 BM cells 
succumbed to leukemia 64 to 134 days after transplantation (Figure 2.2 C, pink line). 
None of the control groups (WT BM transduced with miR-17-92, and Cbfb+/MYH11 BM 
transduced with vector alone developed a disease for over 180 days (experimental 
endpoint). Secondary transplantation of 5x105 leukemic cells reproduced leukemia with a 
median latency of 3 weeks, and all recipients developed leukemia within 7 weeks (Figure 
2.2C, red line). The pathology of leukemia was characterized by elevated WBC count in 
PB (Figure 2.3B; p < 0.0001), and the presence of immature myeloid blasts (Figure 
2.3A). The PB was enriched with Lin-c-kit+ cells (p < 0.0001), other lineages were 
decreased except for Gr1+ and Ter119+ populations that did not change significantly 
(Figure 2.3C). The GFP+ cells (carrying miR-17-92-expressing retorvirus) were Lin-c-kit+ 
with a small subpopulation of c-kit+Sca1+ cells (Figure 2.3C), reminiscent of early 
hematopoietic progenitors that include the HSCs. In addition, leukemic mice presented 
marked splenomegaly due to infiltration of the leukemic blasts into peripheral organs 
(Figure 2.3D). Taken together, the cooperation between CBFB-MYH11 and miR-17-92 
expression results in a myeloid leukemia with a pathology that is driven by the expression 
of CBFB-MYH11, as it has previously been reported (Kuo et al., 2006; Kuo et al., 2009; 
Landrette et al., 2005).  
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Expression of miR-17-92 associated microRNAs in Cbfb-MYH11 
leukemia cells 
The expression levels of different miRs from the miR-17-92 cluster vary, suggesting 
differential posttranscriptional processing. The expression of miR-17, -20a, and -19a/b 
seems to follow a similar pattern, while that of miR-18a and -92a is different (Hayashita 
et al., 2005; Lu et al., 2007). In collaboration with Dr. Mojca Jongen-Lavrencic, we 
analyzed the expression levels of miRs from the three paralog clusters in human AML 
samples (Jongen-Lavrencic et al., 2008). Analysis of 15 inv(16) AML samples showed 
expression of miRs from the miR-17 (7/15), and miR-18 (6/15) families (Figure 2.4A). 
The analysis in Cbfb+/MYH11/miR-17-92 AML cells in comparison to WT sorted myeloid 
progenitors and to unrelated Cbfb+/MYH11 AMLs using miRNA qPCR showed that miRs-
17-5, -20a, -19a and -19b were upregulated in all Cbfb+/MYH11/miR-17-92 samples (p < 
0.04), while miR-18a and miR-92a were not significantly changed (Figure 2.4B). This 
expression pattern provides correlative evidence suggesting that these miRs are expressed 
in a fraction of human inv(16) AMLs and that miR-17 and/or -19 family miRs may direct 
the leukemic signal in these samples. 
Inhibition of miR-17 and miR-20a in Cbfb
+/MYH11
/miR-17-92 AML cells 
results in increased level of apoptosis 
Based on the miRNA expression data, we focused our studies on the role of miR families 
-17 and -19 in leukemia development. We tested the survival of leukemic cells expressing  
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Cbfb-MYH11 and miR-17-92 after downregulation of miR-17-5p, miR-20a, miR-19a and 
miR-19b. Antagomir-mediated inhibition of miR-17 or -20a significantly increased the 
number of apoptotic cells (p<0.01) as measured by percentage of Annexin V+/7AAD- 
cells compared to scramble oligo or day zero values (Figure 2.5A). Treatment with 
combined anti-miR-17 and -20a further increased cell death (p<0.001). Conversely, cells 
treated with anti-miRs-19a or -19b did not show altered cell death rate. Apoptosis was 
also estimated in a similar experiment measuring the levels of caspase cleavage by means 
of the percentage of PE-FMK-VAD+ label (Figure 2.5B). Cells treated with antagomirs 
for single or combined miR-17 and -20a significantly increased caspase activity, while 
treatment with anti-miR-19a/b had no significant effect. The anti-apoptotic effect of miR-
17 and miR-20a was specific to Cbfb+/MYH11/miR-17-92 AMLs, as unrelated Cbfb-MYH11 
AML cells did not exhibit changes in apoptosis upon treatment with any of the 
antagomirs (Figure 2.5C). The cell cycle phases distribution was not altered by treatment 
of Cbfb+/MYH11/miR-17-92 AML cells with antagomirs (Figure 2.5D). These data indicate 
that miR-17 family miRs and not miR-19 family miRs provide an anti-apoptotic signal in 
Cbfb+/MYH11/miR-17-92 leukemic cells, sugesting a possible mechanism of miR-17-92 
cooperation with Cbfb-MYH11. 
MiR-17-92 cluster downregulates Pten expression in the Cbfb
+/MYH11/miR-
17-92 leukemic blasts 
The miRs of families miR-17 and -19 regulate protein levels of factors associated with 
proliferation, differentiation and survival. Considering that such regulation is cell type  
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specific, we tested the expression of miR-17 targets in a panel of Cbfb-MYH11 AML cells 
with or without overexpression of the miR-17-92 cluster using Western blot analysis. In 
order to minimize contamination from non-leukemic cells, leukemic cells were enriched 
from spleen for c-kit+ using magnetic beads to obtain highly GFP+c-kit+ cells with more 
than 90% purity (Figure 2.6A). The expression of Rb2 and Runx1 in Cbfb+/MYH11 AML 
cells (n=3) and Cbfb+/MYH11/miR17-92 AML (n=7) cells showed an irregular expression 
pattern in both groups (Figure 2.6 B). Similarly, levels of p21 protein and the anti-
apoptotic Mcl-1L isoform were unchanged, while expression of the pro-apoptotic short 
Mcl-1S isoform was also inconsistently changed (Figure 2.6.C). However, we found 
consistent and significant decrease (p=0.02) in Pten protein levels only in AML samples 
expressing the miR-17-92 cluster, when compared to AML cells not expressing the 
cluster and to hematopoietic progenitor and myeloid progenitor controls (quantification 
of the Western blot in Figure 2.6D). These data suggest that miR-17-92 overexpression in 
the AML cells results in down-regulation of Pten with possible activation of PI3K/Akt 
pathway. 
miR-17-92 activates PI3K/Akt signaling via Pten downregulation 
The 3‟-UTR of Pten contains two target sites for miR-17 family and one target site for 
miR-19 family, and it has been shown to be a target of these miRs (Olive et al., 2009; 
Takakura et al., 2008; Xiao et al., 2008). Since Pten levels are reduced in 
Cbfb+/MYH11/miR-17-92 leukemias, we reasoned that miR-17/20a and -19a/b may affect 
Akt phosphorylation. Leukemic cells from Cbfb+/MYH11 and Cbfb+/MYH11/miR-17-92  
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groups were stimulated with IL3, and levels of Akt and Akt phosphorylation at S473 
residue was tested. We found that while Akt levels were not significantly altered, S473-
phospho Akt was increased only in Cbfb+/MYH11/miR-17-92 AML cells upon stimulation 
with IL-3 in a dose-dependent manner (Figure 2.7A). 
An Akt-mediated anti-apoptotic signaling occurs in part through inhibiting 
activity of the BCL2-related Bad protein via phosphorylation at its S136 residue. We 
sought to determine whether inhibition miR-17 or miR-19 families in Cbfb+/MYH11/miR-17-
92 cells increase S136 phospho-Bad level. We found that leukemic cells treated with 
miR-17/20a or -19a/b antagomirs presented a significant decrease in S136-pBad levels, 
indicating that both miR-17/20a and miR-19a/b activity results in phosphorylation of Bad 
in the AML cells (Figure. 2.7B). Taken together, the data suggest that both miR-17 and 
miR-19 family of miRNAs from the miR-17-92 cluster induce PI3K/Akt signaling in the 
AML cells. 
Discussion 
The work presented in this chapter demonstrates that upregulation of the miR-17-92 
cluster cooperates with the leukemia fusion protein CBFβ-SMMHC as an oncomiR in 
mouse AML. We determined that the miR-17-5p and miR-20a provide an anti-apoptotic 
advantage, a function that seems to be independent of Bad phosphorylation. 
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MiR-17-92 cooperates with Cbfb-MYH11 in AML development 
Identification of the retroviral insertions upstream of miR-17-92 cluster suggests that this 
cluster can act as an oncomiR. Overexpression of the cluster has been shown to promote 
B-cell lymphomas in a mouse model overexpressing the oncogene Myc (He et al., 2005). 
The cluster was also identified in a RIM screening for T-cell ALL and was shown to be 
overexpressed in a large fraction of human T-cell lymphomas (Landais et al., 2007; 
Landais et al., 2005). MicroRNA expression profiling in human AML showed that these 
miRs are consistently upregulated in MLL-fusions associated leukemia cases bearing 
chromosomal 11q23 translocations, but not CBF AML cases (Jongen-Lavrencic et al., 
2008; Li et al., 2008; Mi et al., 2010). These data suggest that MLL-fusion proteins may 
directly regulate the expression of the cluster, and that miR-17-92 upregulation in CBF 
AMLs may emerge as a cooperating event. Supporting this idea, over 40% of human 
inv(16) AML cases expressed some of the miR-17-92 miRs, mainly miR-17-5p, miR-18a, 
and miR-20a. While a panel of Cbfb+/MYH11 mouse leukemias did not overexpress these 
miRs, the R1 sample from the RIM screening and the Cbfb+/MYH11/miR-17-92 leukemias 
overexpressed miR-17-5p, -18a, -20a, and -19a/b. In addition, the identification of a third 
retroviral insertion at the Kis2 locus upstream of miR-106a-363 cluster suggests that 
upregulation of miRs from this miR-17-92 paralog could also function as an oncomiR in 
AML. 
We did not find any insertions near another miR-17-92 paralog miR-106b-25. This 
cluster is overexpressed in human prostate cancers and is involved in targeting of the 
tumor suppressor PTEN in the prostate cancer cells (Poliseno et al., 2010). miR-106b-25 
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cluster expresses miR-106b, miR-93 (miR-17 family) and miR-25 (miR-92 family), but 
lacks miR-19 family miRNAs. The reason why miR-17-92 was found most frequently out 
of all three paralogs might be explained by small number of samples screened, although 
knock-out studies for all three miRNA clusters indicate that some functions of miR-17-92 
cannot be compensated by other paralogs. Importantly, both miR-17-92 and miR-106b-25 
had similar expression pattern, therefore the observed lack of compensation has to be 
explained by functional differences of the clusters and not just tissue specificity. 
Therefore, it is possible that miRNAs from the same miRNA families still have distinct 
functions, and miR-17-92 provides more efficient cooperation than miR-106a-363 or 
miR-106b-25, if they provide any. Another explanation is that retroviral integration may 
not be completely random, and some loci are more frequently integrated than others. 
Finally, absence of insertions that would upregulate miR-106b-25 expression could 
potentially indicate that miR-19 function is required for the cooperation. The potential 
oncogenic functions of the miR-106a-363 and miR-106b-25 alone or in cooperation with 
Cbfβ-SMMHC can be tested by utilizing murine BM transduction and transplantation 
into recipient mice as described above for miR-17-92. 
Using a conditional Cbfb+/MYH11 knock-in a mouse model of inv(16) AML, we 
proved that miR-17-92 cooperates with Cbfb-MYH11 in development of AML in vivo. 
The leukemia phenotype was similar to the one described in previous Cbfb-MYH11-
associated studies (Kuo et al., 2006; Landrette et al., 2005), supporting the model that the 
fusion protein regulates the disease progression and differentiation block and the miR-17-
92 provides survival and/or proliferative advantage in the myeloid compartment (Fontana 
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et al., 2007). In contrast, in a mouse Eµ-myc model of B-cell lymphoma, miR-17-92 
changed phenotype of leukemic cells by causing earlier differentiation block than c-Myc 
itself (He et al., 2005). Spontaneous Eµ-myc-associated B-cell lymphomas have various 
B-cell phenotypes from pre-B to mature B-cells indicating that the Myc oncogene 
prevents normal B-cell differentiation at later stages than miR-17-92 that blocks pro-B to 
pre-B transition (Ventura et al., 2008). Therefore, effects of miR-17-92 on differentiation 
are dependent on cellular context. 
Importantly, in mice miR-17-92 overexpression by itself was not sufficient for 
AML development, thus it needs a pre-leukemic environment in order to efficiently 
support oncogenic transformation. Unlike ability of miR-17-92 alone to cause 
lymphoproliferative phenotype when overexpressed in lymphoid progenitors (Xiao et al., 
2008), we did not observe any hematopoietic disease, including myelo- or 
lymphoproliverative disorders, upon overexpression of miR-17-92. This discrepancy can 
be explained by the experimental setup: in the Xiao et al. study all or majority of 
lymphoid progenitors expressed miR-17-92, and the expression the miRNAs was strongly 
upregulated. Even in these conditions the mice started to develop lymphoproliferative 
diseases close to 20 weeks after induction of miRNA expression. In our studies only 15-
20% of BM cells expressed Cbfb-MYH11 at the time of transduction (Kuo et al., 2006), 
and the transduction efficiency with miR-17-92 construct was 15% (data not shown). 
Moreover, upregulation of miR-17-92 was less efficient than in the Xiao et al. study. 
Therefore, the latency of the disease could be longer than a 6-months period that the mice 
were monitored. 
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Pten is miR-17-92 target in AML cells 
PTEN phosphatase regulates PIP3 to PIP2 transition in a cell membrane and inhibits 
activity of PDK/AKT signaling. It acts as a tumor suppressor that is mutated in multiple 
types of cancers, and it is a target of miR-17-92 in B- and T-cell leukemias (Mavrakis et 
al., 2010; Olive et al., 2009). PTEN mutations are not common in AML, yet the 
PI3K/AKT pathway is frequently affected downstream of major mutations that are found 
in AML, including RAS and RTK mutations (Martelli et al., 2006). 
We show that Pten was the only miR-17-92 target protein tested that was 
consistently downregulated in the Cbfb+/MYH11/miR-17-92 AML in comparison to 
Cbfb+/MYH11 AML, whereas other targets, including Runx1, Cdkn1a and Rbl2 were not 
consistently changed. This is possibly due to a cell type specific regulation of the miR 
targets. For example, RUNX1 is regulated by miR-17/20a in the cell fate decision of 
granulocytic-myeloid progenitors and human monocytic cell lines that undergo 
granulocytic differentiation (Fontana et al., 2007), a differentiation step posterior to the 
myelomonocytic block directed by the CBFβ-SMMHC. Another possibility is that Cbfb-
MYH11 may need residual RUNX function for its oncogenic activity (as discussed in 
Chapter I), therefore downregulation of RUNX1 with miR-17-92 could be selected 
against in a fraction of AML samples. Thus, miR-17-92 targets that are found in cancers 
may not only reflect ability of the miRNAs to downregulate their targets in a given tissue, 
but also be a result of selection for those targets that promote or at least do not impede the 
tumorigenesis. 
We analyzed effectors downstream of Pten in the PI3K/Akt pathway. The 
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phosphorylation of Akt was increased in response to IL-3 cytokine in Cbfb+/MYH11/miR-
17-92 AML cells but not Cbfb+/MYH11 AML cells. Furthermore, inhibition of either miR-
17/20a, or miR-19a/b decreased inactive (phosphorylated) form of the proapoptotic 
protein Bad. These results are in line with the model that miRs from the miR-17-92 
cluster target Pten levels, triggering signaling through Akt and Bad. This corresponds to 
studies in lymphoid leukemias identifying Pten as a key target in miR-17-92-mediated 
leukemia (Matsubara et al., 2007; Olive et al., 2009; Takakura et al., 2008; Yu et al., 
2010b). 
MiR-17-92 cluster provides anti-apoptotic signal in Cbfb
+/MYH11
/miR-17-92 
AML 
The functional assays on survival of Cbfb+/MYH11/miR-17-92 AML cells after treatment 
with miR-17 or miR-19 inhibitors by measuring caspase cleavage and accumulation of 
Annexin V-positive cells suggest that at least part of the anti-apoptotic response is 
specific to miR-17 family and independent of miR-19. The apparent contradiction with 
the Pten/Bad results seems to point at a second mechanism of survival in the leukemic 
cells. The possible mechanism underlying these results is still unclear. Anti-apoptotic 
function of miR-17-92 was shown in different tissues to be due to E2F1 that is involved 
in a feedback loop with miR-17/20a, and is not regulated by miR-19a/b (Phillips and 
Vousden, 2001; Sylvestre et al., 2007). Another possible mechanism can be BIM 
downregulation that was shown to be an effector in miR-17-92 anti-apoptotic signaling 
(Dai et al., 2011; Molitoris et al., 2011). However, it is not evident that Bim plays a role 
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in these particular AMLs. Bim was not consistently downregulated in the AML samples, 
and it can also be theoretically regulated by both miR-17/20a and miR-19a/b. Examples 
of putative miR-17 specific targets include the MAP2K3 (MEKK2) kinase, which signals 
through JNK and NFκB pathways, and the hematopoiesis-specific Dual specificity 
protein phosphatase (DUSP2), which negatively regulates ERK1 and ERK2 (Ward et al., 
1994). 
An open question is how relevant the observed role of miR-17-92 in Cbfb+/MYH11 
AML is in the context of human AML. The antagomir technology provides an excellent 
opportunity to test a response of human AML samples to inhibition of the miRNAs from 
the miR-17-92 cluster in vitro. If a pro-apoptotic and/or anti-proliferative response that 
correlates with the miRNA expression was determined upon treatment of human AML 
samples with the miRNA inhibitors, this would suggest relevance of the observed data to 
the pathology of human AML. 
Role of individual miRNAs 
We have shown that not all miRNAs from the miR-17-92 cluster are overexpressed in the 
AML samples. The original R1 sample identified from RIM as carrying a retroviral 
insertion next to the miRNA cluster, had most miRNAs from the cluster overexpressed, 
but levels of miR-18a and miR-19a were the same as in a control AML sample. In the 
murine Cbfb+/MYH11/miR-17-92 AMLs obtained as a result of cooperation between the 
fusion protein and miR-17-92, miR-18a and miR-92a were not consistently upregulated 
(although they were upregulated in a subset of the samples). Reports indicate that 
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individual miRNAs from a cluster can be regulated independently, as it was shown for 
miR-18a (Guil and Caceres, 2007). Importantly, absence of overexpression of miR-18a 
and miR-92a from the full length miR-17-92 cluster does not prevent the cooperation 
between Cbfb-MYH11 and miR-17-92, suggesting that the cooperation occurs mostly due 
to the function of members of miR-17 and/or miR-19 miRNA families. In a study of 
cooperation between miR-17-92 and Eµ-myc in B-cell lymphoma development, the 
authors used miR-17-19b truncated version of the cluster that was as efficient in 
cooperation as the full length cluster (He et al., 2005), suggesting that miR-92a is not 
playing a role in the cooperation, which goes in line with our results in AML cells. 
We have shown the functional difference between miR-17/20a and miR-19a/b in 
apoptosis regulation in the Cbfb+/MYH11/miR-17-92 AML cells. In lymphoid leukemias 
with miR-17-92 role of miR-19 miRNA family was shown to be pivotal for leukemia 
development and cooperation with other oncogenes, e.g. c-Myc in a model of B-cell 
lymphoma (Olive et al., 2009). Yet, in lung cancers miR-17 and miR-20a provided the 
strongest anti-apoptotic effect leading to “oncomiR addiction”, when cancer cells 
constantly need high level of miR-17/20a expression in order to keep apoptosis at a low 
level (Matsubara et al., 2007). Our data suggest that despite both miR-17 and miR-19 
families regulating Bad phosphorylation in the AML cells, miR-17 family provides 
additional signaling essential for apoptosis regulation in Cbfb+/MYH11/miR-17-92 AMLs. 
Yet, we cannot exclude a potential role of miR-19a/b in the process that could provide 
changes in gene expression enhancing miR-17/20a effects, or create a correct gene 
expression context that allows miR-17/20a to determine the anti-apoptotic effect. 
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Individual expression of each miRNA alone or in pools in the context of the Cbfb+/MYH11 
conditional knock-in mouse model could clarify this question. 
In summary, the studies presented in this chapter provide evidence for a role of 
miR-17-92 microRNA cluster in acute myeloid leukemia development in cooperation 
with the fusion oncoprotein CBFβ-SMMHC. Furthermore, we provide evidence for the 
survival role of microRNAs of the miR-17 family in the leukemic cells. 
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CHAPTER III 
THPO/MPL signaling participates in the initiation and 
maintenance of RUNX1-ETO acute myeloid leukemia 
via PI3K signaling 
Foreword 
The first part of the work described in this chapter has been published (Landrette et al., 
2011), in which I am a co-first author. My contribution included (1) the investigation of 
activity of different PlagL2 binding sites in Mpl promoter using electrophoretic mobility 
shift assay (EMSA) (Figure 3.5C), (2) participation in the BMT assays of cells expressing 
Cbfb+/MYH11/PlagL2, (3) participation on the BMT assays involving donor cells 
expressing Cbfb+/MYH11/Mpl, and (4) writing and editing parts of the discussion and 
writing of the manuscript.  
The second part of the work described in this chapter is part of a manuscript that 
is currently under revision for publication. This work includes a collaboration with Peter 
Valk, and I am the first author. 
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Introduction 
Acute myeloid leukemia (AML) results from the alteration of genes associated with 
proliferation, differentiation, and survival. These functions can be altered by mutations in 
genes encoding for transcription factors and cytokine receptors that are essential for 
normal hematopoietic function. The leukemia fusion protein RUNX1-ETO is created by 
the chromosome translocation t(8;21), and is found in 12% of AML samples (Look, 
1997). The fusion protein increases survival of hematopoietic progenitors in vitro, and 
inhibits differentiation of hematopoietic progenitors (Mulloy et al., 2002; Okuda et al., 
1998). Expression of RUNX1-ETO is not sufficient for leukemic transformation in 
animal models (Yuan et al., 2001b), but it induces AML in cooperation with oncogenic 
mutations in proteins associated with cytokine signaling. Examples are the oncogenic 
mutations in genes encoding the receptor tyrosine kinases c-KIT and FLT3, and their 
downstream GTPases NRAS and KRAS (Boissel et al., 2006a; Care et al., 2003; Schessl 
et al., 2005b; Speck et al., 1999; Valk et al., 2004a).  
The myelo-proliferative leukemia virus oncogene MPL (c-MPL or CD110) is a 
homodimeric receptor activated by the cytokine THPO, and regulates proliferation in 
HSCs and megakaryocytes (Kaushansky and Ranney, 2009b). The MPL receptor is 
expressed in 70% of cells within the HSC compartment and is markedly reduced upon 
HSC differentiation (Kaushansky et al., 1996; Solar et al., 1998). The THPO/MPL 
signaling regulates the expansion and maintenance of HSCs and early progenitors via 
activation of JAK/STAT, ERK/MEK and PI3K/AKT pathways (Kaushansky, 2009b). 
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The number and function of HSCs is markedly reduced in Mpl-null and Thpo-null mice 
(Alexander et al., 1996; Carver-Moore et al., 1996; Gurney and de Sauvage, 1996; 
Kimura et al., 1998b). Furthermore, the self-renewal capacity of long-term HSCs is 
reduced 10- to 20-fold in Thpo-null recipients, an effect that can be rescued with the 
addition of recombinant-THPO (Fox et al., 2002b).  
Mutations identified in human disease also highlight the importance of MPL 
signaling in homeostasis of the hematopoetic compartment. Nonsense mutations in the 
MPL and THPO genes cause congenital amegakaryocytic thrombocytopenia, with severe 
thrombocytopenia and aplastic anemia (Ballmaier and Germeshausen, 2009). Somatic 
activating mutations in MPL cause constitutive JAK2 activation and are associated with 
myeloproliferative neoplasms, including myelofibrosis with myeloid metaplasia and 
essential thrombocythemia (Pardanani et al., 2006; Pikman et al., 2006). In AML, 
mutations in MPL gene have been detected in a quarter of AMKL (Hussein et al., 2009b). 
However, the functional role of increased levels of wild type MPL in the initiation and 
maintenance of AML is unknown. 
In this study, we used human AML cells and mouse transplantation models to 
study the role of MPL in leukemia development. We find that a large fraction of t(8;21) 
AML samples expresses MPL transcript, and proliferates in response to THPO. We use 
transplantation assays in mice to show that expression of RUNX1-ETO and Mpl synergize 
to induce leukemia. We find that Mpl levels are not regulated by RUNX1-ETO in mouse 
hematopoietic progenitors and leukemic cells, and show negative correlation with RTK 
mutations in human AML cells. Biochemical analysis of the mouse leukemic cells 
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showed that Mpl expression sensitizes leukemic blasts to JAK2, ERK, STAT and AKT 
phosphorylation. Furthermore, the survival signal promoted by THPO can be abrogated 
with a PI3K inhibitor, and leukemia expansion in mice can be delayed by mTOR-
inhibitor rapamycin. These studies show that MPL expression provides an oncogenic 
signal that cooperates with RUNX1-ETO in leukemia development and maintenance. 
Materials and methods 
Reverse transcriptase and quantitative RT-PCR analyses. RNA from mouse BM and 
AML cells was extracted with Trizol (Invitrogen, Carlsbad, CA). First-strand cDNA was 
generated by using 2 μg RNA, 1 U Superscript III reverse transcriptase (Invitrogen, 
Carlsbad, CA), and 0.5 μM oligo-dT or random hexamer primers in a 20-μL reaction. 
SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) was used for 
qPCR according to the manufacturer's instructions. Mpl primers were Mplx1 (5‟-
ACTTTGATCCAGCGGGTGCT-3‟) and Mplx2 (5‟-CAGGAAGTCACTGATTTCAG-
3‟). The β-actin primers were ActbF1 (5‟-CGAGGCCCAGAGCAAGAGAG-3‟) and 
ActbR1 (5‟-CGGTTGGCCTTAGGGTTCAG-3‟). QPCR was performed in a StepOne 
Plus Sequence Detection System (Applied Biosystems Foster City, CA). Samples were 
normalized to β-actin transcript levels, and relative values were determined using 
standard curve or comparative CT methods. 
DNA sequence analysis. The search for PLAG consensus site GRGGC(6–8)RGGK was 
analyzed using the UCSC Genome Browser on Mouse July 2007 (NCBI37/mm9) 
119 
Assembly (http://genome.ucsc.edu). Promoter regions were defined as 1000 bp upstream 
and 200 bp downstream of transcription start site, with this site as position 1000. 
Evolutionary conservation of PLAG sites among six mammal species (human, orangutan, 
mouse, rat, dog and horse) was estimated. The sequence conservation analysis at the Mpl 
proximal promoter was performed using ClustalW-Alignment Analysis from 
MacVector9.5.2 (MacVector Inc., Cary, NC, USA). 
Luciferase assays. A 300 bp fragment of the Mpl proximal promoter was amplified with 
primers MPLFLPromkpnF and MPLFLpromBglR using PFU (Stratagene, La Jolla, CA, 
USA), and the amplicon was digested with KpnI and BglII and cloned into pGL3-Basic 
(Promega, Madison, WI, USA). Mutants were constructed by overlapping PCR with 
primers Mpls1F and Mpls1R for „site-1‟, Mplps2F and Mplps2R for „site-2‟, and 
Mplps3F and Mplps3R for „site-3‟ (for primer sequences, see (Landrette et al., 2011)). 
The mutant primers were used with primers MPLFLpromkpnF and MPLFLpromBglR to 
amplify overlapping fragments that were annealed, digested with KpnI and BglII and 
cloned into the PGL3-basic vector. Constructs were transfected into NIH3T3 cells along 
with MIhCD4 or MIhCD4-PLAGL2 and PRL-TK with Effectene (Qiagen). Cells were 
analyzed for luciferase levels with the Dual-Luciferase Reporter Assay System 
(Promega). 
Electrophoretic mobility shift assay. The electrophoretic mobility shift assay was 
performed as previously described (Javed et al., 2004). Briefly, 3T3 cells transfected with 
MIG-PlagL2 were used for isolation of nuclear proteins and added to protein–DNA 
binding reactions with double-stranded DNA oligos representing PlagL2-binding sites in 
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the Mpl promoter. The sequence for DNA oligos P1ss and P1as, P2ss and P2as, P3ss and 
P3as, mutP1ss and mutP1as, mutP2ss and mutP2as, and mutP3ss and mutP3as are shown 
in (Landrette et al., 2011). The P1ss, P2ss and P3ss oligos were radioactively labeled with 
32P using OptiKinase (USB, Cleveland, OH, USA), and the excess 32P-γATP was 
removed by purifying the labeled oligos using G-25 Mini Quick Spin Oligo columns 
(Roche, Basel, Switzerland). The oligos were annealed with equal amounts of antisense 
oligos (P1as, P2as, P3as respectively) to obtain a double stranded labeled oligo with a 
PlagL2-binding site. In all, 100 pg of the oligo was used for each binding reaction. Cold 
competitors and mutant competitors were obtained the same way, but without labeling 
the oligos. When using cold competitors (wild type or mutant), a 1:200 molar ratio of 
labeled and cold oligo was used. Constant DNA amount was maintained by adding 
scrambled oligos Sss and Sas. The protein–DNA binding reactions were loaded onto a 
4% polyacrylamide gel, ran until unlabeled 32P-gATP went out into buffer, dried and 
exposed for 24 h. 
Analysis of human AML samples. Expression Analysis: Bone marrow leukemia blasts 
from 162 patients with AML at diagnosis (classified according to the French-American-
British nomenclature) and 6 healthy volunteers were obtained after informed consent. 
Approval was obtained from the Erasmus Medical Ethical Review Committee for these 
studies. Blasts from patients with AML and mononucleated fractions from normal BM 
specimens were isolated by Ficoll-Hypaque (Nygaard, Oslo, Norway) centrifugation and 
then cryopreserved. After thawing, cells were washed with Hanks Balanced Salt Solution 
(HBSS) and further processed for RNA isolation. AML samples treated according to this 
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procedure usually contain more than 90% blasts after thawing. Total RNA was extracted 
with guanidium thiocyanate followed by centrifugation in cesium chloride solution. RNA 
(1 μg) was transcribed into cDNA by using Superscript (Life Technologies, Merelbeke, 
Belgium) and random hexamers in a 40-μL reaction, under standard conditions. The 
qPCR amplification was performed in an ABI PRISM 7900 HT Sequence Detector, using 
12.5 μL SYBR Green PCR Master Mix (Applied Biosystems, Nieuwerkerk a/d IJsel, The 
Netherlands), 2 μL (1/20th aliquot) cDNA, 2.5 pmol primer mix (Life Technologies), and 
10 μL water. The PCR conditions included 2 min at 50°C and 10 min at 95°C followed 
by 45 cycles of amplification (each with a 15 sec denaturation step at 95°C and a 1 min 
annealing/extension step at 60°C). The MPL primers were hMPLx1 (5‟-
CCAGCCAGGGGAACTTC-3‟) and hMPLx2 (5‟-GCTTTGGTCCATCTTGCC-3‟). 
MPL expression was determined using the assay-on-demand Hs00180489-m1 
(Applied Biosystems, Foster City, CA). To determine MPL relative expression levels, the 
average CT (threshold cycle) values from duplicate readings were normalized for 
endogenous reference (ΔCt = Ct target - Ct PBGD) and compared with a calibrator using 
the "delta-delta Ct method" (ΔΔCt = ΔCt Sample - ΔCt Calibrator). As calibrator we used 
the average Ct value of MPL in 6 CD34+ samples from healthy volunteers. The relative 
expression was calculated (2-ΔΔCt). Pearson correlation analysis was performed to 
assess the linear relationship between MPL expression and induction of growth by 
THPO. Log transformed data were used for this analysis in order for the three variables to 
be approximately normal. 
Mutation Analysis: The analysis for mutations in KIT, FLT3, NRAS and KRAS 
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genes in AML samples was performed as previously described (Care et al., 2003; Valk et 
al., 2004a). Microstimulation assay with cytokine THPO: Ficoll-isolated mononuclear 
cells of the primary AMLs were suspended in IMDM/1% BSA and plated on tissue 
culture dishes for 1 hour at 37ºC. Non-adherent cells were collected and 2x104 cells were 
stimulated with 100ng/ml THPO for 3 days. 3H-thymidine incorporation was measured 
after an 8 hrs incubation period. 
Retroviral production. The MIG-Mpl construct was generously provided by Harvey 
Lodish (Massachusetts Institutes of Technologies, Cambridge MA). Mpl was subcloned 
into the pMSCV-IRES-hCD4 (MID) vector via the BglII and XhoI sites. The RUNX1-
ETO cDNA (provided by Peter Westervelt, Washington University, Saint Louis MO) was 
cloned into the XhoI site of MIG. PLAGL2 was cloned into MID via the BglII and XhoI 
sites. Phoenix packaging cells (provided by Gary Nolan, Stanford University, Stanford 
CA) were co-transfected with 2 μg retroviral constructs, 2 μg ψ-Eco packaging plasmid 
with Effectene reagent (Qiagen, Valencia, CA) according to manufacturer's protocol. 
Retrovirus supernatants were collected at 48, 56, and 72 hrs and titered in NIH3T3 cells 
by FACS analysis of GFP or hCD4 expression. 
Bone marrow transduction and transplantation (tBMT). Wild type BM progenitor cells 
were spin-infected twice with retrovirus supernatants, and 5x105 to 1x106 BM cells 
transplanted by intravenous injection (iv.) into 4- to 6-week of age sublethally (650rads) 
or lethally (split dose of 500 rads) irradiated 129SvEv wild-type recipient mice. Mice 
were under daily observation for early signs of leukemia, and peripheral blood was taken 
periodically to monitor for the presence of immature cells. The early signs included 
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limited motility, pale paws, and dehydration. FACS analysis of peripheral blood was 
performed by using antibodies to cell-surface markers Gr1, CD11b, B220, CD3, Ter119, 
CD71, and c-kit (BD Biosciences, San Diego, CA). For flow cytometry analysis of Mpl 
receptor expression, we used a polyclonal rabbit anti-Mpl extracellular domain antibody 
(provided by Harvey Lodish, Whitehead Institute for Biomedical Research, Cambridge 
MA) and a PE-anti rabbit secondary antibody (BD Biosciences, San Diego CA). Staining 
of peripheral blood smears and spleen sections were ordered from Histoserv 
(Germantown, MD). 
For secondary transplantations of RUNX1-ETO/MPL AML, leukemic cells were 
harvested from the BM or spleen of affected mice in PBS and sorted for hCD4+ and 
GFP+hCD4+ populations by FACS. 80,000 sorted cells were transplanted i. v. into 
sublethally irradiated 4- to 6-week-old 129SvEv recipients. 
The rapamycin experiments consisted of transplantation of 1x105 RUNX1-
ETO/PL2 AML cells into sublethally irradiated recipients. Recipient mice were daily 
treated intra-peritoneally with 200 μL of 80 μg/mL rapamycin (Calbiochem, San Diego, 
CA) as previously described (Yilmaz et al., 2006). Moribund animals were analyzed as 
described above. 
Immunoblot analysis. Cryopreserved AML cells were thawed and immediately serum 
starved in RPMI media with 1% BSA for 60 min at 37°C (Invitrogen, Carlsbad, CA). 
Cells were then incubated with RPMI media with 0.1% BSA and 0, 5, 25, or 50 ng/ml 
THPO (Peprotech, Rockyhill, NJ) for 10 min. Cells were washed with PBS and 
resuspended in RIPA buffer with protease-inhibitor-cocktail III (Calbiochem, Darmstadt, 
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Germany). Antibodies included anti-Jak2 (cat#sc-294; Santa Cruz Biotechnology Inc., 
Santa Cruz, CA), and antiphospho-Jak2-Tyr221 (cat#3774), anti-phospho-Stat5-Tyr694 
(cat#9351), anti-Stat5 (cat#9310), anti-phospho-Akt-Ser273 (cat#4058), anti-Akt 
(cat#9272), anti-phospho-Erk1/2 -Thr202/Tyr204 (cat#9101), and anti-Erk1/2 (cat#9102; 
all from Cell Signaling Technology, Danvers MA). 
Apoptosis analysis of mouse AML cells in presence of Thpo. Leukemic cells carrying 
RUNX1-ETO and MPL, as well as RUNX1-ETO and MIG were cultured in RPMI 
medium with 20% FBS, 3 ng/ml IL3, 10 ng/ml SCF and 10 ng/ml IL6 (Peprotech, 
Rockyhill, NJ) for 24 hrs. Cells (106/ml) were then resuspended in serum-free medium 
(STEMSPAN SFEM, Stem Cell Technologies) and treated with THPO (20 ng/ml) for 48 
hours. Cell proliferation was measured using Trypan blue exclusion method. Apoptotic 
cells were determined by flow cytometry as Annexin V+ / 7AAD- at 48 hours (BD 
Pharmingen, San Jose, CA) according to manufacturer‟s instructions. The following 
inhibitors were used: MEK (PD98059) at 25 uM and PI3K (LY294002; both from Gibco, 
Carlsbad, CA) at 20 uM. For experiments with inhibitor and THPO, cells were first 
treated with inhibitor for 1 hour followed by THPO induction. 
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Results 
Expression of MPL is increased in t(8;21)-positive human AML samples 
and promotes proliferation 
A previous unsupervised clustering of gene expression in 285 human AML samples 
defined 16 distinct clusters displaying similar gene expression signatures (Valk et al., 
2004b). In order to study the significance of the THPO receptor MPL in AML, we 
queried the MPL expression in this dataset using the 3 independent MPL probe sets 
(Figure 3.1A). We found that MPL transcript is expressed in a fraction of AML samples 
across all clusters, with a marked overrepresentation particularly in cluster #13. This 
cluster aggregates all samples carrying the chromosome translocation t(8;21), which 
expresses the leukemia oncogene RUNX1-ETO. To test if human AML blasts respond to 
THPO, the proliferation of 86 AML cells, including 7 t(8;21) samples, was measured in 
the presence of THPO as single cytokine. After 3 day cultures, cell proliferation was 
estimated by 3H-Thymidine incorporation and THPO specificity adjusted by normalizing 
to the values in the absence of cytokine, thus excluding immortalized samples. 
Approximately 20% of samples (17/86) induced proliferation over 3-fold when 
compared to no-cytokine controls (Figure 3.1B), including 85% (6/7) of t(8;21) samples 
(Figure 3.1B, black bars). The expression of MPL transcript was determined by 
quantitative RT-PCR in the 86 AML samples (Figure 3.1C). The MPL expression 
showed significant correlation with THPO response (R = 0.572, P < 0.0001), and MPL  
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levels of the 7 t(8;21) samples were significantly higher than that of the t(8;21) negative 
group. The panel of AML samples included 16 subtype M2 samples, composed by 7 
t(8;21) and 9 non-t(8;21) samples. Analysis of THPO response and MPL expression in 
the M2 samples also shows a marked correlation of active THPO/MPL signaling in 
t(8;21) positive (85%; 6/7) versus t(8;21) negative (33%; 3/9) samples (Figure 3.1D, E). 
Mutation analysis of 83 of the 86 AML samples for oncogenic mutations in FLT3 
(-ITD and -TKD), NRAS, KRAS, and KIT genes indicated that 5 out of the 7 t(8;21) 
THPO-responsive samples were wild type for these genes, suggesting that MPL-
upregulation was the only known proliferative signal in these AML samples (Tables 3.1 
and 3.2). Together, these results show that human AML cells expand in presence of 
THPO/MPL signaling, and that this effect is preferentially present in RUNX1-ETO 
expressing samples. 
Mpl cooperates with RUNX1-ETO in AML development in mice 
To determine if Mpl expression synergizes with RUNX1-ETO in leukemia development, 
5-FU treated bone marrow cells were co-transduced with pMSCV-IRES-GFP-RUNX1-
ETO (MIG-R1E) and either pMSCV-IRES-humanCD4-Mpl (MID-Mpl) or pMSCV-
IRES-humanCD4 (MID) retroviruses. Since t(8;21) patients express two isoforms of 
RUNX1-ETO fusion protein: the full length (R1E) and a truncated isoform (RUNX1-
ETO9a; R1E9a) missing the C-terminal exons and inducing more aggressive leukemia 
(Yan et al., 2006a), we tested leukemia onset with both isoforms. Transduced cells were 
sorted for GFP and transplanted into irradiated isogenic recipients (Figure 3.2A). Mice  
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transplanted with cells that expressed Mpl and either RUNX1-ETO or RUNX1-ETO9a 
developed leukemia with a median latency of 50 days post transplantation and full 
penetrance (Figure 3.2B, red and green lines). Conversely, mice transplanted with MIG-
R1E/MID did not develop leukemia up to 24 weeks (experimental end point), and mice 
transplanted with MIG-R1E9a/MID presented a delayed leukemia (median latency 140 
days; Figure 3.2B, blue and black lines). Control mice transplanted with cells expressing 
MID-MPL or MID remained healthy over the experiment. Furthermore, 8x104 
GFP+hCD4+ immature cells from RUNX1-ETO/MID and RUNX1-ETO/Mpl moribund 
mice transplanted into sublethally irradiated recipients induced leukemia with a latency 
of 25 days and full penetrance (Figure 3.2C, blue and purple lines).  
Time-course analysis of peripheral blood from MID-Mpl mice revealed the 
gradual increase of erythroid progenitors with hCD4+c-kit-Ter119low immunophenotype. 
These cells peaked at 6 weeks after transplantation, and gradually decreased to be 
undetectable by 24 weeks (Figure 3.2D, E). Transplantation of bone marrow from these 
mice did not replicate the phenotype indicating that the observed disease is not leukemia, 
but rather an erythroproliferative disorder (Figure 3.2C, green line). 
The pathology of leukemia development was comparable among RUNX1-ETO 
groups. The leukemic mice from the RUNX1-ETO9a/MIG, RUNX1-ETO9a/Mpl and 
RUNX1-ETO/Mpl groups exhibited splenomegaly with average spleen weights of 1.1 g, 
0.2g and 0.21g respectively (Figure 3.3A) when compared to wild type spleens (0.07 g), 
and the splenic architecture of white and red pulp was disrupted (Figure 3.3B). The 
peripheral blood of sick mice revealed a consistent increase in white blood cell count   
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(WBC counts > 18 ± 7 x 106 cells/ml; normal WBC count = 4x106 cells/ml), and 
increased presence of immature leukocyte morphologies (Figure 3.3C, D). Flow 
cytometry analysis of peripheral blood revealed that leukemic cells carrying RUNX1-ETO 
and MPL (GFP+hCD4+) were predominantly immature c-kit+ cells that lacked lineage 
specific markers for differentiated leukocytes (Ter119, Mac1, Gr1, B220, and CD3; 
Figure 3.3E). A significant fraction of cells in bone marrow and peripheral blood 
expressed both markers for RUNX1-ETO and Mpl (20 – 40% of the cell populations). 
Similar pathology scenario was observed in RUNX1-ETO leukemic cells expressing Mpl 
or MID vector (Figure 3.3A, B, C, D, F), suggesting that the pathology of leukemia is 
marked by the fusion protein. Together, these studies show that expression of wild type 
Mpl receptor induces transient erythroid expansion and that in the presence of RUNX1-
ETO acts as an oncogenic signal in the development of AML in mice. 
Transcription factor PlagL2 regulates endogenous Mpl expression 
As part of this thesis, I participated in a project that investigated role of PlagL2 
transcription factor in Cbfb-MYH11 AML. The results of this study were published 
(Landrette et al., 2011). Previously, Dr. Castilla‟s group has shown that Plag1 and 
PlagL2 cooperate with Cbfb-MYH11 in development of AML (Landrette et al., 2005). In 
this study we have shown by quantitative reverse transcription-PCR analysis that the 
level of Mpl transcript was increased over 100-fold 48 h after transduction of 
hematopoietic progenitor cells with retroviral constructs expressing human PLAGL2, or   
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with mock control (Figure 3.4A, lanes 1 and 2). A similar increase (30- to 500-fold) was 
observed in Cbfb-MYH11 AML cells expressing PLAGL2 when compared with Cbfb-
MYH11 AML cells not expressing PLAGL2 (Figure 3.4A, lanes 3–10). In addition, the 
levels of Mpl receptor in membrane were markedly increased in AML cells expressing 
PLAGL2 using flow cytometry (Figure 3.4B). 
We have also identified 3 conserved PLAG consensus binding sites in Mpl 
proximal promoter that determine PLAGL2 binding and Mpl regulation (Figure 3.5A). 
To test whether PLAGL2 could directly activate Mpl expression, we tested PLAGL2 
responsiveness of a luciferase reporter carrying the Mpl proximal promoter in NIH3T3 
cells. PLAGL2 activated the reporter over 30-fold relative to control (Figure 3.5B, lanes 
1 and 2). The introduction of previously described point mutations (Voz et al., 2000) in 
PLAG-binding sites 1 (m1) and 2 (m2) resulted in a two- and five-fold reduction in 
luciferase activity, respectively (Figure 3.5B, columns 3-6), indicating that these sites are 
critical for PLAGL2-induced Mpl transcription. Conversely, mutation of the third PLAG 
site (m3) did not change significantly the PLAGL2 responsiveness, suggesting that this 
site may not participate in the Mpl promoter activity (Figure 3.5B, columns 7 and 8). 
Importantly, mutation of all three PLAG-binding sites totally obliterated PLAGL2 
responsiveness of the reporter, confirming that binding of PLAGL2 to the promoter is 
necessary for transcriptional activation (Figure 3.5B, columns 9 and 10). To validate 
PLAGL2 binding to these sites, we performed electrophoretic mobility shift assays using 
oligonucleotides covering each of the three Mpl-binding sites (o) and a combination of 
labeled oligonucleotides with cold competitor (c) or mutated competitor (m)   
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oligonucleotides (Figure 3.5C). These assays show that P1 and P2 sites bind to PLAGL2 
with specificity, but P3 site binding is poorly competed with cold competitor. These 
results suggest that PLAGL2 can directly activate the Mpl proximal promoter using the 
P1 and P2-binding sites. 
Finally, we showed that Cbfb-MYH11/PlagL2 AML cells are hypersensitive to 
thrombopoietin exhibiting hyperphosphorylation of downstream effectors of Mpl 
signaling pathway (Jak2, Stat5, Erk1/2, Akt) upon stimulation with Thpo, and that Mpl 
also cooperates with Cbfb-MYH11 in AML development in vivo (data not shown 
(Landrette et al., 2011)). 
Overexpression of Mpl-regulating PLAGL2 cooperates with RUNX1-ETO 
in leukemia 
Considering that the retrovirus-induced overexpression of Mpl may create unspecific 
activation of cellular pathways, we indirectly tested the ability of the endogenous Mpl 
upregulation to induce leukemia through retroviral overexpression of the transcription 
factor PlagL2, an activator of Mpl transcript expression in hematopoietic cells (Landrette 
et al., 2011). 
Bone marrow cells co-transduced with MIG-R1E and MID-PlagL2 (MID-PL2) 
retroviruses were transplanted into isogenic irradiated recipients (Figure 3.6A). Recipient 
mice carrying RUNX1-ETO/PlagL2 developed leukemia with a median latency of 11 
weeks (range: 8 to 17 weeks; n = 12) and full penetrance. In contrast, only 18% (2/11) of 
RUNX1-ETO/MID transplanted recipients developed leukemia after longer latency  
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(median latency=20 weeks) and incomplete penetrance (Figure 3.6B). Control groups 
including MID or PlagL2 alone did not develop leukemia. The phenotype of the leukemia 
was similar to that observed in RUNX1-ETO/MPL AMLs. These included efficient 
secondary transplantation of RUNX1-ETO/PlagL2 leukemic cells into secondary 
transplants (Figure 3.6B, long dash lines) and splenomegaly (Figure 3.6C). The leukemic 
cells in peripheral blood were GFP+hCD4+, consistent with expression of RUNX1-ETO 
and PlagL2, and expressed the Mpl receptor in the membrane (Figure 3.6D). The 
immunophenotype of the leukemic cells was c-kit+Lin-, although a fraction of samples 
showed Gr1lowMac1low markers (Figure 3.6E). In addition, a fraction of leukemic cells in 
both RUNX1-ETO/MPL and RUNX1-ETO/PlagL2 groups presented c-kit+Sca1+ 
markers, a signature of early progenitor blasts (Figure 3.6F). Together, these results show 
that Mpl expression induces a transient erythroid progenitor expansion, but that in the 
presence of RUNX1-ETO is an oncogenic signal that induces acute myeloid leukemia. 
Mpl expression is not regulated by RUNX1-ETO in mouse progenitor and 
leukemic cells 
Considering that Mpl expression is frequently increased in t(8;21) AML samples and that 
Mpl has been reported as a direct CBF target in hematopoietic stem cells and 
megakaryocytes (Heller et al., 2005; Satoh et al., 2008b), it is possible that RUNX1-ETO 
could directly upregulate Mpl transcript expression. To test this hypothesis we measured 
Mpl expression by quantitative reverse transcriptase PCR (qRT-PCR) in bone marrow 
cells transduced with MIG, MIG-R1E, or MID-PL2 retroviruses, and sorted for GFP or   
150 
  
151 
hCD4 markers. The Mpl levels were similar between MIG and RUNX1-ETO groups, and 
increased 3 fold in bone marrow cells transduced with PLAGL2 (Figure 3.7A). The 
expression of Mpl was also tested on AML cells expressing RUNX1-ETO/MIG, 
RUNX1-ETO/PLAGL2 and RUNX1-ETO/MPL, and compared to AML cells carrying 
the CBFB-MYH11 fusion gene (CM). The Mpl levels in RUNX1-ETO AML cells were 
comparable to controls, and increased markedly in AML cells expressing PLAGL2 or 
Mpl (Figure 3.7B). Together, these results suggest that Mpl levels are not induced by 
RUNX1-ETO in hematopoietic progenitors and leukemic cells. 
THPO/MPL signaling activates survival pathway in leukemic cells 
expressing Mpl 
The activation of THPO/MPL signaling in hematopoietic progenitors includes the 
phosphorylation of JAK2 and antiapoptotic and proliferative response via activation of 
PI3K/AKT, JAK2/STAT5, and MAPK/ERK pathways (Kaushansky, 2009b). In order to 
determine the downstream signal activation by Mpl expressing leukemic cells we tested 
phosphorylation levels of Jak2, Stat3/5, Akt1, and Erk1/2 in RUNX1-ETO/PlagL2 
(expressing endogenous Mpl) and control RUNX1-ETO/MIG leukemic cells. The 
RUNX1-ETO/PlagL2 leukemic cells showed THPO hypersensitivity as phosphorylation 
of Jak2, Stat5, ERK1/2 and Akt1 was detected at low THPO concentrations (5 ng/mL 
THPO), and saturated at 25 ng/mL (Figure 3.8A). These results suggest that Mpl-
expressing leukemic cells may expand by a hypersensitive signaling downstream of Mpl. 
If Mpl expression elicits survival and proliferative response in RUNX1-ETO 
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leukemic cells, their expansion and cell-death in culture with THPO as single cytokine 
should be THPO dependent. The RUNX1-ETO/MPL leukemic cells were cultured for 48 
hours in serum-free medium to test the effect of THPO addition in cell number and 
apoptosis. The levels of apoptosis and proliferation in AML cells expressing RUNX1-
ETO but not MPL were unaltered in presence of THPO, but in RUNX1-ETO/MPL 
leukemic cells the apoptosis was increased by 20% in the absence of ligand, and cell 
number reduced by 80% (Figure 3.8B, C). Cell cycle analysis failed to reveal a 
significant change in proliferation rate (data not shown). To identify the mechanism 
underlying the THPO/Mpl mediated survival advantage in RUNX1-ETO/MPL leukemic 
cells, the apoptosis assay was repeated using cells preincubated with the PI3K-inhibitor 
LY294002 or the MEK-inhibitor PD98059. The group treated with LY294002 
significantly blocked THPO survival signal while those with PD98059 remained sensitive 
to THPO signaling (Figure 3.8B, C), thus indicating that PI3K and not MEK function in 
the survival signaling. 
Since RUNX1-ETO/MPL cells showed functional PI3K signaling and a 
hypersensitive Akt/mTor pathway, the role of the Akt/mTor pathway was tested in vivo 
by analyzing the engraftment efficiency of the leukemic cells using the mTor inhibitor 
rapamycin. Recipient mice were transplanted with 1x105 leukemic cells and administered 
with daily injections of rapamycin or vehicle. Mice treated with vehicle succumbed with 
AML with a median latency of 30 days (range 28 to 38 days), while rapamycin-treated 
mice showed significant delay in disease latency (P < 0.0001, long-rank test) and 
incomplete penetrance (Figure 3.8D). These results suggest that the hyperactive   
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Akt1/mTor signaling is an important component on the MPL-mediated survival of AML 
cells. 
Discussion 
The regulation of cytokine signaling moderates proliferation, differentiation and survival 
of hematopoietic stem and progenitor cells. Components of these pathways are prime 
targets of mutations in leukemia initiation, compromising their proliferative and survival 
functions (Scholl et al., 2008b). Patients with AML frequently present mutations in genes 
encoding components of the receptor tyrosine kinase pathways. In this study we show 
that increased expression of the wild type thrombopoetin receptor MPL acts as an 
oncogenic mutation, activating proliferative and survival signals. These signals cooperate 
with the differentiation block caused by the fusion gene RUNX1-ETO to induce leukemia. 
The expression analysis of a large panel of AMLs in our study shows that MPL 
expression is present in a fraction of samples across cytogenetic groups as previously 
reported (Kaushansky, 1998; Matsumura et al., 1995). However, we find that most 
t(8;21) AMLs express moderate to high Mpl levels and proliferate in response to THPO 
ligand. Importantly, this bias was also observed when comparing leukemic cells of 
similar morphology within the M2 FAB subtype. The unexpected finding that Mpl 
transcript levels were unchanged in mouse hematopoietic progenitor and leukemic cells 
expressing RUNX1-ETO, strongly suggests that Mpl expression is not a direct target of 
the fusion protein in mouse bone marrow hematopoietic progenitors. Alternatively, it is 
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likely that MPL and RUNX1-ETO function may effectively synergize to induce 
leukemia. The RUNX1-ETO preleukemic cells accumulate in the bone marrow as 
myeloid progenitors unable to differentiate and with increased self-renewal function 
(Yuan et al., 2001b), and accumulate additional mutations that transforms them into full 
blown leukemia. These leukemia progenitors may be selected for increased MPL levels 
by their response to THPO, therefore promoting leukemia transformation.  
The MPL gene can present oncogenic mutations or be expressed at higher levels 
in myeloproliferative disorders (Kaushansky, 2003), and abnormal MPL function can 
induce expansion of erythroid progenitors. Overexpression of MPL in mouse 
hematopoietic progenitors promotes proliferation of erythroid progenitors (Yan et al., 
1999). Consistent with these observations, we find a significant and transient erythroid 
expansion in mice transplanted with cells overexpressing MPL. This expansion, however, 
was not observed when MPL was co-transduced with RUNX1-ETO. Instead, cells 
remained in bone marrow and emerged as leukemic cells in both mouse models 
(RUNX1-ETO/MPL and RUNX1-ETO/PLAGL2), suggesting that the combined 
expression preempts the MPD phenotype and induces leukemia. 
The t(8;21) AML cells co-express the full-length RUNX1-ETO and the 
alternative spliced (and more aggressive) RUNX1-ETO9a isoform (Yan et al., 2006a). 
We find that both isoforms efficiently induce leukemia in cooperation with MPL. Further, 
the pathology of leukemia is similar in retrovirally expressed Mpl and PLAGL2-activated 
Mpl, indicating that constitutive Mpl expression at moderate levels is sufficient for 
leukemia development. In the simplistic but valid model of a multistep pathogenesis of 
158 
AML, these “class-I” mutations provide proliferative and survival advantage and 
cooperate with “class II” mutations, such as RUNX1-ETO, which inhibit differentiation 
and apoptosis (Kelly and Gilliland, 2002b). Our results implicate MPL expression as a 
class-I oncogenic signal able to initiate leukemia in mice and expand murine and human 
leukemic cells. 
Activation of MPL elicits proliferative and pro-survival functions through 
activation of PI3K/AKT/mTOR/FOXO, RAS/MAPK/MEK/ERK, and STAT5/Bcl-xL 
cascades (Kaushansky, 2009b). The MPL receptor lacks intrinsic tyrosine kinase activity, 
contrary to other members of the cytokine receptor superfamily. Activation of Jak2 is 
critical for Mpl phosphorylation and activation. The phosphorylation of Jak2 was rapidly 
increased upon incubation with low THPO concentrations. Furthermore, RUNX1-
ETO/Mpl leukemic cells showed a hypersensitivity to THPO on the phosphorylation of 
AKT1, ERK1/2, and STAT5 factors. The inhibition of PI3K pathway (but not 
MEK/ERK) abrogated the THPO mediated survival, and suggests that the 
PI3K/AKT/mTOR pathway plays a critical function in RUNX1-ETO/MPL leukemia. 
Furthermore, this finding was confirmed in vivo as treatment with the mTor inhibitor 
rapamycin significantly delayed leukemia development in secondary transplants. In 
addition to PI3KAKT/mTor, the THPO/MPL survival response probably results from 
interaction between downstream effectors of other pathways. 
Considering that the RUNX1-ETO/MPL blasts seem to be “addicted” to TPO 
ligand for proliferation and survival in human and mouse leukemias, inhibitors of 
PI3K/AKT may hold promising therapeutic value if able to target the leukemia initiating 
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cells (L-ICs). The challenge will likely reside on identifying drugs that show high 
efficacy inducing apoptosis of L-ICs rather than reducing the other cells of the leukemic 
cell population. These may reside in the stem cell-like (lin-c-kit+Sca1+) compartment 
found to be expanded in RUNX1-ETO AMLs (de Guzman et al., 2002b; Peterson et al., 
2007), including the RUNX1-ETO/MPL and RUNX1-ETO/PLAGL2. 
Mutations in MPL are frequently found in several hematopoietic malignancies, 
but rarely in AML. Our studies show that expression of wild type MPL creates a 
hypersensitive signaling pathway, and support the idea that the hypersensitive MPL 
signaling causes an oncogenic response when co-expressed with a cooperating mutation 
such as RUNX1-ETO. Although this study focused on the role of MPL in AML cells 
carrying the t(8;21) translocation, it is reasonable to assume that the oncogenic function 
of upregulated MPL on initiation and maintenance of leukemia can play a role in other 
AML subtypes. Therefore, the therapeutic value of targeting MPL-mediated survival 
signals could be extended to other AML cases expressing MPL. 
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CHAPTER IV 
Discussion 
In Chapters II and III I discussed specific results that were obtained by us and compared 
the novel data with what was previously known. In this Chapter, I will discuss the results 
from a more global perspective, with focus on their relevance in frame with the general 
field of AML. I will also explore immediate future questions that are raised by these 
studies. 
Cooperation of miR-17-92 miRNA cluster with Cbfb-MYH11 in 
AML development 
MiR-17-92 in leukemia 
The study of miRNA expression profiling in large panels of human AML samples 
provide a start-point for the identification of candidate miRNAs with roles in leukemia 
development, and as markers of AML subtypes (Jongen-Lavrencic et al., 2008; Li et al., 
2008). For example, the miR-126/126* was found to be upregulated in CBF leukemias 
with t(8;21) and inv(16), when compared to other AML samples, and was shown to 
promote proliferation and inhibit apoptosis in the AML cells in vitro by targeting a tumor 
suppressor gene Polo-like kinase 2 (PLK2) (Li et al., 2008). The miR-126/126* was 
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shown to regulate vascular formation by targeting Spred1 and PIK3R (Zou et al., 2011), 
and megakaryocytic differentiation by targeting Myb in zebrafish (Grabher et al., 2011). 
In addition, miR-126 was recently reported to participate in gastric carcinogenesis by 
repressing SRY-box 2 (SOX2) (Otsubo et al., 2011). Its functional role in CBF AML has 
not been studied, but from the abovementioned studies it would be expected that miR-126 
may promote proliferation of leukemic cells through activation of AKT and ERK 
pathways. 
The miR-29 was not shown to directly cooperate with CBF fusion genes either, 
but its role in a regulatory feedback loop with c-Kit RTK in c-KIT+ AMLs indicated a 
strong possibility that miR-29 may be playing a role in CBF AMLs with c-KIT oncogenic 
mutations. Treatment of c-KIT-transfected FDCP-1 cells with inhibitors of the feedback 
loop effectors (Sp1/NFκB complex) and overexpression of miR-29 in vitro resulted in 
decreased proliferation and clonogenic activity of the cells. Moreover, inhibiting the 
feedback loop in a xenograft mouse model of c-KIT+ leukemia increased latency of the 
disease, further suggesting its role in c-Kit+ AML (Liu et al., 2010a). The miR-29 family 
may play a specific role in CBF AMLs because the CBF fusion proteins suppress 
expression of C/EBPα, which is an activator of miR-29a/b expression (Eyholzer et al., 
2010). Suppression of the miR-29a/b in the AML cells could result in increased c-KIT 
expression and signaling. Indeed, according to a study of Lück et al., more than 10% of 
human CBF AMLs without mutations in KIT or its known regulators, have a gene 
expression profile similar to that of CBF AMLs that carry c-KIT activating mutations 
(Lück et al., 2010). The loss-of-function of miR-29 could potentially explain this result, 
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so a study of miR-29 expression in CBF AMLs with wild type KIT may reveal a role of 
miR-29 in CBF AML. 
Another example of potential miRNA involvement in CBF AML is the function 
of miR-221/222, which are shown to downregulate c-KIT expression in erythropoiesis 
(Felli et al., 2005). They are also shown to be direct targets of RUNX1 fusion proteins 
and to be downregulated in human CBF leukemias with high c-KIT expression, probably 
due to direct repression with the CBF fusions. However, cooperation between oncogenic 
CBF fusion proteins and loss of miR-221/222 in AML development was not tested 
(Brioschi et al., 2010). 
To date, there are no reports that would implicate miR-17-92 cluster in CBF 
leukemia, although it is shown to be involved in pathogenesis of several other leukemias. 
Specifically, miR-17-92 is consistently overexpressed in MLL-associated AMLs (Jongen-
Lavrencic et al., 2008; Li et al., 2008; Wong et al., 2010), when compared to other 
AMLs. Moreover, MLL fusions have high affinity to miR-17-92 promoter and directly 
upregulate miR-17-92 expression (Mi et al., 2010). Role of miR-19 and the whole cluster 
in B- and T-cell lympocytic leukemias is also well documented (He et al., 2005; Inomata 
et al., 2009; Lenz et al., 2008; Mavrakis et al., 2010; Mu et al., 2009; Olive et al., 2009; 
Wang et al., 2006). 
Our study for the first time links miR-17-92 with Cbfb-MYH11-associated AML, 
defining an example of a miRNA involved in CBF AML pathogenesis, and introducing 
miR-17-92 as a player in CBF leukemias. Importantly, this is the first study that proves 
direct cooperation between a miRNA and a CBF fusion protein in vivo, unlike previous 
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reports that contained only correlative data. Also our study, combined with data from 
other groups, indicates that miR-17-92 is a pan-leukemic oncogene that cooperates with 
variety of oncogenes in all types of leukemias derived from different progenitor 
compartments (lymphoid, myeloid, mixed lineages and erythroid). 
Role of individual miRNAs in Cbfb-MYH11-related AML 
It has been shown previously that miR-17-92 can provide an advantage to cancer cells by 
increasing survival and/or proliferation (Chow et al., 2010; He et al., 2005; Hong et al., 
2010; Matsubara et al., 2007; Mu et al., 2009; Olive et al., 2009; Takakura et al., 2008; 
Yu et al., 2010b). Here we found a pro-survival effect in leukemic cells dependent on 
miR-17 and miR-20a function. To date, the establishment of a molecular mechanism of 
this effect in Cbfb-MYH11 AML is evolving, and our studies point at miR-17 family and 
not at miR-19 family as CBF oncomiRs. This is contrary to the findings reported in B-cell 
lymphoma model that identified Pten as the main target of miR-19 that was involved in 
tumorigenicity and the anti-apoptotic effect (Olive et al., 2009). 
The miR-17 and miR-19 families of miRNAs are co-expressed from the same 
clusters (miR-17-92 and miR-106a-363), and have been shown to regulate expression of 
both common and specific targets. Probably, the best known common target is the tumor 
suppressor PTEN, and over 185 other putative common targets are predicted by miRNA 
target algorithms, including BCL2L11, CCND1, CCND2. This regulation raises several 
questions. Does the regulation depend on cell type and is it synergistic? Are both miRNA 
families relevant to cancer development, or only one family plays a role in the process in 
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a given cancer type? Studies that have characterized individual role of miRNAs 
concluded that either miR-17 or miR-19 families play main role in cancer development, 
but not together (Cloonan et al., 2008; Matsubara et al., 2007; Olive et al., 2009; Sun et 
al., 2010; Yu et al., 2010b). The results from our study suggest that the same may be true 
in Cbfb-MYH11 AML, as only miR-17/20a miRNAs provided survival capacity in mouse 
leukemic cells. One of the questions that remains unanswered by our study is the specific 
molecular function of miR-17 family in CBF AML. Top-down approaches studying miR-
17-specific targets (such as MEKK2, MAPK9, DUSP2, and BCL2L11), or bottom-up 
approaches studying the effect of miR-17 family miRs on the phosphorylation or protein 
levels of pro- and anti-apoptotic proteins are currently being pursued. 
It is also possible that some of the functional effects of miR-19a/b on the AML 
cells were not detected due to limitations of the in vitro settings or the antagomir-based 
experiments. Experimental data suggest that proliferation effects may be difficult to 
detect in cells that were previously cryopreserved (Peter Valk, personal communication). 
The ultimate readout of individual miRNA roles in AML development in cooperation 
with Cbfβ-SMMHC will come from cooperation studies with single miRNAs in the 
mouse model. 
Activation of PI3K/Akt pathway in the AML cells by miR-17-92 
The miRNAs may regulate a single miRNA target responsible for an observed phenotype 
(Molitoris et al., 2011; Sun et al., 2010; Wang, 2008; Wong et al., 2010; Zhang et al., 
2011). In other cases, miRNAs could cause relatively small effects on potentially 
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hundreds of targets, so that each individual change may not be a determining cause of a 
functional effect.  
Our study shows that miR-17-92 downregulates Pten protein levels in mouse 
Cbfb-MYH11/miR-17-92 AML blasts. Considering that Pten is a common target of both 
miR-17 and miR-19 family miRs and the fact that Bad-phosphorylation (pBad) levels are 
increased, these data strongly suggest that these miRs may be implicated in Bad-mediated 
survival functions. The mechanism of increased Bad-phosphorylation is not yet clear, but 
it underscores the hypothesis that multiple survival pathways may be altered by these 
miRNAs. For example, downregulation of Pten by both miR-17 and miR-19 miRNA 
families resulted in moderate pBad increase, but may not have sufficiently shifted the 
pro- and anti-apoptotic signals balance to determine the miR-17/20a anti-apoptotic effect. 
Some other regulators of apoptosis (e.g. Bim and E2F1), when targeted by miR-17 
family, could contribute to cell survival, but only in the context of increased pBad. To 
address some of these remaining questions, the Pten put-back and shRNA-mediated 
knock-down experiments in the context of individual miRNA silencing could dissect the 
role of Pten targeting by each miRNA family. Additionally, analysis of expression and 
regulation of other apoptotic regulators (including those not targeted directly by the 
miRNAs, e.g. Bcl-xL and Bcl2) would allow us to determine what particular signals 
contribute to the anti-apoptotic effect of miR-17, but not miR-19 family. 
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Role of miR-17-92 in wild type and cancer cells 
Upregulation of miR-17-92 has been shown to play an oncogenic role in multiple cell 
types. Also, miR-17-92 is implicated in normal regulation of differentiation, survival and 
cell cycle in a number of cell types. It remains unclear whether (1) miR-17-92 normal 
function in a particular cell type is related to its oncogenic effect in these cells or (2) the 
oncogenic function is completely unrelated to its normal functions in the cell type. 
Previously we saw an example that can be interpreted as an illustration of the first 
possibility. The miR-17-92 is involved in myeloid differentiation at late stages of myeloid 
maturation (Fontana et al., 2007), whereas it blocks B-cell development at pro-B stage 
(Ventura et al., 2008). In our study, in the leukemic setting with Cbf-SMMHC, 
expression of miR-17-92 did not affect block of myeloid differentiation by the fusion 
protein (by blast morphology and FACS), yet, it led to earlier block of B-cell 
differentiation in the Eµ-Myc B-cell lymphoma model (He et al., 2005). Interestingly, in 
MLL fusions-associated AMLs, miR-17-92 enhances a block in myeloid differentiation, 
presumably due to the fact that MLL fusions block myeloid differentiation at later stages 
where miR-17-92 is involved (Wong et al., 2010). Based on these examples, it is 
plausible that miR-17-92 effect on differentiation of leukemic cells depends on its normal 
function. If the cluster has no function in differentiation of a lineage before the stage 
where it is blocked by a cooperating oncogene, the overexpression of the cluster does not 
affect the differentiation of the cells. On the contrary, if the miR-17-92 normal function in 
differentiation of a particular cell type is before a differentiation block provided by a 
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cooperating oncogene, overexpression of miR-17-92 affects differentiation of the 
leukemic cells. 
Emerging data from different cancer cell types suggest that miR-17-92 may have 
distinct functions in normal and tumor cells. The overexpression of miR-17-92 in normal 
lungs resulted in impaired differentiation and increased proliferation (Lu et al., 2007). 
However, in lung cancer the function of miR-17-92 was determined to be anti-apoptotic 
(Matsubara et al., 2007). Another example comes from a study of human B-cell 
lymphoma cell lines. The overexpression of miR-17-92 in Raji cells provides an anti-
apoptotic response, while its overexpression in SUDHL4 cells promotes proliferation of 
the cells by inhibiting p21 expression (Inomata et al., 2009). This example suggests that 
within the same cancer type, gene expression context provided by other oncogenes 
dictates function of miR-17-92 in the cells, rather than its normal functions in the cell 
type determining its oncogenic activity. 
While in most cases miR-17-92 functions as an oncogene, it has been also shown 
to function as a tumor suppressor in breast cancer cells (Hossain et al., 2006). Therefore, 
even the role of miR-17-92 as an oncogene or (in rare cases) as a tumor suppressor seems 
to be determined by the cell context, suggesting that miR-17-92 signaling by itself is not a 
direct oncogenic signal, but is complex and ambiguous, and can provide a functional 
readout only working in a cancer cell context determined by other signals. 
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Oncogenic role of miR-17-92 cluster in the context of CBFB-MYH11 
expression 
As described previously, CBFB-MYH11 is considered a class II oncogenic mutation that 
provides a block in differentiation, but fails to transform the cells due to absence of self-
renewal and/or pro-survival signals. Therefore, it is often found in AMLs to be associated 
with class I mutations that confer such signals. In this study we have shown that miR-17-
92 is one of the possible class I mutations that cooperate with Cbfb-MYH11 in a mouse 
model of AML. The mechanism of this cooperation is suggested to be due to an anti-
apoptotic effect elicited by miR-17-92 in the AML cells. The suggested cooperation 
between Cbfb-MYH11 and miR-17-92 fits the two-hit hypothesis of AML development. 
Whether tertiary mutations are necessary for the cooperation to occur (for example, 
mutations that would increase proliferation of the cells), is an open question that can be 
addressed by identification of CISs for the miR-17-92-expressing retroviruses and by 
determination of clonality of the AMLs. Relatively long latency of the primary AML 
development and high variability in expression of tested miR-17-92 targets suggest that 
the acquisition of additional mutations during leukemogenesis is likely. 
The molecular mechanism for the observed cooperation remains unclear. The 
upregulation of the PI3K/Akt pathway may be one of them, but it may not be upregulated 
strongly enough to explain the cooperation in this particular cellular context. Similar 
effects of miR-17 and miR-19 families on regulation of Bad phosphorylation, yet different 
effect of the two miRNA families on apoptosis suggest that additional molecular 
pathways play a role. Due to hundreds of potential miRNA targets and post-
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transcriptional mode of their regulation by the miRNAs, it is hard to identify all relevant 
changes caused by the miR-17-92 cluster in the AML cells. We did not find significant 
deregulation of Rb2, Runx1, E2f1, Mcl-1 and Bim in the Cbfb-MYH11/miR-17-92 
AMLs. Yet, other possibilities remain, including Jnk2, Mekk2, MAPK regulator Dusp2 
that were also shown to be involved in apoptosis regulation. Careful analysis of 
regulation of these and other proteins in the Cbfb+/MYH11/miR-17-92 AML cells by the 
miR-17-92 cluster and the effect of such regulation on apoptosis and, potentially, other 
cellular mechanisms is one of the future directions necessary for a deeper understanding 
of the observed role of miR-17-92 in the Cbfb-MYH11-associated AMLs. 
Upregulation of wild type Mpl cooperates with RUNX1-ETO 
in AML development 
Wild type RTK functions are different from mutant RTK functions 
Oncogenic mutations in RTKs have been shown to be involved in many cancer types, 
including AML (Boissel et al., 2006b; Care et al., 2003; Shih et al., 2008). Here we show 
for the first time that upregulation of a wild type RTK that does not bear mutations can 
also serve as a second hit in AML development. This result is novel because to our 
knowledge previous studies determined the role of mutated RTKs in AML development 
(Brandts et al., 2005; Kohl et al., 2005; Mizuki et al., 2000; Ning et al., 2001b; Schessl et 
al., 2005a; Wang et al., 2011b), while overexpression of wild type RTKs was found, but 
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functional role of this overexpression was not properly assessed (Drexler, 1996; Muroi et 
al., 1998; Rosnet et al., 1996; Turner et al., 1996; Wang et al., 1989). 
Functional studies show that signaling downstream of mutated RTKs may be 
qualitatively different from wild type RTK-induced signaling, and not just mimic wild 
type signaling with the only difference of having higher activation levels of the same 
effectors and ligand independence. For example, wild type FLT3 receptor does not 
induce STAT5 phosphorylation and activation upon stimulation with FLT3 ligand, while 
FLT3-ITD mutant strongly induces STAT5 activity, and the STAT5 activity was shown 
to be functionally relevant to oncogenic signaling of FLT3-ITD in vitro (Choudhary et 
al., 2007; Hayakawa et al., 2000; Masson et al., 2009; Mizuki et al., 2000; Spiekermann 
et al., 2003). Therefore, a finding that an overexpressed wild type RTK is involved in 
cancer is distinct from identification of a mutant RTK involvement in cancer. 
The aforementioned possible difference in wild type and mutant RTK signaling 
together with our finding of wild type Mpl cooperation with CBF fusion proteins in 
AML, raises a question that is relevant to the biology of human AML. A significant 
fraction of acute megakaryoblastic leukemias carry activating mutations of MPL (most 
commonly mutations in the amino acid W515 residing in the JM domain) (Hussein et al., 
2009a), yet they are not detected in other AML cases, including CBF fusions-associated 
AML. This may seem to contradict our results that suggest that MPL upregulation 
cooperates with RUNX1-ETO fusion and, importantly, is found upregulated in a large 
fraction of AML in general and in t(8;21) AML in particular. Of note, JAK2 activating 
mutations are readily found particularly in CBF AML (Dohner et al., 2006; Illmer et al., 
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2007; Schnittger et al., 2007b), making the absence of MPL mutations in AML even 
more puzzling. A possible explanation would imply differences in signaling from 
upregulated wild type and constitutively activated mutant MPL. For example, MPL 
W515 mutants fail to increase phosphorylation of STAT3 without thrombopoietin 
induction (Staerk et al., 2006). Such changes in signaling could result in a different 
overall effect on oncogenic cells and prevent cooperation of the mutant MPL with other 
AML-associated oncogenes, for example, by inducing myeloid differentiation (Staerk et 
al., 2006). Analysis of cooperation between mutant MPL and CBF fusions in AML in 
vivo would allow to determine possible functional differences between upregulated wild 
type and mutant MPL. 
The described finding may be relevant to strategies of leukemia treatment. Most 
common ways of subclassification of leukemic cases currently rely on search for 
mutations in known oncogenes involved in a particular type of cancer. The example of a 
role of wild type Mpl in AML illustrates the importance of assessing actual expression 
levels of genes rather than sole reliance on mutation search. In this aspect, microarray 
profiling studies in leukemia may be a valuable complementing strategy in diagnosis and 
classification of leukemia (at least in cases where known mutations were not found). 
Different second hits, same pathways 
In order to develop AML, CBF fusions require presence of additional mutations often 
called “second hits.” A number of the second hits have been found either by studying 
mutations in human AML or by searching for cooperating genes in mouse models. As 
172 
described earlier, majority of the second hit mutations found in human AML activate 
PI3K/Akt, Jak/Stat and Ras/Raf/Mek/Erk pathways or are players in these pathways. Our 
data presents other examples of this consistent pattern. All three pathways are activated in 
the RUNX1-ETO/Mpl mouse leukemic cells, and functional importance of PI3K/Akt 
pathway for AML development was shown in vivo. In vitro data also indicates that PI3K 
and Mek activity plays an anti-apoptotic role in the cells. Importantly, majority of other 
studies suggesting activation of the PI3K/Akt, Mek/Erk and Jak/Stat pathways in AML is 
correlative and comes from studying of human AML samples (Haferlach et al., 2010; 
Neubauer et al., 2008; Tamburini et al., 2007; Xu et al., 2003). Our data on Mpl 
cooperation, on the other hand, provides a direct biochemical link between the pathways 
activity and AML development in a mouse model and primary human AML. This 
underscores previous findings and makes PI3K/AKT and other MPL-activated pathways 
promising targets for AML treatment. 
Upregulation of Mpl by PlagL2 
We have previously shown that PlagL2 upregulates endogenous Mpl expression 
(Landrette et al., 2011). In this study we show that PLAGL2 cooperates with RUNX1-
ETO in AML development, upregulates Mpl expression and its signaling pathways. 
However, we did not directly show that Mpl is necessary and sufficient for oncogenic 
activity of PLAGL2 in the presence of RUNX1-ETO and/or Cbfβ-SMMHC. We 
attempted to address this question using the Mpl blocking antibody AMM2 (Arai et al., 
2009) in secondary transplantation assays of RUNX1-ETO/PLAGL2 AML cells. 
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Unfortunately, we were unable to complete the study due to the severe anemia and HSC 
mobilization/depletion caused by Mpl blockade. This question is being addressed 
currently in our lab using two alternative approaches. First, by testing whether RUNX1-
ETO and PLAGL2 can induce leukemia in BM transplantation assays when co-
transduced with Mpl shRNA-expressing constructs. Second, we are testing whether 
RUNX1-ETO and PLAGL2 can induce leukemia using Mpl-null BM cells. 
Oncogenic role of Mpl in the context of RUNX1-ETO expression 
We have shown that wild type Mpl cooperates with Cbfβ-SMMHC (Landrette et al., 
2011) and with RUNX1-ETO in development of AML in vivo. We have also determined 
that in the context of both CBF fusion proteins expression the wild type Mpl activates 
PI3K/Akt, Jak/Stat and MAPK8 pathways and provides pro-survival and (in human AML 
samples) a pro-proliferative signals. These results fit the two-hit model of AML 
development and characterize Mpl overexpression as a potent class I cooperating event. 
We have shown that inhibition of PI3K/Akt pathway components or Mek in vitro 
alleviated the anti-apoptotic or pro-proliferative signaling of MPL in the human and 
mouse AML cells. We demonstrated that inhibition of mTOR effector of PI3K/AKT 
pathway in vivo delayed development of AML in vivo, further supporting the idea that 
activation of PI3K/AKT signaling is important for AML progression. Finally, we 
demonstrated that a large fraction of t(8;21) human AML samples overexpress MPL and 
are sensitive to THPO. Taken together, these results suggest a possible clinical relevance 
of inhibition of MPL and its downstream signaling to treatment of CBF-associated AML. 
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